Packaging of immunostimulatory substances into virus-like particles: method of preparation and use

ABSTRACT

The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.13/294,006, filed Nov. 10, 2011, now patented, which is a continuationof U.S. application Ser. No. 10/244,065, filed Sep. 16, 2002, nowabandoned, which claims the benefit of U.S. Provisional Application No.60/318,994, filed Sep. 14, 2001, and U.S. Provisional Application No.60/374,145, filed Apr. 22, 2002, each of which is hereby incorporated byreference in its entirety.

REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

The content of the electronically submitted sequence listing Name:1700_(—)0220004_RevisedListing_ascii.txt; Size 152,065 bytes; and Dateof Creation: Aug. 10, 2012) filed herewith, is incorporated herein byreference in its entirety.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention is related to the fields of vaccinology,immunology and medicine. The invention provides compositions and methodsfor enhancing immunological responses against virus-like particles(VLPs) or against antigens coupled, fused or attached otherwise to VLPsby packaging immunostimulatory substances, in particularimmunostimulatory nucleic acids, and even more particularoligonucleotides containing at least one non-methylated CpG sequence,into the VLPs. The invention can be used to induce strong and sustainedT cell responses particularly useful for the treatment of tumors andchronic viral diseases as well as allergies and other chronic diseases.

2. Related Art

The essence of the immune system is built on two separate foundationpillars: one is specific or adaptive immunity which is characterized byrelatively slow response-kinetics and the ability to remember; the otheris non-specific or innate immunity exhibiting rapid response-kineticsbut lacking memory. Lymphocytes are the key players of the adaptiveimmune system. Each lymphocyte expresses antigen-receptors of uniquespecificity. Upon recognizing an antigen via the receptor, lymphocytesproliferate and develop effector function. Few lymphocytes exhibitspecificity for a given antigen or pathogen, and massive proliferationis usually required before an effector response can be measured—hence,the slow kinetics of the adaptive immune system. Since a significantproportion of the expanded lymphocytes survive and may maintain someeffector function following elimination of the antigen, the adaptiveimmune system reacts faster when encountering the antigen a second time.This is the basis of its ability to remember.

In contrast to the situation with lymphocytes, where specificity for apathogen is confined to few cells that must expand to gain function, thecells and molecules of the innate immune system are usually present inmassive numbers and recognize a limited number of invariant featuresassociated with pathogens (Medzhitov, R. and Janeway, C. A., Jr., Cell91:295-298 (1997)). Examples of such patterns includelipopolysaccharides (LPS), non-methylated CG-rich DNA (CpG) or doublestranded RNA, which are specific for bacterial and viral infections,respectively.

Most research in immunology has focused on the adaptive immune systemand only recently has the innate immune system entered the focus ofinterest. Historically, the adaptive and innate immune system weretreated and analyzed as two separate entities that had little in commonSuch was the disparity that few researchers wondered why antigens weremuch more immunogenic for the specific immune system when applied withadjuvants that stimulated innate immunity (Sotomayor, E. M., et al.,Nat. Med. 5:780 (1999); Diehl, L., et al., Nat. Med. 5:774 (1999);Weigle, W. O., Adv. Immunol. 30:159 (1980)). However, the answer posedby this question is critical to the understanding of the immune systemand for comprehending the balance between protective immunity andautoimmunity.

Rationalized manipulation of the innate immune system and in particularactivation of APCs involved in T cell priming to deliberately induce aself-specific T cell response provides a means for T cell-basedtumor-therapy. Accordingly, the focus of most current therapies is onthe use of activated dendritic cells (DCs) as antigen-carriers for theinduction of sustained T cell responses (Nestle et al., Nat. Med. 4:328(1998)). Similarly, in vivo activators of the innate immune system, suchas CpGs or anti-CD40 antibodies, are applied together with tumor cellsin order to enhance their immunogenicity (Sotomayor, E. M., et al., Nat.Med. 5:780 (1999); Diehl, L., et al., Nat. Med. 5:774 (1999)).

Generalized activation of APCs by factors that stimulate innate immunitymay often be the cause for triggering self-specific lymphocytes andautoimmunity. Activation may result in enhanced expression ofcostimulatory molecules or cytokines such as IL-12 or IFNα. This view iscompatible with the observation that administration of LPS together withthyroid extracts is able to overcome tolerance and trigger autoimmunethyroiditis (Weigle, W. O., Adv. Immunol. 30:159 (1980)). Moreover, in atransgenic mouse model, it was recently shown that administration ofself-peptide alone failed to cause auto-immunity unless APCs wereactivated by a separate pathway (Garza, K. M., et al., J. Exp. Med.191:2021 (2000)). The link between innate immunity and autoimmunedisease is further underscored by the observation that LPS, viralinfections or generalized activation of APCs delays or prevents theestablishment of peripheral tolerance (Vella, A. T., et al., Immunity2:261 (1995); Ehl, S., et al., J. Exp. Med. 187:763 (1998); Maxwell, J.R., et al., J. Immunol. 162:2024 (1999)). In this way, innate immunitynot only enhances the activation of self-specific lymphocytes but alsoinhibits their subsequent elimination. These findings may extend totumor biology and the control of chronic viral diseases.

Induction of cytotoxic T lymphocyte (CTL) responses after immunizationwith minor histocompatibility antigens, such as the HY-antigen, requiresthe presence of T helper cells (Th cells) (Husmann, L. A., and M. J.Bevan, Ann. NY. Acad. Sci. 532:158 (1988); Guerder, S., and P.Matzinger, J. Exp. Med. 176:553 (1992)). CTL-responses induced bycross-priming, i.e. by priming with exogenous antigens that reached theclass I pathway, have also been shown to require the presence of Thcells (Bennett, S. R. M., et al., J. Exp. Med. 186:65 (1997)). Theseobservations have important consequences for tumor therapy where T helpmay be critical for the induction of protective CTL responses by tumorcells (Ossendorp, F., et al., J. Exp. Med. 187:693 (1998)).

An important effector molecule on activated Th cells is the CD40-ligand(CD40L) interacting with CD40 on B cells, macrophages and dendriticcells (DCs) (Foy, T. M., et al., Annu. Rev. Immunol. 14:591 (1996)).Triggering of CD40 on B cells is essential for isotype switching and thegeneration of B cell memory (Foy, T. M., et al., Ann. Rev. Immunol.14:591 (1996)). More recently, it was shown that stimulation of CD40 onmacrophages and DCs leads to their activation and maturation (Cella, M.,et al., Curr. Opin. Immunol. 9:10 (1997); Banchereau, J., and R. M.Steinman Nature 392:245 (1998)). Specifically, DCs upregulatecostimulatory molecules and produce cytokines such as IL-12 uponactivation. Interestingly, this CD40L-mediated maturation of DCs seemsto be responsible for the helper effect on CTL responses. In fact, ithas recently been shown that CD40-triggering by Th cells renders DCsable to initiate a CTL-response (Ridge, J. P., et al., Nature 393:474(1998); Bennett, S. R. M., et al., Nature 393:478 (1998);Schoenenberger, S. P., et al., Nature 393:480 (1998)). This isconsistent with the earlier observation that Th cells have to recognizetheir ligands on the same APC as the CTLs, indicating that a cognateinteraction is required (Bennett, S. R. M., et al., J. Exp. Med. 186:65(1997)). Thus CD40L-mediated stimulation by Th cells leads to theactivation of DCs, which subsequently are able to prime CTL-responses.In the human, type I interferons, in particular interferon α and β maybe equally important as IL-12.

In contrast to these Th-dependent CTL responses, viruses are often ableto induce protective CTL-responses in the absence of T help (for review,see (Bachmann, M. F., et al., J. Immunol. 161:5791 (1998)).Specifically, lymphocytic choriomeningitis virus (LCMV) (Leist, T. P.,et al., J. Immunol. 138:2278 (1987); Ahmed, R., et al., J. Virol.62:2102 (1988); Battegay, M., et al., Cell Immunol. 167:115 (1996);Borrow, P., et al., J. Exp. Med. 183:2129 (1996); Whitmire, J. K., etal., J. Virol. 70:8375 (1996)), vesicular stomatitis virus (VSV)(Kundig, T. M., et al., Immunity 5:41 (1996)), influenza virus (Tripp,R. A., et al., J. Immunol. 155:2955 (1995)), vaccinia virus (Leist, T.P., et al., Scand. J. Immunol. 30:679 (1989)) and ectromelia virus(Buller, R., et al., Nature 328:77 (1987)) were able to primeCTL-responses in mice depleted of CD4⁺ T cells or deficient for theexpression of class II or CD40. The mechanism for this Th cellindependent CTL-priming by viruses is presently not understood.Moreover, most viruses do not stimulate completely Th cell independentCTL-responses, but virus-specific CTL-activity is reduced in Th-celldeficient mice. Thus, Th cells may enhance anti-viral CTL-responses butthe mechanism of this help is not fully understood yet. DCs haverecently been shown to present influenza derived antigens bycross-priming (Albert, M. L., et al., J. Exp. Med. 188:1359 (1998);Albert, M. L., et al., Nature 392:86 (1998)). It is therefore possiblethat, similarly as shown for minor histocompatibility antigens and tumorantigens (Ridge, J. P., et al., Nature 393:474 (1998); Bennett, S. R.M., et al., Nature 393:478 (1998); Schoenenberger, S. P., et al., Nature393:480 (1998)), Th cells may assist induction of CTLs via CD40triggering on DCs. Thus, stimulation of CD40 using CD40L or anti-CD40antibodies may enhance CTL induction after stimulation with viruses ortumor cells.

However, although CD40L is an important activator of DCs, there seem tobe additional molecules that can stimulate maturation and activation ofDCs during immune responses. In fact, CD40 is not measurably involved inthe induction of CTLs specific for LCMV or VSV (Ruedl, C., et al., J.Exp. Med. 189:1875 (1999)). Thus, although VSV-specific CTL responsesare partly dependent upon the presence of CD4⁺ T cells (Kundig, T. M.,et al., Immunity 5:41 (1996)), this helper effect is not mediated byCD40L. Candidates for effector molecules triggering maturation of DCsduring immune responses include Trance and TNFα (Bachmann, M. F., etal., J Exp. Med. 189:1025 (1999); Sallusto, F., and A. Lanzavecchia, JExp Med 179:1109 (1994)).

It is well established that the administration of purified proteinsalone is usually not sufficient to elicit a strong immune response;isolated antigen generally must be given together with helper substancescalled adjuvants. Within these adjuvants, the administered antigen isprotected against rapid degradation, and the adjuvant provides anextended release of a low level of antigen.

Unlike isolated proteins, viruses induce prompt and efficient immuneresponses in the absence of any adjuvants both with and without T-cellhelp (Bachmann & Zinkernagel, Ann. Rev. Immunol. 15:235-270 (1997)).Although viruses often consist of few proteins, they are able to triggermuch stronger immune responses than their isolated components. For Bcell responses, it is known that one crucial factor for theimmunogenicity of viruses is the repetitiveness and order of surfaceepitopes. Many viruses exhibit a quasi-crystalline surface that displaysa regular array of epitopes which efficiently crosslinksepitope-specific immunoglobulins on B cells (Bachmann & Zinkernagel,Immunol. Today 17:553-558 (1996)). This crosslinking of surfaceimmunoglobulins on B cells is a strong activation signal that directlyinduces cell-cycle progression and the production of IgM antibodies.Further, such triggered B cells are able to activate T helper cells,which in turn induce a switch from IgM to IgG antibody production in Bcells and the generation of long-lived B cell memory—the goal of anyvaccination (Bachmann & Zinkernagel, Ann. Rev. Immunol. 15:235-270(1997)). Viral structure is even linked to the generation ofanti-antibodies in autoimmune disease and as a part of the naturalresponse to pathogens (see Fehr, T., et al., J. Exp. Med. 185:1785-1792(1997)). Thus, antigens on viral particles that are organized in anordered and repetitive array are highly immunogenic since they candirectly activate B cells.

In addition to strong B cell responses, viral particles are also able toinduce the generation of a cytotoxic T cell response, another crucialarm of the immune system. These cytotoxic T cells are particularlyimportant for the elimination of non-cytopathic viruses such as HIV orHepatitis B virus and for the eradication of tumors. Cytotoxic T cellsdo not recognize native antigens but rather recognize their degradationproducts in association with MHC class I molecules (Townsend & Bodmer,Ann. Rev. Immunol. 7:601-624 (1989)). Macrophages and dendritic cellsare able to take up and process exogenous viral particles (but not theirsoluble, isolated components) and present the generated degradationproduct to cytotoxic T cells, leading to their activation andproliferation (Kovacsovics-Bankowski et al., Proc. Natl. Acad. Sci. USA90:4942-4946 (1993); Bachmann et al., Eur. J. Immunol. 26:2595-2600(1996)).

Viral particles as antigens exhibit two advantages over their isolatedcomponents: (1) due to their highly repetitive surface structure, theyare able to directly activate B cells, leading to high antibody titersand long-lasting B cell memory; and (2) viral particles, but not solubleproteins, have the potential to induce a cytotoxic T cell response, evenif the viruses are non-infectious and adjuvants are absent.

Several new vaccine strategies exploit the inherent immunogenicity ofviruses. Some of these approaches focus on the particulate nature of thevirus particle; for example see Harding, C. V. and Song, R., (J.Immunology 153:4925 (1994)), which discloses a vaccine consisting oflatex beads and antigen; Kovacsovics-Bankowski, M., et al. (Proc. Natl.Acad. Sci. USA 90:4942-4946 (1993)), which discloses a vaccineconsisting of iron oxide beads and antigen; U.S. Pat. No. 5,334,394 toKossovsky, N., et al., which discloses core particles coated withantigen; U.S. Pat. No. 5,871,747, which discloses synthetic polymerparticles carrying on the surface one or more proteins covalently bondedthereto; and a core particle with a non-covalently bound coating, whichat least partially covers the surface of said core particle, and atleast one biologically active agent in contact with said coated coreparticle (see, e.g., WO 94/15585).

In a further development, virus-like particles (VLPs) are beingexploited in the area of vaccine production because of both theirstructural properties and their non-infectious nature. VLPs aresupermolecular structures built in a symmetric manner from many proteinmolecules of one or more types. They lack the viral genome and,therefore, are noninfectious. VLPs can often be produced in largequantities by heterologous expression and can be easily be purified.

In addition, DNA rich in non-methylated CG motifs (CpG), as present inbacteria and most non-vertebrates, exhibits a potent stimulatoryactivity on B cells, dendritic cells and other APC's in vitro as well asin vivo. Although bacterial DNA is immunostimulatory across manyvertebrate species, the individual CpG motifs may differ. In fact, CpGmotifs that stimulate mouse immune cells may not necessarily stimulatehuman immune cells and vice versa.

Although DNA oligomers rich in CpG motifs can exhibit immunostimulatorycapacity, their efficiency is often limited, since they are unstable invitro and in vivo. Thus, they exhibit unfavorable pharmacokinetics. Inorder to render CpG-oligonucleotides more potent, it is thereforeusually necessary to stabilize them by introducing phosphorothioatemodifications of the phosphate backbone.

A second limitation for the use of CpG-oligonucleotides to stimulateimmune responses is their lack of specificity, since all APC's and Bcells in contact with CpG-oligonucleotides become stimulated. Thus, theefficiency and specificity of CpG-oligonucleotides may be improved bystabilizing them or packaging them in a way that restricts cellularactivation to those cells that also present the relevant antigen.

In addition, immunostimulatory CpG-oligodeoxynucleotides induce strongside effects by causing extramedullary hemopoiesis accompanied bysplenomegaly and lymphadenopathy in mice (Sparwasser et al., J. Immunol.(1999), 162:2368-74 and Example 18).

VLPs have been shown to be efficiently presented on MHC class Imolecules as they, presumably after uptake by macropinocytosis, areefficiently processed and crossprimed onto MHC class I. The mechanism ofcrosspriming is not clear to date, but TAP-dependent and TAP-independentpathways have been proposed.

There have been remarkable advances made in vaccination strategiesrecently, yet there remains a need for improvement on existingstrategies. In particular, there remains a need in the art for thedevelopment of new and improved vaccines that promote a strong CTLimmune response and anti-pathogenic protection as efficiently as naturalpathogens in the absence of generalized activation of APCs and othercells.

SUMMARY OF THE INVENTION

This invention is based on the surprising finding that immunostimulatorysubstances such as DNA oligonucleotides can be packaged into VLPs whichrenders them more immunogenic. Unexpectedly, the nucleic acids andoligonucleotides, respectively, present in VLPs can be replacedspecifically by the immunostimulatory substances andDNA-oligonucleotides containing CpG motifs, respectively. Surprisingly,these packaged immunostimulatory substances, in particularimmunostimulatory nucleic acids such as unmethylated CpG-containingoligonucleotides retained their immunostimulatory capacity withoutwidespread activation of the innate immune system. The compositionscomprising VLP's and the immunostimulatory substances in accordance withthe present invention, and in particular the CpG-VLPs are dramaticallymore immunogenic than their CpG-free counterparts and induce enhanced Band T cell responses. The immune response against antigens optionallycoupled, fused or attached otherwise to the VLPs is similarly enhancedas the immune response against the VLP itself. In addition, the T cellresponses against both the VLPs and antigens are especially directed tothe Th1 type. Antigens attached to CpG-loaded VLPs may therefore beideal vaccines for prophylactic or therapeutic vaccination againstallergies, tumors and other self-molecules and chronic viral diseases.

In a first embodiment, the invention provides a composition forenhancing an immune response in an animal comprising a virus-likeparticle and an immunostimulatory substance, preferably animmunostimulatory nucleic acid, an even more preferably an unmethylatedCpG-containing oligonucleotide, where the substance, nucleic acid oroligonucleotide is coupled, fused, or otherwise attached to or enclosedby, i.e., bound, to the virus-like particle. In another embodiment, thecomposition further comprises an antigen bound to the virus-likeparticle.

In a preferred embodiment of the invention, the immunostimulatorynucleic acids, in particular the unmethylated CpG-containingoligonucleotides are stabilized by phosphorothioate modifications of thephosphate backbone. In another preferred embodiment, theimmunostimulatory nucleic acids, in particular the unmethylatedCpG-containing oligonucleotides are packaged into the VLPs by digestionof RNA within the VLPs and simultaneous addition of the DNAoligonucleotides containing CpGs of choice. In an equally preferredembodiment, the VLPs can be disassembled before they are reassembled inthe presence of CpGs.

In a further preferred embodiment, the immunostimulatory nucleic acidsdo not contain CpG motifs but nevertheless exhibit immunostimulatoryactivities. Such nucleic acids are described in WO 01/22972. Allsequences described therein are hereby incorporated by way of reference.

In a further preferred embodiment, the virus-like particle is arecombinant virus-like particle. Also preferred, the virus-like particleis free of a lipoprotein envelope. Preferably, the recombinantvirus-like particle comprises, or alternatively consists of, recombinantproteins of Hepatitis B virus, BK virus or other human Polyoma virus,measles virus, Sindbis virus, Rotavirus, Foot-and-Mouth-Disease virus,Retrovirus, Norwalk virus or human Papilloma virus, RNA-phages,Qβ-phage, GA-phage, fr-phage and Ty. In a specific embodiment, thevirus-like particle comprises, or alternatively consists of, one or moredifferent Hepatitis B virus core (capsid) proteins (HBcAgs).

In a further preferred embodiment, the virus-like particle comprisesrecombinant proteins, or fragments thereof, of a RNA-phage. PreferredRNA-phages are Qβ-phage, AP 205-phage, GA-phage, fr-phage

In another embodiment, the antigen is a recombinant antigen. In yetanother embodiment, the antigen can be selected from the groupconsisting of: (1) a polypeptide suited to induce an immune responseagainst cancer cells; (2) a polypeptide suited to induce an immuneresponse against infectious diseases; (3) a polypeptide suited to inducean immune response against allergens; (4) a polypeptide suited to inducean improved response against self-antigens; and (5) a polypeptide suitedto induce an immune response in farm animals or pets.

In yet another embodiment, the antigen can be selected from the groupconsisting of: (1) an organic molecule suited to induce an immuneresponse against cancer cells; (2) an organic molecule suited to inducean immune response against infectious diseases; (3) an organic moleculesuited to induce an immune response against allergens; (4) an organicmolecule suited to induce an improved response against self-antigens;(5) an organic molecule suited to induce an immune response in farmanimals or pets; and (6) an organic molecule suited to induce a responseagainst a drug, a hormone or a toxic compound.

In a particular embodiment, the antigen comprises, or alternativelyconsists of, a cytotoxic T cell epitope. In a related embodiment, thevirus-like particle comprises the Hepatitis B virus core protein and thecytotoxic T cell epitope is fused to the C-terminus of said Hepatitis Bvirus core protein. In one embodiment, they are fused by a leucinelinking sequence.

In another aspect of the invention, there is provided a method ofenhancing an immune response in a human or other animal speciescomprising introducing into the animal a composition comprising avirus-like particle and immunostimulatory substance, preferably animmunostimulatory nucleic acid, an even more preferably an unmethylatedCpG-containing oligonucleotide where the substance, preferably thenucleic acid, and even more preferably the oligonucleotide is bound(i.e. coupled, attached or enclosed) to the virus-like particle. In afurther embodiment, the composition further comprises an antigen boundto the virus-like particle.

In yet another embodiment of the invention, the composition isintroduced into an animal subcutaneously, intramuscularly, intranasally,intradermally, intravenously or directly into a lymph node. In anequally preferred embodiment, the immune enhancing composition isapplied locally, near a tumor or local viral reservoir against which onewould like to vaccinate.

In a preferred aspect of the invention, the immune response is a T cellresponse, and the T cell response against the antigen is enhanced. In aspecific embodiment, the T cell response is a cytotoxic T cell response,and the cytotoxic T cell response against the antigen is enhanced.

The present invention also relates to a vaccine comprising animmunologically effective amount of the immune enhancing composition ofthe present invention together with a pharmaceutically acceptablediluent, carrier or excipient. In a preferred embodiment, the vaccinefurther comprises at least one adjuvant, such as incomplete Freund'sadjuvant. The invention also provides a method of immunizing and/ortreating an animal comprising administering to the animal animmunologically effective amount of the disclosed vaccine.

In a preferred embodiment of the invention, the immunostimulatorysubstance-containing VLPs, preferably the immunostimulatory nucleicacid-containing VLP's, an even more preferably the unmethylatedCpG-containing oligonucleotide VLPs are used for vaccination of animalsor humans against the VLP itself or against antigens coupled, fused orattached otherwise to the VLP. The modified VLPs can be used tovaccinate against tumors, viral diseases, self-molecules and selfantigens, respectively, or non-peptidic small molecules, for example.The vaccination can be for prophylactic or therapeutic purposes, orboth. Also, the modified VLPs can be used to vaccinate against allergiesin order to induce immune-deviation.

In the majority of cases, the desired immune response will be directedagainst antigens coupled, fused or attached otherwise to theimmunostimulatory substance-containing VLPs, preferably theimmunostimulatory nucleic acid-containing VLP's, an even more preferablythe unmethylated CpG-containing oligonucleotide VLPs. The antigens canbe peptides, proteins, domains, carbohydrates or small molecules suchas, for example, steroid hormones or drugs, such as nicotine. Under someconditions, the desired immune response can be directed against the VLPitself. This latter application will be used in cases where the VLPoriginates from a virus against which one would like to vaccinate.

The route of injection is preferably subcutaneous or intramuscular, butit would also be possible to apply the CpG-containing VLPsintradermally, intranasally, intravenously or directly into the lymphnode. In an equally preferred embodiment, the CpG-containingantigen-coupled or free VLPs are applied locally, near a tumor or localviral reservoir against which one would like to vaccinate.

It is to be understood that both the foregoing general description andthe following detailed description are exemplary and explanatory onlyand are intended to provide further explanation of the invention asclaimed.

BRIEF DESCRIPTION OF THE DRAWINGS/FIGURES

FIGS. 1A and 1B show the DNA sequence of the CpG-oligonucleotide (SEQ IDNO:109) (FIG. 1A) and the DNA sequence (SEQ ID NO:1) and thecorresponding protein sequence (SEQ ID NO:2) of the peptidep33-containing VLP derived from hepatitis B core (FIG. 1B). Thenonameric p33 epitope is genetically fused to the C-terminus of thehepatitis B core protein at position 185 via a three leucine linkingsequence.

FIGS. 2A and 2B show the structure of the p33-VLPs as assessed byelectron microscopy (FIG. 2A) and SDS PAGE (FIG. 2B). Recombinantlyproduced wild-type VLPs (composed of HBcAg [aa 1-185] monomers) andp33-VLPs were loaded onto a Sephacryl S-400 gel filtration column(Amersham Pharmacia Biotechnology AG) for purification. Pooled fractionswere loaded onto a Hydroxyapatite column. Flow through (which containspurified HBc capsids) was collected and loaded onto a reducing SDS-PAGEgel for monomer molecular weight analysis (FIG. 2B).

FIGS. 3A and 3B show p33-VLPs in a native agarose gel electrophoresis(1% agarose) after control incubation or after digestion with RNase Aupon staining with ethidium bromide (FIG. 3A) or Coomassie blue (FIG.3B) in order to assess for the presence of RNA or protein. Recombinantlyproduced p33-VLPs were diluted at a final concentration of 0.5 ug/ulprotein in PBS buffer and incubated in the absence (lane 1) or presence(lane 2) of RNase A (100 ug/ml) (Sigma, Division of Fluka AG,Switzerland) for 2 h at 37° C. The samples were subsequentlycomplemented with 6-fold concentrated DNA-loading buffer (MBS FermentasGmbH, Heidelberg, Germany) and run for 30 min at 100 volts in a 1%native agarose gel. The Gene Ruler marker (MBS Fermentas GmbH,Heidelberg, Germany) was used as reference for p33-VLPs migrationvelocity (lane M). Arrows are indicating the presence of RNA packaged inp33-VLPs (FIG. 3A) or p33-VLP capsids themselves (FIG. 3B). Identicalresults were obtained in 3 independent experiments.

FIGS. 4A and 4B show p33-VLPs in a native agarose gel electrophoresis(1% agarose) after control incubation or after digestion with RNase A inthe presence of buffer only or CpG-containing DNA-oligomers uponstaining with ethidium bromide (FIG. 4A) or Coomassie blue (FIG. 4B) inorder to assess for the presence of RNA/DNA or protein. Recombinantp33-VLPs were diluted at a final concentration of 0.5 ug/ul protein inPBS buffer and incubated in the absence (lane 1) or presence (lane 2 and3) of RNase A (100 ug/ml) (Sigma, Division of Fluka AG, Switzerland) for2 h at 37° C. 5 nmol CpG-oligonucleotides (containing phosphorothioatemodification of the backbone) were added to sample 3 before RNase Adigestion. The Gene Ruler marker (MBS Fermentas GmbH, Heidelberg,Germany) was used as reference for p33-VLPs migration velocity (lane M).Arrows are indicating the presence of RNA or CpG-oligonucleotides inp33-VLPs (FIG. 4A) or p33-VLPs capsids themselves (FIG. 4B). Identicalresults were obtained when CpG oligonucleotides with phosphodiesterbonds were used for co-incubation of VLPs with RNase A.

FIGS. 5A and 5B show p33-VLPs in a native agarose gel electrophoresis(1% agarose) before and after digestion with RNase A in the presence ofCpG-containing DNA-oligomers and subsequent dialysis (for theelimination of VLP-unbound CpG DNA) upon staining with ethidium bromide(FIG. 5A) or Coomassie blue (FIG. 5B) in order to assess for thepresence of DNA or protein. Recombinant p33-VLPs were diluted at a finalconcentration of 0.5 ug/ul protein in PBS buffer and incubated inabsence (lane 1) or in presence (lanes 2 to 5) of RNase A (100 ug/ml)(Sigma, Division of Fluka AG, Switzerland) for 2 h at 37° C. 50 nmolCpG-oligonucleotides (containing phosphorothioate modification of thephosphate backbone: lanes 2 and 3, containing phosphodiester bonds:lanes 4 and 5) were added to VLPs before RNase A digestion. Treatedsamples were extensively dialysed for 24 hours against PBS (4500-folddilution) with a 300 kDa MWCO dialysis membrane (Spectrum MedicalIndustries Inc., Houston, USA) to eliminate the in excess DNA (lanes 3and 5). The Gene Ruler marker (MBS Fermentas GmbH, Heidelberg, Germany)was used as reference for p33-VLPs migration velocity (lane M). Arrowsare indicating the presence of RNA or CpG-oligonucleotides in p33-VLPs(FIG. 5A) or p33-VLP capsids themselves (FIG. 5B).

FIGS. 6A and 6B show p33-VLPs in a native agarose gel electrophoresis(1% agarose) after control incubation or after digestion with RNase Awhere CpG-containing oligonucleotides were added only after completingthe RNA digestion upon staining with ethidium bromide (FIG. 6A) orCoomassie blue (FIG. 6B) in order to assess for the presence of RNA/DNAor protein. Recombinant p33-VLPs were diluted at a final concentrationof 0.5 ug/ul protein in PBS buffer and incubated in the absence (lane 1)or presence (lane 2 and 3) of RNase A (100 ug/ml) (Sigma, Division ofFluka AG, Switzerland) for 2 h at 37° C. 5 nmol CpG-oligonucleotides(containing phosphorothioate modification of the phosphate backbone)were added to sample 3 only after the RNase A digestion. The Gene Rulermarker (MBS Fermentas GmbH, Heidelberg, Germany) was used as referencefor p33-VLPs migration velocity (lane M). Arrows are indicating thepresence of RNA or CpG-oligonucleotides in p33-VLPs (FIG. 6A) or p33-VLPcapsids themselves (FIG. 6B). Identical results were obtained when CpGoligonucleotides with phosphodiester bonds were used for reassembly ofVLPs.

FIG. 7 shows that p33-VLPs packaged with CpG-oligonucleotides(containing phosphorothioate modification of the phosphate backbone),are effective at inducing viral protection. Mice were subcutaneouslyprimed with 100 μg p33-VLP alone, mixed with 20 nmol CpG-oligonucleotide(p33-VLP+CpG) or p33-VLP packaged with CpG-oligonucleotide afterdialysis of free CpG-oligonucleotide (p33-VLP/CpG). Untreated naïve miceserved as negative control. Twenty-one days later, mice were challengedwith LCMV (200 pfu, intravenously) and viral titers were assessed in thespleens 5 days later as described in Bachmann, M. F., “Evaluation oflymphocytic choriomeningitis virus-specific cytotoxic T cell responses,”in Immunology Methods Manual, Lefkowitz, I., ed., Academic Press Ltd.,New York, N.Y. (1997) p. 1921.

FIG. 8 shows that p33-VLPs packaged with CpG-oligonucleotide (containingphosphodiester bonds) are effective at inducing viral protection. Micewere subcutaneously primed with 100 μg p33-VLP alone, mixed with 20 nmolCpG-oligonucleotides (p33-VLP+CpG) or p33-VLPs packaged withCpG-oligonucleotides after dialysis of free CpG-oligonucleotides)(p33-VLP/CpG). Untreated naïve mice served as negative control.Twenty-one days later, mice were challenged with LCMV (200 pfu,intravenously) and viral titers were assessed in the spleens 5 dayslater as described in Bachmann, M. F., “Evaluation of lymphocyticchoriomeningitis virus-specific cytotoxic T cell responses,” inImmunology Methods Manual, Lefkowitz, I., ed., Academic Press Ltd., NewYork, N.Y. (1997) p. 1921.

FIG. 9 shows that mice treated with CpG-oligonucleotides alone are notprotected from viral infection. Mice were subcutaneously primed with 20nmol CpG-oligonucleotides (CpG), or left untreated as negative control(naive). Twenty-one days later, mice were challenged with LCMV (200 pfu,intravenously) and viral titers were assessed in the spleens 5 dayslater as described in Bachmann, M. F., “Evaluation of lymphocyticchoriomeningitis virus-specific cytotoxic T cell responses,” inImmunology Methods Manual, Lefkowitz, I., ed., Academic Press Ltd., NewYork, N.Y. (1997) p. 1921.

FIG. 10 shows the amino acid sequence of the BKV (AS) VP1 protein(GI:332779, SEQ ID NO:3). This sequence was expressed in yeast toproduce BKV capsids (Sasnauskas K. et al., J. Biol Chem 380(3):381(1999); K. et al., Generation of recombinant virus-like particles ofdifferent polyomaviruses in yeast. 3^(rd) International Workshop“Virus-like particles as vaccines” Berlin, (2001)).

FIG. 11 shows the DNA sequence of the 246 bp double stranded DNAfragment (SEQ ID NO:4) used for packaging and stabilization of BKV VLPs.

FIGS. 12A and 12B show BKV VLPs (15 μg) in a native 0.8% agarose gelelectrophoresis after control incubation or after digestion with RNase Aand subsequent incubation with fluorescent phosphorothioate (pt)CpG-oligonucleotides. UV excitation leads to detection of DNA in anethidium bromide stained gel (FIG. 12A) and to fluorescence of CpG-FAMoligomers in the absence of ethidium bromide (FIG. 12B). Lane 1: BKVVLPs untreated; lane 2: BKV VLPs RNase A treated; lane 3: BKV VLPs RNaseA treated with CpG(pt)-FAM; lane 4: BKV VLPs RNase A treated withCpG(pt)-FAM plus DNaseI treatment; lane M: Gene Ruler 1 kb DNA ladder(MBI Fermentas GmbH, Heidelberg, Germany). Arrows are indicating thepresence of RNA or CpG-FAM oligomers in BKV VLPs.

FIGS. 13A and 13B show BKV VLPs (15 μg) in a native 0.8% agarose gelelectrophoresis after control incubation or after digestion with RNase Aand subsequent incubation with double stranded (ds) DNA (246 bp) uponstaining with ethidium bromide (FIG. 13A) or Coomassie Blue (FIG. 13B).Lane 1: BKV VLPs untreated; lane 2: BKV VLPs RNase A treated; lane 3:BKV VLPs treated with RNase A and incubated with ds DNA; lane M: GeneRuler 1 kb DNA ladder (MBI Fermentas GmbH, Heidelberg, Germany). Arrowsindicate the presence of RNA or ds DNA in BKV VLPs.

FIGS. 14A and 14B show BKV VLPs (15 μg) in a native 0.8% agarose gelelectrophoresis after control incubation or after digestion with RNase Aand subsequent incubation with CpG-oligonucleotides (with phosphate- orwith phosphorothioate (pt) backbone) upon staining with ethidium bromide(FIG. 14A) or Coomassie Blue (FIG. 14B). Lane 1: BKV VLPs stock (PBS/50%glycerol); lane 2: BKV VLPs untreated (PBS buffer); lane 3: BKV VLPsRNase A treated; lane 4: BKV VLPs RNase A treated post-dialysis; lane 5:BKV VLPs RNase A treated with CpG-oligonucleotides; lane 6: BKV VLPsRNase A treated with CpG(pt)-oligomers; lane 7: BKV VLPs RNase A treatedwith CpG(pt)-oligomers post-dialysis; lane M: Gene Ruler 1 kb DNA ladder(MBI Fermentas GmbH, Heidelberg, Germany). Arrows indicate the presenceof RNA or CpG-oligonucleotides in BKV VLPs.

FIGS. 15A and 15B show mouse IgG1 and IgG2a OD50% antibody titers to BKVVLPs on day 14 after immunization with BKV VLPs and phosphorothioate(pt) CpG-oligonucleotides. Lane 1: RNase treated BKV VLPs; lane 2: RNasetreated BKV VLPs in combination with 0.3 nmol CpG(pt)-oligomer; lane 3:RNase treated BKV VLPs in combination with 20 nmol CpG(pt)-oligomer;lane 4: RNase treated BKV VLPs containing 0.3 nmol CpG(pt)-oligomer.

FIGS. 16A and 16B show p33-VLPs in a native agarose gel electrophoresis(1% agarose) after control incubation or after digestion with RNase Awhere linear double-stranded DNA (350 base pairs long) was added onlyafter completing the RNA digestion upon staining with ethidium bromide(FIG. 16A) or Coomassie blue (FIG. 16B) in order to assess for thepresence of RNA/DNA or protein. Recombinant p33-VLPs were diluted at afinal concentration of 0.5 ug/ul protein in PBS buffer and incubated inthe absence (lane 1) or presence (lanes 2, 3 and 4) of RNase A (100ug/ml) (Sigma, Division of Fluka AG, Switzerland) for 2 h at 37° C.Linear double-stranded DNA of 350 bp in length was added to sample 3 and4 only after the RNase A digestion to a final concentration of 100 ng/mland incubated for 3 hours at 37° C. Sample 4 was further digested withDNase I (50 IU/ml)(Sigma, Division of Fluka AG, Switzerland) foradditional 3 hours at 37° C. The Gene Ruler marker (MBS Fermentas GmbH,Heidelberg, Germany) was used as reference for p33-VLPs migrationvelocity (lane M). Arrows are indicating the presence of RNA/dsDNA freeor enclosed in p33-VLPs (FIG. 16A) and p33-VLPs (FIG. 16B).

FIGS. 17A, 17B, and 17C show packaging of B-CpG (SEQ ID NO: 112) intoHBc33 VLPs.

FIGS. 18A, 18B, and 18C show packaging of NKCpG (SEQ ID NO:114) intoHBc33 VLPs.

FIGS. 19A and 19B show packaging of g10gacga-PO (SEQ ID NO:116) intoHBc33 VLPs.

FIGS. 20A, 20B, and 20C show packaging of CyCpG-150 (SEQ ID NO:123) intoHBc33 VLPs.

FIGS. 21A and 21B show packaging of NKCpGpt (SEQ ID NO:113) into HBcP1AVLPs.

FIG. 22 shows coupling of p33 to HBcAg VLPs.

FIGS. 23A and 23B show packaging of B-CpGpt (SEQ ID NO:111) into HBx33VLPs.

FIGS. 24A and 24B show coupling of p33 to Qβ VLPs.

FIGS. 25A, 25B, 25C, and 25D show ionic strength and low proteinconcentration allow RNA hydrolysis by RNase A in Qβ VLPs.

FIGS. 26A and 26B show ionic strength increases immunostimulatorynucleic acid packaging into Qβ VLPs.

FIGS. 27A, 27B, 27C, 27D, 27E, 27F, and 27G show packaging of B-CpGpt(SEQ ID NO:111), g10gacga-PO (SEQ ID NO:116) and dsCyCpG (SEQ ID NO:124)into Qbx33 VLPs.

FIG. 28 shows SDS-PAGE analysis of the fractions from the sucrosegradient centrifugation after Qβ VLP disassembly and reassembly in thepresence of immunostimulatory nucleic acids.

FIGS. 29A and 29B show electron micrographs of Qβ VLP after disassemblyand reassembly in the presence of oligonucleotide (CpG)₂₀OpA (SEQ IDNO:120).

FIGS. 30A and 30B show ouchterlony analysis (immunodiffusion) of thediassembled and reassembled Qβ VLP.

FIGS. 31A and 31B show gelelectrophoretic analysis of disassembled andreassembled Qβ VLP.

FIG. 32 shows electron micrographs of the disassembled and reassembledQβ VLP with the oligonucleotide CyOpA (SEQ ID NO:121).

FIGS. 33A, 33B, 33C, and 33D show electron micrographs of the purifieddisassembled and reassembled Qβ VLP with the different immunostimulatorynucleic acids.

FIG. 34 shows SDS-PAGE analysis of the coupling of Qβ VLP reassembledwith the oligodeoxynucleotide CyOpA (SEQ ID NO:121) to the p33GGCpeptide.

FIG. 35 shows packaged oligodeoxynucleotides after disassembly andreassembly of Qβ VLPs and subsequent coupling to p33 GGC peptide.

FIGS. 36A, 36B, 36C, 36D, 36E, 36F, 36G, and 36H show purification ofdisassembled Qβ coat protein by size exclusion chromatography.

FIGS. 37A, 37B, 37C, and 37D show purification of reassembled Qβ VLPs bysize exclusion chromatography.

FIG. 38 shows electron micrographs of Qβ VLPs that were reassembled inthe presence of different oligodeoxynucleotides.

FIG. 39 shows analysis of the disulfide-bond pattern in reassembled andpurified Qβ capsids.

FIGS. 40A and 40B show analysis of nucleic acid content of thereassembled Qβ VLPs by nuclease treatment and agarosegelelectrophoresis.

FIG. 41 shows analysis of nucleic acid content of the reassembled QβVLPs by proteinase K treatment and polyacrylamide TBE/Ureagelelectrophoresis.

FIGS. 42A and 42B show electron micrographs AP205 VLP disassembled andsubsequently reassembled in the presence of CyCpG (SEQ ID NO:110).

FIGS. 43A and 43B show agarose gel-electrophoresis analysis of AP205VLPs diassembled and reassembled in the presence of CyCpG (SEQ IDNO:110).

FIGS. 44A, 44B, and 44C show electron micrograph of disassembled andreassembled AP205.

FIGS. 45A and 45B show Agarose gel-electrophoresis analysis of AP205VLPs diassembled and reassembled in the presence of CyCpG (SEQ IDNO:110).

FIG. 46 shows SDS-PAGE analysis of disassembled and reassembled AP205VLPs.

FIG. 47 shows SDS-PAGE analysis of the peptide coupling to disassembledand reassembled AP205 VLPs.

FIGS. 48A and 48B show free immunostimulatory nucleic acids but notimmunostimulatory nucleic acids packaged in VLPs induce splenomegaly.

FIG. 49 shows different immunostimulatory nucleic acids packaged in VLPfused to antigen result in a potent antigen-specific CTL response andvirus protection.

FIG. 50 shows the immunostimulatory nucleic acid g10gacga-PS (SEQ IDNO:117) packaged in VLP fused to antigen result in a potentantigen-specific CTL response and virus protection.

FIG. 51 shows immunostimulatory nucleic acids packaged in HBcAg and QβVLPs result in a potent antigen-specific CTL response and virusprotection.

FIGS. 52A, 52B, and 52C show immunostimulatory nucleic acids packaged inVLPs are even more efficient in inducing CTL responses than VLPs mixedwith immunostimulatory nucleic acids.

FIG. 53 shows analysis of non-enzymatic RNA hydrolysis of the RNA in QβVLPs.

FIG. 54 shows packaging of oligodeoxynucleotides into Qβ VLPs afternon-enzymatic RNA hydrolysis.

FIG. 55 shows analysis of packaging of oligodeoxynucleotides into QβVLPs after non-enzymatic RNA hydrolysis.

DETAILED DESCRIPTION OF THE INVENTION

Unless defined otherwise, all technical and scientific terms used hereinhave the same meanings as commonly understood by one of ordinary skillin the art to which this invention belongs. Although any methods andmaterials similar or equivalent to those described herein can be used inthe practice or testing of the present invention, the preferred methodsand materials are hereinafter described.

1. Definitions

Amino acid linker: An “amino acid linker”, or also just termed “linker”within this specification, as used herein, either associates the antigenor antigenic determinant with the second attachment site, or morepreferably, already comprises or contains the second attachment site,typically—but not necessarily—as one amino acid residue, preferably as acysteine residue. The term “amino acid linker” as used herein, however,does not intend to imply that such an amino acid linker consistsexclusively of amino acid residues, even if an amino acid linkerconsisting of amino acid residues is a preferred embodiment of thepresent invention. The amino acid residues of the amino acid linker are,preferably, composed of naturally occurring amino acids or unnaturalamino acids known in the art, all-L or all-D or mixtures thereof.However, an amino acid linker comprising a molecule with a sulfhydrylgroup or cysteine residue is also encompassed within the invention. Sucha molecule comprise preferably a C1-C6 alkyl-, cycloalkyl (C5, C6), arylor heteroaryl moiety. However, in addition to an amino acid linker, alinker comprising preferably a C1-C6 alkyl-, cycloalkyl-(C5, C6), aryl-or heteroaryl-moiety and devoid of any amino acid(s) shall also beencompassed within the scope of the invention. Association between theantigen or antigenic determinant or optionally the second attachmentsite and the amino acid linker is preferably by way of at least onecovalent bond, more preferably by way of at least one peptide bond.

Animal: As used herein, the term “animal” is meant to include, forexample, humans, sheep, horses, cattle, pigs, dogs, cats, rats, mice,mammals, birds, reptiles, fish, insects and arachnids.

Antibody: As used herein, the term “antibody” refers to molecules whichare capable of binding an epitope or antigenic determinant. The term ismeant to include whole antibodies and antigen-binding fragments thereof,including single-chain antibodies. Most preferably the antibodies arehuman antigen binding antibody fragments and include, but are notlimited to, Fab, Fab′ and F(ab′)2, Fd, single-chain Fvs (scFv),single-chain antibodies, disulfide-linked Fvs (sdFv) and fragmentscomprising either a V_(L) or V_(H) domain. The antibodies can be fromany animal origin including birds and mammals. Preferably, theantibodies are human, murine, rabbit, goat, guinea pig, camel, horse orchicken. As used herein, “human” antibodies include antibodies havingthe amino acid sequence of a human immunoglobulin and include antibodiesisolated from human immunoglobulin libraries or from animals transgenicfor one or more human immunoglobulins and that do not express endogenousimmunoglobulins, as described, for example, in U.S. Pat. No. 5,939,598by Kucherlapati et al.

Antigen: As used herein, the term “antigen” refers to a molecule capableof being bound by an antibody or a T cell receptor (TCR) if presented byMHC molecules. The term “antigen”, as used herein, also encompassesT-cell epitopes. An antigen is additionally capable of being recognizedby the immune system and/or being capable of inducing a humoral immuneresponse and/or cellular immune response leading to the activation of B-and/or T-lymphocytes. This may, however, require that, at least incertain cases, the antigen contains or is linked to a Th cell epitopeand is given in adjuvant. An antigen can have one or more epitopes (B-and T-epitopes). The specific reaction referred to above is meant toindicate that the antigen will preferably react, typically in a highlyselective manner, with its corresponding antibody or TCR and not withthe multitude of other antibodies or TCRs which may be evoked by otherantigens.

A “microbial antigen” as used herein is an antigen of a microorganismand includes, but is not limited to, infectious virus, infectiousbacteria, parasites and infectious fungi. Such antigens include theintact microorganism as well as natural isolates and fragments orderivatives thereof and also synthetic or recombinant compounds whichare identical to or similar to natural microorganism antigens and inducean immune response specific for that microorganism. A compound issimilar to a natural microorganism antigen if it induces an immuneresponse (humoral and/or cellular) to a natural microorganism antigen.Such antigens are used routinely in the art and are well known to theskilled artisan.

Examples of infectious viruses that have been found in humans includebut are not limited to: Retroviridae (e.g. human immunodeficiencyviruses, such as HIV-1 (also referred to as HTLV-III, LAV orHTLV-III/LAV, or HIV-III); and other isolates, such as HIV-LP);Picornaviridae (e.g. polio viruses, hepatitis A virus; enteroviruses,human Coxsackie viruses, rhinoviruses, echoviruses); Calciviridae (e.g.strains that cause gastroenteritis); Togaviridae (e.g. equineencephalitis viruses, rubella viruses); Flaviridae (e.g. dengue viruses,encephalitis viruses, yellow fever viruses); Coronoviridae (e.g.coronaviruses); Rhabdoviradae (e.g. vesicular stomatitis viruses, rabiesviruses); Filoviridae (e.g. ebola viruses); Paramyxoviridae (e.g.parainfluenza viruses, mumps virus, measles virus, respiratory syncytialvirus); Orthomyxoviridae (e.g. influenza viruses); Bungaviridae (e.g.Hantaan viruses, bunga viruses, phleboviruses and Nairo viruses); Arenaviridae (hemorrhagic fever viruses); Reoviridae (e.g. reoviruses,orbiviurses and rotaviruses); Birnaviridae; Hepadnaviridae (Hepatitis Bvirus); Parvovirida (parvoviruses); Papovaviridae (papilloma viruses,polyoma viruses); Adenoviridae (most adenoviruses); Herpesviridae(herpes simplex virus (HSV) 1 and 2, varicella zoster virus,cytomegalovirus (CMV), herpes virus); Poxviridae (variola viruses,vaccinia viruses, pox viruses); and Iridoviridae (e.g. African swinefever virus); and unclassified viruses (e.g. the etiological agents ofSpongiform encephalopathies, the agent of delta hepatitis (thought to bea defective satellite of hepatitis B virus), the agents of non-A, non-Bhepatitis (class 1=internally transmitted; class 2=parenterallytransmitted (i.e. Hepatitis C); Norwalk and related viruses, andastroviruses).

Both gram negative and gram positive bacteria serve as antigens invertebrate animals. Such gram positive bacteria include, but are notlimited to, Pasteurella species, Staphylococci species and Streptococcusspecies. Gram negative bacteria include, but are not limited to,Escherichia coli, Pseudomonas species, and Salmonella species. Specificexamples of infectious bacteria include but are not limited to:Helicobacter pyloris, Borelia burgdorferi, Legionella pneumophilia,Mycobacteria sps. (e.g. M. tuberculosis, M. avium, M. intracellulare, M.kansaii, M. gordonae), Staphylococcus aureus, Neisseria gonorrhoeae,Neisseria meningitidis, Listeria monocytogenes, Streptococcus pyogenes(Group A Streptococcus), Streptococcus agalactiae (Group BStreptococcus), Streptococcus (viridans group), Streptococcus faecalis,Streptococcus bovis, Streptococcus (anaerobic sps.), Streptococcuspneumoniae, pathogenic Campylobacter sp., Enterococcus sp., Haemophilusinfluenzae, Bacillus antracis, Corynebacterium diphtheriae,Corynebacterium sp., Erysipelothrix rhusiopathiae, Clostridiumperfringens, Clostridium tetani, Enterobacter aerogenes, Klebsiellapneumoniae, Pasturella multocida, Bacteroides sp., Fusobacteriumnucleatum, Streptobacillus moniliformis, Treponema pallidium, Treponemapertenue, Leptospira, Rickettsia, Actinomyces israelli and Chlamydia.

Examples of infectious fungi include: Cryptococcus neoformans,Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis,Chlamydia trachomatis and Candida albicans. Other infectious organisms(i.e., protists) include: Plasmodium such as Plasmodium falciparum,Plasmodium malariae, Plasmodium ovale, Plasmodium vivax, Toxoplasmagondii and Shistosoma.

Other medically relevant microorganisms have been descried extensivelyin the literature, e.g., see C. G. A. Thomas, “Medical Microbiology”,Bailliere Tindall, Great Britain 1983, the entire contents of which ishereby incorporated by reference.

The compositions and methods of the invention are also useful fortreating cancer by stimulating an antigen-specific immune responseagainst a cancer antigen. A “tumor antigen” as used herein is acompound, such as a peptide, associated with a tumor or cancer and whichis capable of provoking an immune response. In particular, the compoundis capable of provoking an immune response when presented in the contextof an MHC molecule. Tumor antigens can be prepared from cancer cellseither by preparing crude extracts of cancer cells, for example, asdescribed in Cohen, et al., Cancer Research, 54:1055 (1994), bypartially purifying the antigens, by recombinant technology or by denovo synthesis of known antigens. Tumor antigens include antigens thatare antigenic portions of or are a whole tumor or cancer polypeptide.Such antigens can be isolated or prepared recombinantly or by any othermeans known in the art. Cancers or tumors include, but are not limitedto, biliary tract cancer; brain cancer; breast cancer; cervical cancer;choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer;gastric cancer; intraepithelial neoplasms; lymphomas; liver cancer; lungcancer (e.g. small cell and non-small cell); melanoma; neuroblastomas;oral cancer; ovarian cancer; pancreas cancer; prostate cancer; rectalcancer; sarcomas; skin cancer; testicular cancer; thyroid cancer; andrenal cancer, as well as other carcinomas and sarcomas.

Antigenic determinant: As used herein, the term “antigenic determinant”is meant to refer to that portion of an antigen that is specificallyrecognized by either B- or T-lymphocytes. B-lymphocytes respond toforeign antigenic determinants via antibody production, whereasT-lymphocytes are the mediator of cellular immunity. Thus, antigenicdeterminants or epitopes are those parts of an antigen that arerecognized by antibodies, or in the context of an MHC, by T-cellreceptors.

Antigen presenting cell: As used herein, the term “antigen presentingcell” is meant to refer to a heterogenous population of leucocytes orbone marrow derived cells which possess an immunostimulatory capacity.For example, these cells are capable of generating peptides bound to MHCmolecules that can be recognized by T cells. The term is synonymous withthe term “accessory cell” and includes, for example, Langerhans' cells,interdigitating cells, B cells, macrophages and dendritic cells. Undersome conditions, epithetral cells, endothelial cells and other, non-bonemarrow derived cells may also serve as antigen presenting cells.

Association: As used herein, the term “association” as it applies to thefirst and second attachment sites, refers to the binding of the firstand second attachment sites that is preferably by way of at least onenon-peptide bond. The nature of the association may be covalent, ionic,hydrophobic, polar or any combination thereof, preferably the nature ofthe association is covalent.

Attachment Site, First: As used herein, the phrase “first attachmentsite” refers to an element of non-natural or natural origin, to whichthe second attachment site located on the antigen or antigenicdeterminant may associate. The first attachment site may be a protein, apolypeptide, an amino acid, a peptide, a sugar, a polynucleotide, anatural or synthetic polymer, a secondary metabolite or compound(biotin, fluorescein, retinol, digoxigenin, metal ions,phenylmethylsulfonylfluoride), or a combination thereof, or a chemicallyreactive group thereof. The first attachment site is located, typicallyand preferably on the surface, of the virus-like particle. Multiplefirst attachment sites are present on the surface of virus-like particletypically in a repetitive configuration.

Attachment Site, Second: As used herein, the phrase “second attachmentsite” refers to an element associated with the antigen or antigenicdeterminant to which the first attachment site located on the surface ofthe virus-like particle may associate. The second attachment site of theantigen or antigenic determinant may be a protein, a polypeptide, apeptide, a sugar, a polynucleotide, a natural or synthetic polymer, asecondary metabolite or compound (biotin, fluorescein, retinol,digoxigenin, metal ions, phenylmethylsulfonylfluoride), or a combinationthereof, or a chemically reactive group thereof. At least one secondattachment site is present on the antigen or antigenic determinant. Theterm “antigen or antigenic determinant with at least one secondattachment site” refers, therefore, to an antigen or antigenic constructcomprising at least the antigen or antigenic determinant and the secondattachment site. However, in particular for a second attachment site,which is of non-natural origin, i.e. not naturally occurring within theantigen or antigenic determinant, these antigen or antigenic constructscomprise an “amino acid linker”.

Bound: As used herein, the term “bound” refers to binding that may becovalent, e.g., by chemically coupling, or non-covalent, e.g., ionicinteractions, hydrophobic interactions, hydrogen bonds, etc. Covalentbonds can be, for example, ester, ether, phosphoester, amide, peptide,imide, carbon-sulfur bonds, carbon-phosphorus bonds, and the like. Theterm also includes the enclosement, or partial enclosement, of asubstance. The term “bound” is broader than and includes terms such as“coupled,” “fused,” “enclosed”, “packaged” and “attached.” For example,the immunostimulatory substance such as the unmethylated CpG-containingoligonucleotide can be enclosed by the VLP without the existence of anactual binding, neither covalently nor non-covalently.

Coat protein(s): As used herein, the term “coat protein(s)” refers tothe protein(s) of a bacteriophage or a RNA-phage capable of beingincorporated within the capsid assembly of the bacteriophage or theRNA-phage. However, when referring to the specific gene product of thecoat protein gene of RNA-phages the term “CP” is used. For example, thespecific gene product of the coat protein gene of RNA-phage Qβ isreferred to as “Qβ CP”, whereas the “coat proteins” of bacteriophage Qβcomprise the “Qβ CP” as well as the A1 protein. The capsid ofBacteriophage Qβ is composed mainly of the Qβ CP, with a minor contentof the A1protein. Likewise, the VLP Qβ coat protein contains mainly QβCP, with a minor content of A1protein.

Coupled: As used herein, the term “coupled” refers to attachment bycovalent bonds or by strong non-covalent interactions. Any methodnormally used by those skilled in the art for the coupling ofbiologically active materials can be used in the present invention.

Fusion: As used herein, the term “fusion” refers to the combination ofamino acid sequences of different origin in one polypeptide chain byin-frame combination of their coding nucleotide sequences. The term“fusion” explicitly encompasses internal fusions, i.e., insertion ofsequences of different origin within a polypeptide chain, in addition tofusion to one of its termini.

CpG: As used herein, the term “CpG” refers to an oligonucleotide whichcontains an unmethylated cytosine, guanine dinucleotide sequence (e.g.“CpG DNA” or DNA containing a cytosine followed by guanosine and linkedby a phosphate bond) and stimulates/activates, e.g. has a mitogeniceffect on, or induces or increases cytokine expression by, a vertebratecell. For example, CpGs can be useful in activating B cells, NK cellsand antigen-presenting cells, such as monocytes, dendritic cells andmacrophages, and T cells. The CpGs can include nucleotide analogs suchas analogs containing phosphorothioester bonds and can bedouble-stranded or single-stranded. Generally, double-stranded moleculesare more stable in vivo, while single-stranded molecules have increasedimmune activity.

Epitope: As used herein, the term “epitope” refers to portions of apolypeptide having antigenic or immunogenic activity in an animal,preferably a mammal, and most preferably in a human. An “immunogenicepitope,” as used herein, is defined as a portion of a polypeptide thatelicits an antibody response or induces a T-cell response in an animal,as determined by any method known in the art. (See, for example, Geysenet al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1983)). The term“antigenic epitope,” as used herein, is defined as a portion of aprotein to which an antibody can immunospecifically bind its antigen asdetermined by any method well known in the art Immunospecific bindingexcludes non-specific binding but does not necessarily excludecross-reactivity with other antigens. Antigenic epitopes need notnecessarily be immunogenic. Antigenic epitopes can also be T-cellepitopes, in which case they can be bound immunospecifically by a T-cellreceptor within the context of an MHC molecule.

An epitope can comprise 3 amino acids in a spatial conformation which isunique to the epitope. Generally, an epitope consists of at least about5 such amino acids, and more usually, consists of at least about 8-10such amino acids. If the epitope is an organic molecule, it may be assmall as Nitrophenyl.

Immune response: As used herein, the term “immune response” refers to ahumoral immune response and/or cellular immune response leading to theactivation or proliferation of B- and/or T-lymphocytes. In someinstances, however, the immune responses may be of low intensity andbecome detectable only when using at least one substance in accordancewith the invention “Immunogenic” refers to an agent used to stimulatethe immune system of a living organism, so that one or more functions ofthe immune system are increased and directed towards the immunogenicagent. An “immunogenic polypeptide” is a polypeptide that elicits acellular and/or humoral immune response, whether alone or linked to acarrier in the presence or absence of an adjuvant.

Immunization: As used herein, the terms “immunize” or “immunization” orrelated terms refer to conferring the ability to mount a substantialimmune response (comprising antibodies or cellular immunity such aseffector CTL) against a target antigen or epitope. These terms do notrequire that complete immunity be created, but rather that an immuneresponse be produced which is substantially greater than baseline. Forexample, a mammal may be considered to be immunized against a targetantigen if the cellular and/or humoral immune response to the targetantigen occurs following the application of methods of the invention.

Immunostimulatory nucleic acid: As used herein, the termimmunostimulatory nucleic acid refers to a nucleic acid capable ofinducing and/or enhancing an immune response Immunostimulatory nucleicacids, as used herein, comprise ribonucleic acids and in particulardeoxyribonucleic acids. Preferably, immunostimulatory nucleic acidscontain at least one CpG motif e.g. a CG dinucleotide in which the C isunmethylated. The CG dinucleotide can be part of a palindromic sequenceor can be encompassed within a non-palindromic sequenceImmunostimulatory nucleic acids not containing CpG motifs as describedabove encompass, by way of example, nucleic acids lacking CpGdinucleotides, as well as nucleic acids containing CG motifs with amethylated CG dinucleotide. The term “immunostimulatory nucleic acid” asused herein should also refer to nucleic acids that contain modifiedbases such as 4-bromo-cytosine.

Immunostimulatory substance: As used herein, the term “immunostimulatorysubstance” refers to a substance capable of inducing and/or enhancing animmune response Immunostimulatory substances, as used herein, include,but are not limited to, toll-like receptor activating substances andsubstances inducing cytokine secretion. Toll-like receptor activatingsubstances include, but are not limited to, immunostimulatory nucleicacids, peptideoglycans, lipopolysaccharides, lipoteichonic acids,imidazoquinoline compounds, flagellins, lipoproteins, andimmunostimulatory organic substances such as taxol.

Natural origin: As used herein, the term “natural origin” means that thewhole or parts thereof are not synthetic and exist or are produced innature.

Non-natural: As used herein, the term generally means not from nature,more specifically, the term means from the hand of man.

Non-natural origin: As used herein, the term “non-natural origin”generally means synthetic or not from nature; more specifically, theterm means from the hand of man.

Ordered and repetitive antigen or antigenic determinant array: As usedherein, the term “ordered and repetitive antigen or antigenicdeterminant array” generally refers to a repeating pattern of antigen orantigenic determinant, characterized by a typically and preferablyuniform spacial arrangement of the antigens or antigenic determinantswith respect to the core particle and virus-like particle, respectively.In one embodiment of the invention, the repeating pattern may be ageometric pattern. Typical and preferred examples of suitable orderedand repetitive antigen or antigenic determinant arrays are those whichpossess strictly repetitive paracrystalline orders of antigens orantigenic determinants, preferably with spacings of 0.5 to 30nanometers, more preferably 5 to 15 nanometers.

Oligonucleotide: As used herein, the terms “oligonucleotide” or“oligomer” refer to a nucleic acid sequence comprising 2 or morenucleotides, generally at least about 6 nucleotides to about 100,000nucleotides, preferably about 6 to about 2000 nucleotides, and morepreferably about 6 to about 300 nucleotides, even more preferably about20 to about 300 nucleotides, and even more preferably about 20 to about100 nucleotides. The terms “oligonucleotide” or “oligomer” also refer toa nucleic acid sequence comprising more than 100 to about 2000nucleotides, preferably more than 100 to about 1000 nucleotides, andmore preferably more than 100 to about 500 nucleotides.“Oligonucleotide” also generally refers to any polyribonucleotide orpolydeoxribonucleotide, which may be unmodified RNA or DNA or modifiedRNA or DNA. “Oligonucleotide” includes, without limitation, single- anddouble-stranded DNA, DNA that is a mixture of single- anddouble-stranded regions, single- and double-stranded RNA, and RNA thatis mixture of single- and double-stranded regions, hybrid moleculescomprising DNA and RNA that may be single-stranded or, more typically,double-stranded or a mixture of single- and double-stranded regions. Inaddition, “oligonucleotide” refers to triple-stranded regions comprisingRNA or DNA or both RNA and DNA. Further, an oligonucleotide can besynthetic, genomic or recombinant, e.g., λ-DNA, cosmid DNA, artificialbacterial chromosome, yeast artificial chromosome and filamentous phagesuch as M13.

The term “oligonucleotide” also includes DNAs or RNAs containing one ormore modified bases and DNAs or RNAs with backbones modified forstability or for other reasons. For example, suitable nucleotidemodifications/analogs include peptide nucleic acid, inosin, tritylatedbases, phosphorothioates, alkylphosphorothioates, 5-nitroindoledeoxyribofuranosyl, 5-methyldeoxycytosine and5,6-dihydro-5,6-dihydroxydeoxythymidine. A variety of modifications havebeen made to DNA and RNA; thus, “oligonucleotide” embraces chemically,enzymatically or metabolically modified forms of polynucleotides astypically found in nature, as well as the chemical forms of DNA and RNAcharacteristic of viruses and cells. Other nucleotideanalogs/modifications will be evident to those skilled in the art.

Packaged: The term “packaged” as used herein refers to the state of animmunostimulatory substance, in particular an immunostimulatory nucleicacid in relation to the VLP. The term “packaged” as used herein includesbinding that may be covalent, e.g., by chemically coupling, ornon-covalent, e.g., ionic interactions, hydrophobic interactions,hydrogen bonds, etc. Covalent bonds can be, for example, ester, ether,phosphoester, amide, peptide, imide, carbon-sulfur bonds,carbon-phosphorus bonds, and the like. The term also includes theenclosement, or partial enclosement, of a substance. The term “packaged”includes terms such as “coupled, “enclosed” and “attached.” For example,the immunostimulatory substance such as the unmethylated CpG-containingoligonucleotide can be enclosed by the VLP without the existence of anactual binding, neither covalently nor non-covalently. In preferredembodiments, in particular, if immunostimulatory nucleic acids are theimmunostimulatory substances, the term “packaged” indicates that thenucleic acid in a packaged state is not accessible to DNAse or RNAsehydrolysis. In preferred embodiments, the immunostimulatory nucleic acidis packaged inside the VLP capsids, most preferably in a non-covalentmanner.

The compositions of the invention can be combined, optionally, with apharmaceutically-acceptable carrier. The term“pharmaceutically-acceptable carrier” as used herein means one or morecompatible solid or liquid fillers, diluents or encapsulating substanceswhich are suitable for administration into a human or other animal. Theterm “carrier” denotes an organic or inorganic ingredient, natural orsynthetic, with which the active ingredient is combined to facilitatethe application.

Organic molecule: As used herein, the term “organic molecule” refers toany chemical entity of natural or synthetic origin. In particular theterm “organic molecule” as used herein encompasses, for example, anymolecule being a member of the group of nucleotides, lipids,carbohydrates, polysaccharides, lipopolysaccharides, steroids,alkaloids, terpenes and fatty acids, being either of natural orsynthetic origin. In particular, the term “organic molecule” encompassesmolecules such as nicotine, cocaine, heroin or other pharmacologicallyactive molecules contained in drugs of abuse. In general an organicmolecule contains or is modified to contain a chemical functionalityallowing its coupling, binding or other method of attachment to thevirus-like particle in accordance with the invention.

Polypeptide: As used herein, the term “polypeptide” refers to a moleculecomposed of monomers (amino acids) linearly linked by amide bonds (alsoknown as peptide bonds). It indicates a molecular chain of amino acidsand does not refer to a specific length of the product. Thus, peptides,oligopeptides and proteins are included within the definition ofpolypeptide. This term is also intended to refer to post-expressionmodifications of the polypeptide, for example, glycosolations,acetylations, phosphorylations, and the like. A recombinant or derivedpolypeptide is not necessarily translated from a designated nucleic acidsequence. It may also be generated in any manner, including chemicalsynthesis.

A substance which “enhances” an immune response refers to a substance inwhich an immune response is observed that is greater or intensified ordeviated in any way with the addition of the substance when compared tothe same immune response measured without the addition of the substance.For example, the lytic activity of cytotoxic T cells can be measured,e.g. using a ⁵¹Cr release assay, with and without the substance. Theamount of the substance at which the CTL lytic activity is enhanced ascompared to the CTL lytic activity without the substance is said to bean amount sufficient to enhance the immune response of the animal to theantigen. In a preferred embodiment, the immune response in enhanced by afactor of at least about 2, more preferably by a factor of about 3 ormore. The amount of cytokines secreted may also be altered.

Effective Amount: As used herein, the term “effective amount” refers toan amount necessary or sufficient to realize a desired biologic effect.An effective amount of the composition would be the amount that achievesthis selected result, and such an amount could be determined as a matterof routine by a person skilled in the art. For example, an effectiveamount for treating an immune system deficiency could be that amountnecessary to cause activation of the immune system, resulting in thedevelopment of an antigen specific immune response upon exposure toantigen. The term is also synonymous with “sufficient amount.”

The effective amount for any particular application can vary dependingon such factors as the disease or condition being treated, theparticular composition being administered, the size of the subject,and/or the severity of the disease or condition. One of ordinary skillin the art can empirically determine the effective amount of aparticular composition of the present invention without necessitatingundue experimentation.

Self antigen: As used herein, the tem “self antigen” refers to proteinsencoded by the host's DNA and products generated by proteins or RNAencoded by the host's DNA are defined as self. In addition, proteinsthat result from a combination of two or several self-molecules or thatrepresent a fraction of a self-molecule and proteins that have a highhomology two self-molecules as defined above (>95%, preferably >97%,more preferably >99%) may also be considered self. In a furtherpreferred embodiment of the present invention, the antigen is a selfantigen. Very preferred embodiments of selfantigens useful for thepresent invention are described WO 02/056905, the disclosures of whichare herewith incorporated by reference in its entirety.

Treatment: As used herein, the terms “treatment”, “treat”, “treated” or“treating” refer to prophylaxis and/or therapy. When used with respectto an infectious disease, for example, the term refers to a prophylactictreatment which increases the resistance of a subject to infection witha pathogen or, in other words, decreases the likelihood that the subjectwill become infected with the pathogen or will show signs of illnessattributable to the infection, as well as a treatment after the subjecthas become infected in order to fight the infection, e.g., reduce oreliminate the infection or prevent it from becoming worse.

Vaccine: As used herein, the term “vaccine” refers to a formulationwhich contains the composition of the present invention and which is ina form that is capable of being administered to an animal. Typically,the vaccine comprises a conventional saline or buffered aqueous solutionmedium in which the composition of the present invention is suspended ordissolved. In this form, the composition of the present invention can beused conveniently to prevent, ameliorate, or otherwise treat acondition. Upon introduction into a host, the vaccine is able to provokean immune response including, but not limited to, the production ofantibodies, cytokines and/or other cellular responses.

Optionally, the vaccine of the present invention additionally includesan adjuvant which can be present in either a minor or major proportionrelative to the compound of the present invention. The term “adjuvant”as used herein refers to non-specific stimulators of the immune responseor substances that allow generation of a depot in the host which whencombined with the vaccine of the present invention provide for an evenmore enhanced immune response. A variety of adjuvants can be used.Examples include incomplete Freund's adjuvant, aluminum hydroxide andmodified muramyldipeptide. The term “adjuvant” as used herein alsorefers to typically specific stimulators of the immune response whichwhen combined with the vaccine of the present invention provide for aneven more enhanced and typically specific immune response. Examplesinclude, but limited to, GM-CSF, IL-2, IL-12, IFNα. Further examples arewithin the knowledge of the person skilled in the art.

Virus-like particle: As used herein, the term “virus-like particle”refers to a structure resembling a virus particle but which has not beendemonstrated to be pathogenic. Typically, a virus-like particle inaccordance with the invention does not carry genetic informationencoding for the proteins of the virus-like particle. In general,virus-like particles lack the viral genome and, therefore, arenoninfectious. Also, virus-like particles can often be produced in largequantities by heterologous expression and can be easily purified. Somevirus-like particles may contain nucleic acid distinct from theirgenome. As indicated, a virus-like particle in accordance with theinvention is non replicative and noninfectious since it lacks all orpart of the viral genome, in particular the replicative and infectiouscomponents of the viral genome. A virus-like particle in accordance withthe invention may contain nucleic acid distinct from their genome. Atypical and preferred embodiment of a virus-like particle in accordancewith the present invention is a viral capsid such as the viral capsid ofthe corresponding virus, bacteriophage, or RNA-phage. The terms “viralcapsid” or “capsid”, as interchangeably used herein, refer to amacromolecular assembly composed of viral protein subunits. Typicallyand preferably, the viral protein subunits assemble into a viral capsidand capsid, respectively, having a structure with an inherent repetitiveorganization, wherein said structure is, typically, spherical ortubular. For example, the capsids of RNA-phages or HBcAg's have aspherical form of icosahedral symmetry. The term “capsid-like structure”as used herein, refers to a macromolecular assembly composed of viralprotein subunits reassembling the capsid morphology in the above definedsense but deviating from the typical symmetrical assembly whilemaintaining a sufficient degree of order and repetitiveness.

Virus-like particle of a bacteriophage: As used herein, the term“virus-like particle of a bacteriophage” refers to a virus-like particleresembling the structure of a bacteriophage, being non replicative andnoninfectious, and lacking at least the gene or genes encoding for thereplication machinery of the bacteriophage, and typically also lackingthe gene or genes encoding the protein or proteins responsible for viralattachment to or entry into the host. This definition should, however,also encompass virus-like particles of bacteriophages, in which theaforementioned gene or genes are still present but inactive, and,therefore, also leading to non-replicative and noninfectious virus-likeparticles of a bacteriophage.

VLP of RNA phage coat protein: The capsid structure formed from theself-assembly of 180 subunits of RNA phage coat protein and optionallycontaining host RNA is referred to as a “VLP of RNA phage coat protein”.A specific example is the VLP of Qβ coat protein. In this particularcase, the VLP of Qβ coat protein may either be assembled exclusivelyfrom Qβ CP subunits (generated by expression of a Qβ CP gene containing,for example, a TAA stop codon precluding any expression of the longerA1protein through suppression, see Kozlovska, T. M., et al.,Intervirology 39: 9-15 (1996)), or additionally contain A1proteinsubunits in the capsid assembly.

The term “virus particle” as used herein refers to the morphologicalform of a virus. In some virus types it comprises a genome surrounded bya protein capsid; others have additional structures (e.g., envelopes,tails, etc.).

Non-enveloped viral particles are made up of a proteinaceous capsid thatsurrounds and protects the viral genome. Enveloped viruses also have acapsid structure surrounding the genetic material of the virus but, inaddition, have a lipid bilayer envelope that surrounds the capsid. In apreferred embodiment of the invention, the VLP's are free of alipoprotein envelope or a lipoprotein-containing envelope. In a furtherpreferred embodiment, the VLP's are free of an envelope altogether.

One, a, or an: When the terms “one,” “a,” or “an” are used in thisdisclosure, they mean “at least one” or “one or more,” unless otherwiseindicated.

As will be clear to those skilled in the art, certain embodiments of theinvention involve the use of recombinant nucleic acid technologies suchas cloning, polymerase chain reaction, the purification of DNA and RNA,the expression of recombinant proteins in prokaryotic and eukaryoticcells, etc. Such methodologies are well known to those skilled in theart and can be conveniently found in published laboratory methodsmanuals (e.g., Sambrook, J. et al., eds., MOLECULAR CLONING, ALABORATORY MANUAL, 2nd. edition, Cold Spring Harbor Laboratory Press,Cold Spring Harbor, N.Y. (1989); Ausubel, F. et al., eds., CURRENTPROTOCOLS IN MOLECULAR BIOLOGY, John H. Wiley & Sons, Inc. (1997)).Fundamental laboratory techniques for working with tissue culture celllines (Celis, J., ed., CELL BIOLOGY, Academic Press, 2^(nd) edition,(1998)) and antibody-based technologies (Harlow, E. and Lane, D.,“Antibodies: A Laboratory Manual,” Cold Spring Harbor Laboratory, ColdSpring Harbor, N.Y. (1988); Deutscher, M. P., “Guide to ProteinPurification,” Meth. Enzymol. 128, Academic Press San Diego (1990);Scopes, R. K., “Protein Purification Principles and Practice,” 3^(rd)ed., Springer-Verlag, New York (1994)) are also adequately described inthe literature, all of which are incorporated herein by reference.

2. Compositions and Methods for Enhancing an Immune Response

The disclosed invention provides compositions and methods for enhancingan immune response against one or more antigens in an animal.Compositions of the invention comprise, or alternatively consist of, avirus-like particle and an immunostimulatory substance, preferably animmunostimulatory nucleic acid, and even more preferably an unmethylatedCpG-containing oligonucleotide where the an immunostimulatory substance,the immunostimulatory nucleic acid or the oligonucleotide is bound tothe virus-like particle. Furthermore, the invention conveniently enablesthe practitioner to construct such a composition for various treatmentand/or prophylactic prevention purposes, which include the preventionand/or treatment of infectious diseases, as well as chronic infectiousdiseases, and the prevention and/or treatment of cancers, for example.

Virus-like particles in the context of the present application refer tostructures resembling a virus particle but which are not pathogenic. Ingeneral, virus-like particles lack the viral genome and, therefore, arenoninfectious. Also, virus-like particles can be produced in largequantities by heterologous expression and can be easily purified.

In a preferred embodiment, the virus-like particle is a recombinantvirus-like particle. The skilled artisan can produce VLPs usingrecombinant DNA technology and virus coding sequences which are readilyavailable to the public. For example, the coding sequence of a virusenvelope or core protein can be engineered for expression in abaculovirus expression vector using a commercially available baculovirusvector, under the regulatory control of a virus promoter, withappropriate modifications of the sequence to allow functional linkage ofthe coding sequence to the regulatory sequence. The coding sequence of avirus envelope or core protein can also be engineered for expression ina bacterial expression vector, for example.

Examples of VLPs include, but are not limited to, the capsid proteins ofHepatitis B virus (Ulrich, et al., Virus Res. 50:141-182 (1998)),measles virus (Warnes, et al., Gene 160:173-178 (1995)), Sindbis virus,rotavirus (U.S. Pat. Nos. 5,071,651 and 5,374,426),foot-and-mouth-disease virus (Twomey, et al., Vaccine 13:1603-1610,(1995)), Norwalk virus (Jiang, X., et al., Science 250:1580-1583 (1990);Matsui, S. M., et al., J. Clin. Invest. 87:1456-1461 (1991)), theretroviral GAG protein (PCT Patent Appl. No. WO 96/30523), theretrotransposon Ty protein p1, the surface protein of Hepatitis B virus(WO 92/11291), human papilloma virus (WO 98/15631), human polyoma virus(Sasnauskas K., et al., Biol. Chem. 380(3):381-386 (1999); SasnauskasK., et al., Generation of recombinant virus-like particles of differentpolyomaviruses in yeast. 3^(rd) Interational Workshop “Virus-likeparticles as vaccines.” Berlin, Sep. 26-29 (2001)), RNA phages, Ty,fr-phage, GA-phage, AP 205-phage and, in particular, Qβ-phage.

As will be readily apparent to those skilled in the art, the VLP of theinvention is not limited to any specific form. The particle can besynthesized chemically or through a biological process, which can benatural or non-natural. By way of example, this type of embodimentincludes a virus-like particle or a recombinant form thereof. In a morespecific embodiment, the VLP can comprise, or alternatively consist of,recombinant polypeptides of Rotavirus; recombinant polypeptides ofNorwalk virus; recombinant polypeptides of Alphavirus; recombinantproteins which form bacterial pili or pilus-like structures; recombinantpolypeptides of Foot and Mouth Disease virus; recombinant polypeptidesof measles virus, recombinant polypeptides of Sindbis virus, recombinantpolypeptides of Retrovirus; recombinant polypeptides of Hepatitis Bvirus (e.g., a HBcAg); recombinant polypeptides of Tobacco mosaic virus;recombinant polypeptides of Flock House Virus; recombinant polypeptidesof human Papillomavirus; recombinant polypeptides of Polyoma virus and,in particular, recombinant polypeptides of human Polyoma virus, and inparticular recombinant polypeptides of BK virus; recombinantpolypeptides of bacteriophages, recombinant polypeptides of RNA phages;recombinant polypeptides of Ty; recombinant polypeptides of fr-phage,recombinant polypeptides of GA-phage, recombinant polypeptides of AP205-phage and, in particular, recombinant polypeptides of Qβ-phage. Thevirus-like particle can further comprise, or alternatively consist of,one or more fragments of such polypeptides, as well as variants of suchpolypeptides. Variants of polypeptides can share, for example, at least80%, 85%, 90%, 95%, 97%, or 99% identity at the amino acid level withtheir wild-type counterparts.

In a preferred embodiment, the virus-like particle comprises, consistsessentially of, or alternatively consists of recombinant proteins, orfragments thereof, of a RNA-phage. Preferably, the RNA-phage is selectedfrom the group consisting of a) bacteriophage Qβ; b) bacteriophage R17;c) bacteriophage fr; d) bacteriophage GA; e) bacteriophage SP; f)bacteriophage MS2; g) bacteriophage M11; h) bacteriophage MX1; i)bacteriophage NL95; k) bacteriophage f2; and 1) bacteriophage PP7.

In another preferred embodiment of the present invention, the virus-likeparticle comprises, or alternatively consists essentially of, oralternatively consists of recombinant proteins, or fragments thereof, ofthe RNA-bacteriophage Qβ or of the RNA-bacteriophage fr.

In a further preferred embodiment of the present invention, therecombinant proteins comprise, or alternatively consist essentially of,or alternatively consist of coat proteins of RNA phages.

RNA-phage coat proteins forming capsids or VLPs, or fragments of thebacteriophage coat proteins compatible with self-assembly into a capsidor a VLP, are, therefore, further preferred embodiments of the presentinvention. Bacteriophage Qβ coat proteins, for example, can be expressedrecombinantly in E. coli. Further, upon such expression these proteinsspontaneously form capsids. Additionally, these capsids form a structurewith an inherent repetitive organization.

Specific preferred examples of bacteriophage coat proteins which can beused to prepare compositions of the invention include the coat proteinsof RNA bacteriophages such as bacteriophage Qβ (SEQ ID NO:10; PIRDatabase, Accession No. VCBPQβ referring to Qβ CP and SEQ ID NO: 11;Accession No. AAA16663 referring to Qβ A1 protein), bacteriophage R17(SEQ ID NO:12; PIR Accession No. VCBPR7), bacteriophage fr (SEQ IDNO:13; PIR Accession No. VCBPFR), bacteriophage GA (SEQ ID NO:14;GenBank Accession No. NP-040754), bacteriophage SP (SEQ ID NO:15;GenBank Accession No. CAA30374 referring to SP CP and SEQ ID NO: 16;Accession No. referring to SP A1protein), bacteriophage MS2 (SEQ IDNO:17; PIR Accession No. VCBPM2), bacteriophage M11 (SEQ ID NO:18;GenBank Accession No. AAC06250), bacteriophage MX1 (SEQ ID NO:19;GenBank Accession No. AAC14699), bacteriophage NL95 (SEQ ID NO:20;GenBank Accession No. AAC14704), bacteriophage f2 (SEQ ID NO: 21;GenBank Accession No. P03611), bacteriophage PP7 (SEQ ID NO: 22).Furthermore, the A1protein of bacteriophage Qβ or C-terminal truncatedforms missing as much as 100, 150 or 180 amino acids from its C-terminusmay be incorporated in a capsid assembly of Qβ coat proteins. Generally,the percentage of Qβ A1protein relative to Qβ CP in the capsid assemblywill be limited, in order to ensure capsid formation.

Qβ coat protein has also been found to self-assemble into capsids whenexpressed in E. coli (Kozlovska™. et al., GENE 137: 133-137 (1993)). Theobtained capsids or virus-like particles showed an icosahedralphage-like capsid structure with a diameter of 25 nm and T=3 quasisymmetry. Further, the crystal structure of phage Qβ has been solved.The capsid contains 180 copies of the coat protein, which are linked incovalent pentamers and hexamers by disulfide bridges (Golmohammadi, R.et al., Structure 4: 543-5554 (1996)) leading to a remarkable stabilityof the capsid of Qβ coat protein. Capsids or VLPs made from recombinantQβ coat protein may contain, however, subunits not linked via disulfidelinks to other subunits within the capsid, or incompletely linked. Thus,upon loading recombinant Qβ capsid on non-reducing SDS-PAGE, bandscorresponding to monomeric Qβ coat protein as well as bandscorresponding to the hexamer or pentamer of Qβ coat protein are visible.Incompletely disulfide-linked subunits could appear as dimer, trimer oreven tetramer bands in non-reducing SDS-PAGE. Qβ capsid protein alsoshows unusual resistance to organic solvents and denaturing agents.Surprisingly, we have observed that DMSO and acetonitrile concentrationsas high as 30%, and Guanidinium concentrations as high as 1 M do notaffect the stability of the capsid. The high stability of the capsid ofQβ coat protein is an advantageous feature, in particular, for its usein immunization and vaccination of mammals and humans in accordance ofthe present invention.

Upon expression in E. coli, the N-terminal methionine of Qβ coat proteinis usually removed, as we observed by N-terminal Edman sequencing asdescribed in Stoll, E. et al. J. Biol. Chem. 252:990-993 (1977). VLPcomposed from Qβ coat proteins where the N-terminal methionine has notbeen removed, or VLPs comprising a mixture of Qβ coat proteins where theN-terminal methionine is either cleaved or present are also within thescope of the present invention.

Further RNA phage coat proteins have also been shown to self-assembleupon expression in a bacterial host (Kastelein, R A. et al., Gene 23:245-254 (1983), Kozlovskaya, T M. et al., Dokl. Akad. Nauk SSSR 287:452-455 (1986), Adhin, M R. et al., Virology 170: 238-242 (1989), Ni,CZ., et al., Protein Sci. 5: 2485-2493 (1996), Priano, C. et al., J.Mol. Biol. 249: 283-297 (1995)). The Qβ phage capsid contains, inaddition to the coat protein, the so called read-through protein A1 andthe maturation protein A2. A1 is generated by suppression at the UGAstop codon and has a length of 329 aa. The capsid of phage Qβrecombinant coat protein used in the invention is devoid of the A2 lysisprotein, and contains RNA from the host. The coat protein of RNA phagesis an RNA binding protein, and interacts with the stem loop of theribosomal binding site of the replicase gene acting as a translationalrepressor during the life cycle of the virus. The sequence andstructural elements of the interaction are known (Witherell, G W. &Uhlenbeck, O C. Biochemistry 28: 71-76 (1989); Lim F. et al., J. Biol.Chem. 271: 31839-31845 (1996)). The stem loop and RNA in general areknown to be involved in the virus assembly (Golmohammadi, R. et al.,Structure 4: 543-5554 (1996)).

In a further preferred embodiment of the present invention, thevirus-like particle comprises, or alternatively consists essentially of,or alternatively consists of recombinant proteins, or fragments thereof,of a RNA-phage, wherein the recombinant proteins comprise, consistessentially of or alternatively consist of mutant coat proteins of a RNAphage, preferably of mutant coat proteins of the RNA phages mentionedabove. In another preferred embodiment, the mutant coat proteins of theRNA phage have been modified by removal of at least one lysine residueby way of substitution, or by addition of at least one lysine residue byway of substitution; alternatively, the mutant coat proteins of the RNAphage have been modified by deletion of at least one lysine residue, orby addition of at least one lysine residue by way of insertion.

In another preferred embodiment, the virus-like particle comprises, oralternatively consists essentially of, or alternatively consists ofrecombinant proteins, or fragments thereof, of the RNA-bacteriophage Qβ,wherein the recombinant proteins comprise, or alternatively consistessentially of, or alternatively consist of coat proteins having anamino acid sequence of SEQ ID NO:10, or a mixture of coat proteinshaving amino acid sequences of SEQ ID NO:10 and of SEQ ID NO: 11 ormutants of SEQ ID NO: 11 and wherein the N-terminal methionine ispreferably cleaved.

In a further preferred embodiment of the present invention, thevirus-like particle comprises, consists essentially of or alternativelyconsists of recombinant proteins of Qβ, or fragments thereof, whereinthe recombinant proteins comprise, or alternatively consist essentiallyof, or alternatively consist of mutant Qβ coat proteins. In anotherpreferred embodiment, these mutant coat proteins have been modified byremoval of at least one lysine residue by way of substitution, or byaddition of at least one lysine residue by way of substitution.Alternatively, these mutant coat proteins have been modified by deletionof at least one lysine residue, or by addition of at least one lysineresidue by way of insertion.

Four lysine residues are exposed on the surface of the capsid of Qβ coatprotein. Qβ mutants, for which exposed lysine residues are replaced byarginines can also be used for the present invention. The following Qβcoat protein mutants and mutant Qβ VLPs can, thus, be used in thepractice of the invention: “Qβ-240” (Lys13-Arg; SEQ ID NO:23), “Qβ-243”(Asn 10-Lys; SEQ ID NO:24), “Qβ-250” (Lys 2-Arg, Lys13-Arg; SEQ IDNO:25), “Qβ-251” (SEQ ID NO:26) and “Qβ-259” (Lys 2-Arg, Lys16-Arg; SEQID NO:27). Thus, in further preferred embodiment of the presentinvention, the virus-like particle comprises, consists essentially of oralternatively consists of recombinant proteins of mutant Qβ coatproteins, which comprise proteins having an amino acid sequence selectedfrom the group of a) the amino acid sequence of SEQ ID NO: 23; b) theamino acid sequence of SEQ ID NO:24; c) the amino acid sequence of SEQID NO: 25; d) the amino acid sequence of SEQ ID NO:26; and e) the aminoacid sequence of SEQ ID NO: 27. The construction, expression andpurification of the above indicated Qβ coat proteins, mutant Qβ coatprotein VLPs and capsids, respectively, are disclosed in pending U.S.application Ser. No. 10/050,902 filed on Jan. 18, 2002. In particular ishereby referred to Example 18 of above mentioned application.

In a further preferred embodiment of the present invention, thevirus-like particle comprises, or alternatively consists essentially of,or alternatively consists of recombinant proteins of Qβ, or fragmentsthereof, wherein the recombinant proteins comprise, consist essentiallyof or alternatively consist of a mixture of either one of the foregoingQβ mutants and the corresponding A1 protein.

In a further preferred embodiment of the present invention, thevirus-like particle comprises, or alternatively essentially consists of,or alternatively consists of recombinant proteins, or fragments thereof,of RNA-phage AP205.

The AP205 genome consists of a maturation protein, a coat protein, areplicase and two open reading frames not present in related phages; alysis gene and an open reading frame playing a role in the translationof the maturation gene (Klovins, J., et al., J. Gen. Virol. 83: 1523-33(2002)). AP205 coat protein can be expressed from plasmid pAP283-58 (SEQID NO: 79), which is a derivative of pQb10 (Kozlovska, T. M. et al.,Gene 137:133-37 (1993)), and which contains an AP205 ribosomal bindingsite. Alternatively, AP205 coat protein may be cloned into pQb185,downstream of the ribosomal binding site present in the vector. Bothapproaches lead to expression of the protein and formation of capsids asdescribed in the co-pending US provisional patent application with thetitle “Molecular Antigen Arrays” (Application No. 60/396,126) and havingbeen filed on Jul. 17, 2002, which is incorporated by reference in itsentirety. Vectors pQb10 and pQb185 are vectors derived from pGEM vector,and expression of the cloned genes in these vectors is controlled by thetrp promoter (Kozlovska, T. M. et al., Gene 137:133-37 (1993)). PlasmidpAP283-58 (SEQ ID NO:79) comprises a putative AP205 ribosomal bindingsite in the following sequence, which is downstream of the XbaI site,and immediately upstream of the ATG start codon of the AP205 coatprotein: tctagaATTTTCTGCGCACCCAT CCCGGGTGGCGCCCAAAGTGAGGAAAATCACatg (SEQID NO:5). The vector pQb185 comprises a Shine Delagarno sequencedownstream from the XbaI site and upstream of the start codon(tctagaTTAACCCAACGCGTAGGAG TCAGGCCatg, Shine Delagarno sequenceunderlined SEQ ID NO:6).

In a further preferred embodiment of the present invention, thevirus-like particle comprises, or alternatively essentially consists of,or alternatively consists of recombinant coat proteins, or fragmentsthereof, of the RNA-phage AP205.

This preferred embodiment of the present invention, thus, comprisesAP205 coat proteins that form capsids. Such proteins are recombinantlyexpressed, or prepared from natural sources. AP205 coat proteinsproduced in bacteria spontaneously form capsids, as evidenced byElectron Microscopy (EM) and immunodiffusion. The structural propertiesof the capsid formed by the AP205 coat protein (SEQ ID NO: 80) and thoseformed by the coat protein of the AP205 RNA phage are nearlyindistinguishable when seen in EM. AP205 VLPs are highly immunogenic,and can be linked with antigens and/or antigenic determinants togenerate vaccine constructs displaying the antigens and/or antigenicdeterminants oriented in a repetitive manner. High titers are elicitedagainst the so displayed antigens showing that bound antigens and/orantigenic determinants are accessible for interacting with antibodymolecules and are immunogenic.

In a further preferred embodiment of the present invention, thevirus-like particle comprises, or alternatively essentially consists of,or alternatively consists of recombinant mutant coat proteins, orfragments thereof, of the RNA-phage AP205.

Assembly-competent mutant forms of AP205 VLPs, including AP205 coatprotein with the substitution of proline at amino acid 5 to threonine(SEQ ID NO: 81), may also be used in the practice of the invention andleads to a further preferred embodiment of the invention. These VLPs,AP205 VLPs derived from natural sources, or AP205 viral particles, maybe bound to antigens to produce ordered repetitive arrays of theantigens in accordance with the present invention.

AP205 P5-T mutant coat protein can be expressed from plasmid pAP281-32(SEQ ID No. 82), which is derived directly from pQb185, and whichcontains the mutant AP205 coat protein gene instead of the Qβ coatprotein gene. Vectors for expression of the AP205 coat protein aretransfected into E. coli for expression of the AP205 coat protein.

Methods for expression of the coat protein and the mutant coat protein,respectively, leading to self-assembly into VLPs are described inco-pending US provisional patent application with the title “MolecularAntigen Arrays” (Application No. 60/396,126) and having been filed onJul. 17, 2002, which is incorporated by reference in its entirety.Suitable E. coli strains include, but are not limited to, E. coli K802,JM 109, RR1. Suitable vectors and strains and combinations thereof canbe identified by testing expression of the coat protein and mutant coatprotein, respectively, by SDS-PAGE and capsid formation and assembly byoptionally first purifying the capsids by gel filtration andsubsequently testing them in an immunodiffusion assay (Ouchterlony test)or Electron Microscopy (Kozlovska, T. M. et al., Gene 137:133-37(1993)).

AP205 coat proteins expressed from the vectors pAP283-58 and pAP281-32may be devoid of the initial Methionine amino-acid, due to processing inthe cytoplasm of E. coli. Cleaved, uncleaved forms of AP205 VLP, ormixtures thereof are further preferred embodiments of the invention.

In a further preferred embodiment of the present invention, thevirus-like particle comprises, or alternatively essentially consists of,or alternatively consists of a mixture of recombinant coat proteins, orfragments thereof, of the RNA-phage AP205 and of recombinant mutant coatproteins, or fragments thereof, of the RNA-phage AP205.

In a further preferred embodiment of the present invention, thevirus-like particle comprises, or alternatively essentially consists of,or alternatively consists of fragments of recombinant coat proteins orrecombinant mutant coat proteins of the RNA-phage AP205.

Recombinant AP205 coat protein fragments capable of assembling into aVLP and a capsid, respectively are also useful in the practice of theinvention. These fragments may be generated by deletion, eitherinternally or at the termini of the coat protein and mutant coatprotein, respectively. Insertions in the coat protein and mutant coatprotein sequence or fusions of antigen sequences to the coat protein andmutant coat protein sequence, and compatible with assembly into a VLP,are further embodiments of the invention and lead to chimeric AP205 coatproteins, and particles, respectively. The outcome of insertions,deletions and fusions to the coat protein sequence and whether it iscompatible with assembly into a VLP can be determined by electronmicroscopy.

The particles formed by the AP205 coat protein, coat protein fragmentsand chimeric coat proteins described above, can be isolated in pure formby a combination of fractionation steps by precipitation and ofpurification steps by gel filtration using e.g. Sepharose CL-4B,Sepharose CL-2B, Sepharose CL-6B columns and combinations thereof asdescribed in the co-pending US provisional patent application with thetitle “Molecular Antigen Arrays (Application No. 60/396,126) and havingbeen filed on Jul. 17, 2002, which is incorporated by reference in itsentirety. Other methods of isolating virus-like particles are known inthe art, and may be used to isolate the virus-like particles (VLPs) ofbacteriophage AP205. For example, the use of ultracentrifugation toisolate VLPs of the yeast retrotransposon Ty is described in U.S. Pat.No. 4,918,166, which is incorporated by reference herein in itsentirety.

The crystal structure of several RNA bacteriophages has been determined(Golmohammadi, R. et al., Structure 4:543-554 (1996)). Using suchinformation, surface exposed residues can be identified and, thus,RNA-phage coat proteins can be modified such that one or more reactiveamino acid residues can be inserted by way of insertion or substitution.As a consequence, those modified forms of bacteriophage coat proteinscan also be used for the present invention. Thus, variants of proteinswhich form capsids or capsid-like structures (e.g., coat proteins ofbacteriophage Qβ, bacteriophage R17, bacteriophage fr, bacteriophage GA,bacteriophage SP, and bacteriophage MS2, bacteriophage AP 205) can alsobe used to prepare compositions of the present invention.

Although the sequence of the variants proteins discussed above willdiffer from their wild-type counterparts, these variant proteins willgenerally retain the ability to form capsids or capsid-like structures.Thus, the invention further includes compositions and vaccinecompositions, respectively, which further includes variants of proteinswhich form capsids or capsid-like structures, as well as methods forpreparing such compositions and vaccine compositions, respectively,individual protein subunits used to prepare such compositions, andnucleic acid molecules which encode these protein subunits. Thus,included within the scope of the invention are variant forms ofwild-type proteins which form capsids or capsid-like structures andretain the ability to associate and form capsids or capsid-likestructures.

As a result, the invention further includes compositions and vaccinecompositions, respectively, comprising proteins, which comprise, oralternatively consist essentially of, or alternatively consist of aminoacid sequences which are at least 80%, 85%, 90%, 95%, 97%, or 99%identical to wild-type proteins which form ordered arrays and have aninherent repetitive structure, respectively.

Further included within the scope of the invention are nucleic acidmolecules which encode proteins used to prepare compositions of thepresent invention.

In other embodiments, the invention further includes compositionscomprising proteins, which comprise, or alternatively consistessentially of, or alternatively consist of amino acid sequences whichare at least 80%, 85%, 90%, 95%, 97%, or 99% identical to any of theamino acid sequences shown in SEQ ID NOs:10-27.

Proteins suitable for use in the present invention also includeC-terminal truncation mutants of proteins which form capsids orcapsid-like structures, or VLPs. Specific examples of such truncationmutants include proteins having an amino acid sequence shown in any ofSEQ ID NOs:10-27 where 1, 2, 5, 7, 9, 10, 12, 14, 15, or 17 amino acidshave been removed from the C-terminus Typically, theses C-terminaltruncation mutants will retain the ability to form capsids orcapsid-like structures.

Further proteins suitable for use in the present invention also includeN-terminal truncation mutants of proteins which form capsids orcapsid-like structures. Specific examples of such truncation mutantsinclude proteins having an amino acid sequence shown in any of SEQ IDNOs:10-27 where 1, 2, 5, 7, 9, 10, 12, 14, 15, or 17 amino acids havebeen removed from the N-terminus Typically, these N-terminal truncationmutants will retain the ability to form capsids or capsid-likestructures.

Additional proteins suitable for use in the present invention include N-and C-terminal truncation mutants which form capsids or capsid-likestructures. Suitable truncation mutants include proteins having an aminoacid sequence shown in any of SEQ ID NOs:10-27 where 1, 2, 5, 7, 9, 10,12, 14, 15, or 17 amino acids have been removed from the N-terminus and1, 2, 5, 7, 9, 10, 12, 14, 15, or 17 amino acids have been removed fromthe C-terminus. Typically, these N-terminal and C-terminal truncationmutants will retain the ability to form capsids or capsid-likestructures.

The invention further includes compositions comprising proteins whichcomprise, or alternatively consist essentially of, or alternativelyconsist of, amino acid sequences which are at least 80%, 85%, 90%, 95%,97%, or 99% identical to the above described truncation mutants.

The invention thus includes compositions and vaccine compositionsprepared from proteins which form capsids or VLPs, methods for preparingthese compositions from individual protein subunits and VLPs or capsids,methods for preparing these individual protein subunits, nucleic acidmolecules which encode these subunits, and methods for vaccinatingand/or eliciting immunological responses in individuals using thesecompositions of the present invention.

Fragments of VLPs which retain the ability to induce an immune responsecan comprise, or alternatively consist of, polypeptides which are about15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100,110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, 350, 400,450 or 500 amino acids in length, but will obviously depend on thelength of the sequence of the subunit composing the VLP. Examples ofsuch fragments include fragments of proteins discussed herein which aresuitable for the preparation of the immune response enhancingcomposition.

In another preferred embodiment of the invention, the VLP's are free ofa lipoprotein envelope or a lipoprotein-containing envelope. In afurther preferred embodiment, the VLP's are free of an envelopealtogether.

The lack of a lipoprotein envelope or lipoprotein-containing envelopeand, in particular, the complete lack of an envelope leads to a moredefined virus-like particle in its structure and composition. Such moredefined virus-like particles, therefore, may minimize side-effects.Moreover, the lack of a lipoprotein-containing envelope or, inparticular, the complete lack of an envelope avoids or minimizesincorporation of potentially toxic molecules and pyrogens within thevirus-like particle.

As previously stated, the invention includes virus-like particles orrecombinant forms thereof. Skilled artisans have the knowledge toproduce such particles and attach antigens thereto. By way of providingother examples, the invention provides herein for the production ofHepatitis B virus-like particles as virus-like particles (Example 1).

In one embodiment, the particles used in compositions of the inventionare composed of a Hepatitis B capsid (core) protein (HBcAg) or afragment of a HBcAg which has been modified to either eliminate orreduce the number of free cysteine residues. Zhou et al. (J. Virol.66:5393-5398 (1992)) demonstrated that HBcAgs which have been modifiedto remove the naturally resident cysteine residues retain the ability toassociate and form multimeric structures. Thus, core particles suitablefor use in compositions of the invention include those comprisingmodified HBcAgs, or fragments thereof, in which one or more of thenaturally resident cysteine residues have been either deleted orsubstituted with another amino acid residue (e.g., a serine residue).

The HBcAg is a protein generated by the processing of a Hepatitis B coreantigen precursor protein. A number of isotypes of the HBcAg have beenidentified and their amino acids sequences are readily available tothose skilled in the art. For example, the HBcAg protein having theamino acid sequence shown in FIG. 1 is 185 amino acids in length and isgenerated by the processing of a 212 amino acid Hepatitis B core antigenprecursor protein. This processing results in the removal of 29 aminoacids from the N-terminus of the Hepatitis B core antigen precursorprotein. Similarly, the HBcAg protein that is 185 amino acids in lengthis generated by the processing of a 214 amino acid Hepatitis B coreantigen precursor protein.

In preferred embodiments, vaccine compositions of the invention will beprepared using the processed form of a HBcAg (i.e., a HBcAg from whichthe N-terminal leader sequence of the Hepatitis B core antigen precursorprotein have been removed).

Further, when HBcAgs are produced under conditions where processing willnot occur, the HBcAgs will generally be expressed in “processed” form.For example, bacterial systems, such as E. coli, generally do not removethe leader sequences, also referred to as “signal peptides,” of proteinswhich are normally expressed in eukaryotic cells. Thus, when an E. coliexpression system directing expression of the protein to the cytoplasmis used to produce HBcAgs of the invention, these proteins willgenerally be expressed such that the N-terminal leader sequence of theHepatitis B core antigen precursor protein is not present.

The preparation of Hepatitis B virus-like particles, which can be usedfor the present invention, is disclosed, for example, in WO 00/32227,and hereby in particular in Examples 17 to 19 and 21 to 24, as well asin WO 01/85208, and hereby in particular in Examples 17 to 19, 21 to 24,31 and 41, and in pending U.S. application Ser. No. 10/050,902 filed onJan. 18, 2002. For the latter application, it is in particular referredto Example 23, 24, 31 and 51. All three documents are explicitlyincorporated herein by reference.

The present invention also includes HBcAg variants which have beenmodified to delete or substitute one or more additional cysteineresidues. Thus, the vaccine compositions of the invention includecompositions comprising HBcAgs in which cysteine residues not present inthe amino acid sequence shown in FIG. 1 have been deleted.

It is well known in the art that free cysteine residues can be involvedin a number of chemical side reactions. These side reactions includedisulfide exchanges, reaction with chemical substances or metabolitesthat are, for example, injected or formed in a combination therapy withother substances, or direct oxidation and reaction with nucleotides uponexposure to UV light. Toxic adducts could thus be generated, especiallyconsidering the fact that HBcAgs have a strong tendency to bind nucleicacids. The toxic adducts would thus be distributed between amultiplicity of species, which individually may each be present at lowconcentration, but reach toxic levels when together.

In view of the above, one advantage to the use of HBcAgs in vaccinecompositions which have been modified to remove naturally residentcysteine residues is that sites to which toxic species can bind whenantigens or antigenic determinants are attached would be reduced innumber or eliminated altogether.

A number of naturally occurring HBcAg variants suitable for use in thepractice of the present invention have been identified. Yuan et al., (J.Virol. 73:10122-10128 (1999)), for example, describe variants in whichthe isoleucine residue at position corresponding to position 97 in SEQID NO:28 is replaced with either a leucine residue or a phenylalanineresidue. The amino acid sequences of a number of HBcAg variants, as wellas several Hepatitis B core antigen precursor variants, are disclosed inGenBank reports AAF121240 (SEQ ID NO:29), AF121239 (SEQ ID NO:30),X85297 (SEQ ID NO:31), X02496 (SEQ ID NO:32), X85305 (SEQ ID NO:33),X85303 (SEQ ID NO:34), AF151735 (SEQ ID NO:35), X85259 (SEQ ID NO:36),X85286 (SEQ ID NO:37), X85260 (SEQ ID NO:38), X85317 (SEQ ID NO:39),X85298 (SEQ ID NO:40), AF043593 (SEQ ID NO:41), M20706 (SEQ ID NO:42),X85295 (SEQ ID NO:43), X80925 (SEQ ID NO:44), X85284 (SEQ ID NO:45),X85275 (SEQ ID NO:46), X72702 (SEQ ID NO:47), X85291 (SEQ ID NO:48),X65258 (SEQ ID NO:49), X85302 (SEQ ID NO:50), M32138 (SEQ ID NO:51),X85293 (SEQ ID NO:52), X85315 (SEQ ID NO:53), U95551 (SEQ ID NO:54),X85256 (SEQ ID NO:55), X85316 (SEQ ID NO:56), X85296 (SEQ ID NO:57),AB033559 (SEQ ID NO:58), X59795 (SEQ ID NO:59), X85299 (SEQ ID NO:60),X85307 (SEQ ID NO:61), X65257 (SEQ ID NO:62), X85311 (SEQ ID NO:63),X85301 (SEQ ID NO:64), X85314 (SEQ ID NO:65), X85287 (SEQ ID NO:66),X85272 (SEQ ID NO:67), X85319 (SEQ ID NO:68), AB010289 (SEQ ID NO:69),X85285 (SEQ ID NO:70), AB010289 (SEQ ID NO:71), AF121242 (SEQ ID NO:72),M90520 (SEQ ID NO:73), P03153 (SEQ ID NO:74), AF110999 (SEQ ID NO:75),and M95589 (SEQ ID NO:76), the disclosures of each of which areincorporated herein by reference. These HBcAg variants differ in aminoacid sequence at a number of positions, including amino acid residueswhich corresponds to the amino acid residues located at positions 12,13, 21, 22, 24, 29, 32, 33, 35, 38, 40, 42, 44, 45, 49, 51, 57, 58, 59,64, 66, 67, 69, 74, 77, 80, 81, 87, 92, 93, 97, 98, 100, 103, 105, 106,109, 113, 116, 121, 126, 130, 133, 135, 141, 147, 149, 157, 176, 178,182 and 183 in SEQ ID NO:77. Further HBcAg variants suitable for use inthe compositions of the invention, and which may be further modifiedaccording to the disclosure of this specification are described in WO00/198333, WO 00/177158 and WO 00/214478.

HBcAgs suitable for use in the present invention can be derived from anyorganism so long as they are able to enclose or to be coupled orotherwise attached to, in particular as long as they are capable ofpackaging, an unmethylated CpG-containing oligonucleotide and induce animmune response.

As noted above, generally processed HBcAgs (i.e., those which lackleader sequences) will be used in the vaccine compositions of theinvention. The present invention includes vaccine compositions, as wellas methods for using these compositions, which employ the abovedescribed variant HBcAgs.

Further included within the scope of the invention are additional HBcAgvariants which are capable of associating to form dimeric or multimericstructures. Thus, the invention further includes vaccine compositionscomprising HBcAg polypeptides comprising, or alternatively consistingof, amino acid sequences which are at least 80%, 85%, 90%, 95%, 97% or99% identical to any of the wild-type amino acid sequences, and forms ofthese proteins which have been processed, where appropriate, to removethe N-terminal leader sequence.

Whether the amino acid sequence of a polypeptide has an amino acidsequence that is at least 80%, 85%, 90%, 95%, 97% or 99% identical toone of the wild-type amino acid sequences, or a subportion thereof, canbe determined conventionally using known computer programs such theBestfit program. When using Bestfit or any other sequence alignmentprogram to determine whether a particular sequence is, for instance, 95%identical to a reference amino acid sequence, the parameters are setsuch that the percentage of identity is calculated over the full lengthof the reference amino acid sequence and that gaps in homology of up to5% of the total number of amino acid residues in the reference sequenceare allowed.

The HBcAg variants and precursors having the amino acid sequences setout in SEQ ID NOs: 29-72 and 73-76 are relatively similar to each other.Thus, reference to an amino acid residue of a HBcAg variant located at aposition which corresponds to a particular position in SEQ ID NO:77,refers to the amino acid residue which is present at that position inthe amino acid sequence shown in SEQ ID NO:77. The homology betweenthese HBcAg variants is for the most part high enough among Hepatitis Bviruses that infect mammals so that one skilled in the art would havelittle difficulty reviewing both the amino acid sequence shown in SEQ IDNO:77 and in FIG. 1, respectively, and that of a particular HBcAgvariant and identifying “corresponding” amino acid residues.Furthermore, the HBcAg amino acid sequence shown in SEQ ID NO:73, whichshows the amino acid sequence of a HBcAg derived from a virus whichinfect woodchucks, has enough homology to the HBcAg having the aminoacid sequence shown in SEQ ID NO:77 that it is readily apparent that athree amino acid residue insert is present in SEQ ID NO:73 between aminoacid residues 155 and 156 of SEQ ID NO:77.

The invention also includes vaccine compositions which comprise HBcAgvariants of Hepatitis B viruses which infect birds, as wells as vaccinecompositions which comprise fragments of these HBcAg variants. As oneskilled in the art would recognize, one, two, three or more of thecysteine residues naturally present in these polypeptides could beeither substituted with another amino acid residue or deleted prior totheir inclusion in vaccine compositions of the invention.

As discussed above, the elimination of free cysteine residues reducesthe number of sites where toxic components can bind to the HBcAg, andalso eliminates sites where cross-linking of lysine and cysteineresidues of the same or of neighboring HBcAg molecules can occur.Therefore, in another embodiment of the present invention, one or morecysteine residues of the Hepatitis B virus capsid protein have beeneither deleted or substituted with another amino acid residue.

In other embodiments, compositions and vaccine compositions,respectively, of the invention will contain HBcAgs from which theC-terminal region (e.g., amino acid residues 145-185 or 150-185 of SEQID NO: 77) has been removed. Thus, additional modified HBcAgs suitablefor use in the practice of the present invention include C-terminaltruncation mutants. Suitable truncation mutants include HBcAgs where 1,5, 10, 15, 20, 25, 30, 34, 35, amino acids have been removed from theC-terminus.

HBcAgs suitable for use in the practice of the present invention alsoinclude N-terminal truncation mutants. Suitable truncation mutantsinclude modified HBcAgs where 1, 2, 5, 7, 9, 10, 12, 14, 15, or 17 aminoacids have been removed from the N-terminus.

Further HBcAgs suitable for use in the practice of the present inventioninclude N- and C-terminal truncation mutants. Suitable truncationmutants include HBcAgs where 1, 2, 5, 7, 9, 10, 12, 14, 15, and 17 aminoacids have been removed from the N-terminus and 1, 5, 10, 15, 20, 25,30, 34, 35 amino acids have been removed from the C-terminus.

The invention further includes compositions and vaccine compositions,respectively, comprising HBcAg polypeptides comprising, or alternativelyessentially consisting of, or alternatively consisting of, amino acidsequences which are at least 80%, 85%, 90%, 95%, 97%, or 99% identicalto the above described truncation mutants.

In certain embodiments of the invention, a lysine residue is introducedinto a HBcAg polypeptide, to mediate the binding of the antigen orantigenic determinant to the VLP of HBcAg. In preferred embodiments,compositions of the invention are prepared using a HBcAg comprising, oralternatively consisting of, amino acids 1-144, or 1-149, 1-185 of SEQID NO:77, which is modified so that the amino acids corresponding topositions 79 and 80 are replaced with a peptide having the amino acidsequence of Gly-Gly-Lys-Gly-Gly (SEQ ID NO:78). These compositions areparticularly useful in those embodiments where an antigenic determinantis coupled to a VLP of HBcAg. In further preferred embodiments, thecysteine residues at positions 48 and 107 of SEQ ID NO:77 are mutated toserine. The invention further includes compositions comprising thecorresponding polypeptides having amino acid sequences shown in any ofSEQ ID NOs:29-74 which also have above noted amino acid alterations.Further included within the scope of the invention are additional HBcAgvariants which are capable of associating to form a capsid or VLP andhave the above noted amino acid alterations. Thus, the invention furtherincludes compositions and vaccine compositions, respectively, comprisingHBcAg polypeptides which comprise, or alternatively consist of,identical to any of the wild-type amino acid sequences, and forms ofthese proteins which have been processed, where appropriate, to removethe N-terminal leader sequence and modified with above notedalterations.

Compositions or vaccine compositions of the invention may comprisemixtures of different HBcAgs. Thus, these vaccine compositions may becomposed of HBcAgs which differ in amino acid sequence. For example,vaccine compositions could be prepared comprising a “wild-type” HBcAgand a modified HBcAg in which one or more amino acid residues have beenaltered (e.g., deleted, inserted or substituted). Further, preferredvaccine compositions of the invention are those which present highlyordered and repetitive antigen arrays.

As previously disclosed, the invention is based on the surprisingfinding that immunostimulatory substances, preferably immunostimulatorynucleic acids and even more preferably DNA oligonucleotides can bepackaged into VLPs. Unexpectedly, the nucleic acids present in VLPs canbe replaced specifically by the immunostimulatory substances, preferablyby the immunostimulatory nucleic acids and even more preferably by theDNA-oligonucleotides containing CpG motifs. As an example, the CpG-VLPsare dramatically more immunogenic and elicit more specific effects thantheir CpG-free counterparts and induce enhanced B and T cell responses.The immune response against antigens coupled, fused or attachedotherwise to the VLPs is similarly enhanced as the immune responseagainst the VLP itself. In addition, the T cell responses against boththe VLPs and antigens are especially directed to the Th1 type.Furthermore, the packaged nucleic acids and CpGs, respectively, areprotected from degradation, i.e., they are more stable. Moreover,non-specific activation of cells from the innate immune system isdramatically reduced.

The innate immune system has the capacity to recognize invariantmolecular pattern shared by microbial pathogens. Recent studies haverevealed that this recognition is a crucial step in inducing effectiveimmune responses. The main mechanism by which microbial products augmentimmune responses is to stimulate APC, especially dendritic cells toproduce proinflammatory cytokines and to express high levelscostimulatory molecules for T cells. These activated dendritic cellssubsequently initiate primary T cell responses and dictate the type of Tcell-mediated effector function.

Two classes of nucleic acids, namely 1) bacterial DNA that containsimmunostimulatory sequences, in particular unmethylated CpGdinucleotides within specific flanking bases (referred to as CpG motifs)and 2) double-stranded RNA synthesized by various types of virusesrepresent important members of the microbial components that enhanceimmune responses. Synthetic double stranded (ds) RNA such aspolyinosinic-polycytidylic acid (poly I:C) are capable of inducingdendritic cells to produce proinflammatory cytokines and to express highlevels of costimulatory molecules.

A series of studies by Tokunaga and Yamamoto et al. has shown thatbacterial DNA or synthetic oligodeoxynucleotides induce human PBMC andmouse spleen cells to produce type I interferon (IFN) (reviewed inYamamoto et al., Springer Semin Immunopathol. 22:11-19). Poly (I:C) wasoriginally synthesized as a potent inducer of type I IFN but alsoinduces other cytokines such as IL-12.

Preferred ribonucleic acid encompass polyinosinic-polycytidylic aciddouble-stranded RNA (poly I:C). Ribonucleic acids and modificationsthereof as well as methods for their production have been described byLevy, H. B (Methods Enzymol. 1981, 78:242-251), DeClercq, E (MethodsEnzymol. 1981,78:227-236) and Torrence, P. F. (Methods Enzymol 1981;78:326-331) and references therein. Ribonucleic acids can be isolatedfrom organisms. Ribonucleic acids also encompass further syntheticribonucleic acids, in particular synthetic poly (I:C) oligonucleotidesthat have been rendered nuclease resistant by modification of thephosphodiester backbone, in particular by phosphorothioatemodifications. In a further embodiment the ribose backbone of poly (I:C)is replaced by a deoxyribose. Those skilled in the art know procedureshow to synthesize synthetic oligonucleotides.

In another preferred embodiment of the invention molecules that activetoll-like receptors (TLR) are enclosed. Ten human toll-like receptorsare known uptodate. They are activated by a variety of ligands. TLR2 isactivated by peptidoglycans, lipoproteins, lipoteichonic acid andZymosan; TLR3 is activated by double-stranded RNA such as poly (I:C);TLR4 is activated by lipopolysaccharide, lipoteichoic acids and taxol;TLR5 is activated by bacterial flagella, especially the flagellinprotein; TLR6 is activated by peptidoglycans, TLR7 is activated byimiquimoid and imidazoquinoline compounds, such as R418 and TLR9 isactivated by bacterial DNA, in particular CpG DNA. Ligands for TLR1,TLR8 and TLR10 are not known so far. However, recent reports indicatethat same receptors can react with different ligands and that furtherreceptors are present. The above list of ligands is not exhaustive andfurther ligands are within the knowledge of the person skilled in theart.

Preferably, the unmethylated CpG-containing oligonucleotide comprisesthe sequence:

-   -   5′ X₁X₂CGX₃X₄ 3′        wherein X₁, X₂, X₃ and X₄ are any nucleotide. In addition, the        oligonucleotide can comprise about 6 to about 100,000        nucleotides, preferably about 6 to about 2000 nucleotides, more        preferably about 20 to about 2000 nucleotides, and even more        preferably comprises about 20 to about 300 nucleotides. In        addition, the oligonucleotide can comprise more than 100 to        about 2000 nucleotides, preferably more than 100 to about 1000        nucleotides, and more preferably more than 100 to about 500        nucleotides.

In a preferred embodiment, the CpG-containing oligonucleotide containsone or more phosphorothioate modifications of the phosphate backbone.For example, a CpG-containing oligonucleotide having one or morephosphate backbone modifications or having all of the phosphate backbonemodified and a CpG-containing oligonucleotide wherein one, some or allof the nucleotide phosphate backbone modifications are phosphorothioatemodifications are included within the scope of the present invention.

The CpG-containing oligonucleotide can also be recombinant, genomic,synthetic, cDNA, plasmid-derived and single or double stranded. For usein the instant invention, the nucleic acids can be synthesized de novousing any of a number of procedures well known in the art. For example,the b-cyanoethyl phosphoramidite method (Beaucage, S. L., and Caruthers,M. H., Tet. Let. 22:1859 (1981); nucleoside H-phosphonate method (Garegget al., Tet. Let. 27:4051-4054 (1986); Froehler et al., Nucl. Acid. Res.14:5399-5407 (1986); Garegg et al., Tet. Let. 27:4055-4058 (1986),Gaffney et al., Tet. Let. 29:2619-2622 (1988)). These chemistries can beperformed by a variety of automated oligonucleotide synthesizersavailable in the market. Alternatively, CpGs can be produced on a largescale in plasmids, (see Sambrook, T., et al., “Molecular Cloning: ALaboratory Manual,” Cold Spring Harbor laboratory Press, New York, 1989)which after being administered to a subject are degraded intooligonucleotides. Oligonucleotides can be prepared from existing nucleicacid sequences (e.g., genomic or cDNA) using known techniques, such asthose employing restriction enzymes, exonucleases or endonucleases.

The immunostimulatory substances, the immunostimulatory nucleic acids aswell as the unmethylated CpG-containing oligonucleotide can be bound tothe VLP by any way known is the art provided the composition enhances animmune response in an animal. For example, the oligonucleotide can bebound either covalently or non-covalently. In addition, the VLP canenclose, fully or partially, the immunostimulatory substances, theimmunostimulatory nucleic acids as well as the unmethylatedCpG-containing oligonucleotide. Preferably, the immunostimulatorynucleic acid as well as the unmethylated CpG-containing oligonucleotidecan be bound to a VLP site such as an oligonucleotide binding site(either naturally or non-naturally occurring), a DNA binding site or aRNA binding site. In another embodiment, the VLP site comprises anarginine-rich repeat.

One specific use for the compositions of the invention is to activatedendritic cells for the purpose of enhancing a specific immune responseagainst antigens. The immune response can be enhanced using ex vivo orin vivo techniques. The ex vivo procedure can be used on autologous orheterologous cells, but is preferably used on autologous cells. Inpreferred embodiments, the dendritic cells are isolated from peripheralblood or bone marrow, but can be isolated from any source of dendriticcells. Ex vivo manipulation of dendritic cells for the purposes ofcancer immunotherapy have been described in several references in theart, including Engleman, E. G., Cytotechnology 25:1 (1997); VanSchooten, W., et al., Molecular Medicine Today, June, 255 (1997);Steinman, R. M., Experimental Hematology 24:849 (1996); and Gluckman, J.C., Cytokines, Cellular and Molecular Therapy 3:187 (1997).

The dendritic cells can also be contacted with the inventivecompositions using in vivo methods. In order to accomplish this, theCpGs are administered in combination with the VLP optionally coupled,fused or otherwise attached to an antigen directly to a subject in needof immunotherapy. In some embodiments, it is preferred that theVLPs/CpGs be administered in the local region of the tumor, which can beaccomplished in any way known in the art, e.g., direct injection intothe tumor.

The inventive composition can further comprise an antigen or antigenicdeterminant bound to the virus-like particle. The invention provides forcompositions that vary according to the antigen or antigenic determinantselected in consideration of the desired therapeutic effect. Verypreferred antigens or antigenic determinants suitable for use in thepresent invention are disclosed in WO 00/32227, in WO 01/85208 and in WO02/056905, the disclosures of which are herewith incorporated byreference in their entireties.

The antigen can be any antigen of known or yet unknown provenance. Itcan be isolated from bacteria, viruses or other pathogens or can be arecombinant antigen obtained from expression of suitable nucleic acidcoding therefor. It can also be isolated from prions, tumors,self-molecules, non-peptidic hapten molecules, allergens and hormones.In a preferred embodiment, the antigen is a recombinant antigen. Theselection of the antigen is, of course, dependent upon the immunologicalresponse desired and the host.

In one embodiment of the immune enhancing composition of the presentinvention, the immune response is induced against the VLP itself. Inanother embodiment of the invention a virus-like particle is coupled,fused or otherwise attached to an antigen/immunogen against which anenhanced immune response is desired.

In a further preferred embodiment of the invention, the at least oneantigen or antigenic determinant is fused to the virus-like particle. Asoutlined above, a VLP is typically composed of at least one subunitassembling into a VLP. Thus, in again a further preferred embodiment ofthe invention, the antigen or antigenic determinant is fused to at leastone subunit of the virus-like particle or of a protein capable of beingincorporated into a VLP generating a chimeric VLP-subunit-antigenfusion.

Fusion of the antigen or antigenic determinant can be effected byinsertion into the VLP subunit sequence, or by fusion to either the N-or C-terminus of the VLP-subunit or protein capable of beingincorporated into a VLP. Hereinafter, when referring to fusion proteinsof a peptide to a VLP subunit, the fusion to either ends of the subunitsequence or internal insertion of the peptide within the subunitsequence are encompassed.

Fusion may also be effected by inserting antigen or antigenicdeterminant sequences into a variant of a VLP subunit where part of thesubunit sequence has been deleted, that are further referred to astruncation mutants. Truncation mutants may have N- or C-terminal, orinternal deletions of part of the sequence of the VLP subunit. Forexample, the specific VLP HBcAg with, for example, deletion of aminoacid residues 79 to 81 is a truncation mutant with an internal deletion.Fusion of antigens or antigenic determinants to either the N- orC-terminus of the truncation mutants VLP-subunits also lead toembodiments of the invention. Likewise, fusion of an epitope into thesequence of the VLP subunit may also be effected by substitution, wherefor example for the specific VLP HBcAg, amino acids 79-81 are replacedwith a foreign epitope. Thus, fusion, as referred to hereinafter, may beeffected by insertion of the antigen or antigenic determinant sequencein the sequence of a VLP subunit, by substitution of part of thesequence of the VLP subunit with the antigen or antigenic determinant,or by a combination of deletion, substitution or insertions.

The chimeric antigen or antigenic determinant—VLP subunit will be ingeneral capable of self-assembly into a VLP. VLP displaying epitopesfused to their subunits are also herein referred to as chimeric VLPs. Asindicated, the virus-like particle comprises or alternatively iscomposed of at least one VLP subunit. In a further embodiment of theinvention, the virus-like particle comprises or alternatively iscomposed of a mixture of chimeric VLP subunits and non-chimeric VLPsubunits, i.e. VLP subunits not having an antigen fused thereto, leadingto so called mosaic particles. This may be advantageous to ensureformation of, and assembly to a VLP. In those embodiments, theproportion of chimeric VLP-subunits may be 1, 2, 5, 10, 20, 30, 40, 50,60, 70, 80, 90, 95% or higher.

Flanking amino acid residues may be added to either end of the sequenceof the peptide or epitope to be fused to either end of the sequence ofthe subunit of a VLP, or for internal insertion of such peptidicsequence into the sequence of the subunit of a VLP. Glycine and serineresidues are particularly favored amino acids to be used in the flankingsequences added to the peptide to be fused. Glycine residues conferadditional flexibility, which may diminish the potentially destabilizingeffect of fusing a foreign sequence into the sequence of a VLP subunit.

In a specific embodiment of the invention, the VLP is a Hepatitis B coreantigen VLP. Fusion proteins of the antigen or antigenic determinant toeither the N-terminus of a HBcAg (Neyrinck, S. et al., Nature Med.5:1157-1163 (1999)) or insertions in the so called major immunodominantregion (MIR) have been described (Pumpens, P. and Grens, E.,Intervirology 44:98-114 (2001)), WO 01/98333), and are preferredembodiments of the invention. Naturally occurring variants of HBcAg withdeletions in the MIR have also been described (Pumpens, P. and Grens,E., Intervirology 44:98-114 (2001), which is expressly incorporated byreference in its entirety), and fusions to the N- or C-terminus, as wellas insertions at the position of the MIR corresponding to the site ofdeletion as compared to a wt HBcAg are further embodiments of theinvention. Fusions to the C-terminus have also been described (Pumpens,P. and Grens, E., Intervirology 44:98-114 (2001)). One skilled in theart will easily find guidance on how to construct fusion proteins usingclassical molecular biology techniques (Sambrook, J. et al., eds.,Molecular Cloning, A Laboratory Manual, 2nd. edition, Cold Spring HaborLaboratory Press, Cold Spring Harbor, N.Y. (1989), Ho et al., Gene 77:51(1989)). Vectors and plasmids encoding HBcAg and HBcAg fusion proteinsand useful for the expression of a HBcAg and HBcAg fusion proteins havebeen described (Pumpens, P. & Grens, E. Intervirology 44: 98-114 (2001),Neyrinck, S. et al., Nature Med. 5:1157-1163 (1999)) and can be used inthe practice of the invention. An important factor for the optimizationof the efficiency of self-assembly and of the display of the epitope tobe inserted in the MIR of HBcAg is the choice of the insertion site, aswell as the number of amino acids to be deleted from the HBcAg sequencewithin the MIR (Pumpens, P. and Grens, E., Intervirology 44:98-114(2001); EP 0 421 635; U.S. Pat. No. 6,231,864) upon insertion, or inother words, which amino acids form HBcAg are to be substituted with thenew epitope. For example, substitution of HBcAg amino acids 76-80,79-81, 79-80, 75-85 or 80-81 with foreign epitopes has been described(Pumpens, P. and Grens, E., Intervirology 44:98-114 (2001); EPO421635;U.S. Pat. No. 6,231,864). HBcAg contains a long arginine tail (Pumpens,P. and Grens, E., Intervirology 44:98-114 (2001)) which is dispensablefor capsid assembly and capable of binding nucleic acids (Pumpens, P.and Grens, E., Intervirology 44:98-114 (2001)). HBcAg either comprisingor lacking this arginine tail are both embodiments of the invention.

In a further preferred embodiment of the invention, the VLP is a VLP ofa RNA phage. The major coat proteins of RNA phages spontaneouslyassemble into VLPs upon expression in bacteria, and in particular in E.coli. Specific examples of bacteriophage coat proteins which can be usedto prepare compositions of the invention include the coat proteins ofRNA bacteriophages such as bacteriophage Qβ (SEQ ID NO:10; PIR Database,Accession No. VCBPQβ referring to Qβ CP and SEQ ID NO: 11; Accession No.AAA16663 referring to Qβ A1 protein) and bacteriophage fr (SEQ ID NO:13; PIR Accession No. VCBPFR).

In a more preferred embodiment, the at least one antigen or antigenicdeterminant is fused to a Qβ coat protein. Fusion protein constructswherein epitopes have been fused to the C-terminus of a truncated formof the A1 protein of Qβ, or inserted within the A1protein have beendescribed (Kozlovska, T. M., et al., Intervirology, 39:9-15 (1996)). TheA1protein is generated by suppression at the UGA stop codon and has alength of 329 aa, or 328 aa, if the cleavage of the N-terminalmethionine is taken into account. Cleavage of the N-terminal methioninebefore an alanine (the second amino acid encoded by the Qβ CP gene)usually takes place in E. coli, and such is the case for N-termini ofthe Qβ coat proteins. The part of the A1 gene, 3′ of the UGA amber codonencodes the CP extension, which has a length of 195 amino acids.Insertion of the at least one antigen or antigenic determinant betweenposition 72 and 73 of the CP extension leads to further embodiments ofthe invention (Kozlovska, T. M., et al., Intervirology 39:9-15 (1996)).Fusion of an antigen or antigenic determinant at the C-terminus of aC-terminally truncated Qβ A1 protein leads to further preferredembodiments of the invention. For example, Kozlovska et al.,(Intervirology, 39: 9-15 (1996)) describe Qβ A1protein fusions where theepitope is fused at the C-terminus of the Qβ CP extension truncated atposition 19.

As described by Kozlovska et al. (Intervirology, 39: 9-15 (1996)),assembly of the particles displaying the fused epitopes typicallyrequires the presence of both the A1 protein-antigen fusion and the wtCP to form a mosaic particle. However, embodiments comprising virus-likeparticles, and hereby in particular the VLPs of the RNA phage Qβ coatprotein, which are exclusively composed of VLP subunits having at leastone antigen or antigenic determinant fused thereto, are also within thescope of the present invention.

The production of mosaic particles may be effected in a number of ways.Kozlovska et al., Intervirology, 39:9-15 (1996), describe three methods,which all can be used in the practice of the invention. In the firstapproach, efficient display of the fused epitope on the VLPs is mediatedby the expression of the plasmid encoding the Qβ A1protein fusion havinga UGA stop coding between CP and CP extension in a E. coli strainharboring a plasmid encoding a cloned UGA suppressor tRNA which leads totranslation of the UGA codon into Trp (pISM3001 plasmid (Smiley B. K.,et al., Gene 134:33-40 (1993))). In another approach, the CP gene stopcodon is modified into UAA, and a second plasmid expressing theA1protein-antigen fusion is cotransformed. The second plasmid encodes adifferent antibiotic resistance and the origin of replication iscompatible with the first plasmid (Kozlovska, T. M., et al.,Intervirology 39:9-15 (1996)). In a third approach, CP and theA1protein-antigen fusion are encoded in a bicistronic manner,operatively linked to a promoter such as the Trp promoter, as describedin FIG. 1 of Kozlovska et al., Intervirology, 39:9-15 (1996).

In a further embodiment, the antigen or antigenic determinant isinserted between amino acid 2 and 3 (numbering of the cleaved CP, thatis wherein the N-terminal methionine is cleaved) of the fr CP, thusleading to an antigen or antigenic determinant—fr CP fusion protein.Vectors and expression systems for construction and expression of fr CPfusion proteins self-assembling to VLP and useful in the practice of theinvention have been described (Pushko P. et al., Prot. Eng. 6:883-891(1993)). In a specific embodiment, the antigen or antigenic determinantsequence is inserted into a deletion variant of the fr CP after aminoacid 2, wherein residues 3 and 4 of the fr CP have been deleted (PushkoP. et al., Prot. Eng. 6:883-891 (1993)).

Fusion of epitopes in the N-terminal protuberant β-hairpin of the coatprotein of RNA phage MS-2 and subsequent presentation of the fusedepitope on the self-assembled VLP of RNA phage MS-2 has also beendescribed (WO 92/13081), and fusion of an antigen or antigenicdeterminant by insertion or substitution into the coat protein of MS-2RNA phage is also falling under the scope of the invention.

In another embodiment of the invention, the antigen or antigenicdeterminant is fused to a capsid protein of papillomavirus. In a morespecific embodiment, the antigen or antigenic determinant is fused tothe major capsid protein L1 of bovine papillomavirus type 1 (BPV-1).Vectors and expression systems for construction and expression of BPV-1fusion proteins in a baculovirus/insect cells systems have beendescribed (Chackerian, B. et al., Proc. Natl. Acad. Sci. USA96:2373-2378 (1999), WO 00/23955). Substitution of amino acids 130-136of BPV-1 L1 with an antigen or antigenic determinant leads to a BPV-1L1-antigen fusion protein, which is a preferred embodiment of theinvention. Cloning in a baculovirus vector and expression in baculovirusinfected Sf9 cells has been described, and can be used in the practiceof the invention (Chackerian, B. et al., Proc. Natl. Acad. Sci. USA96:2373-2378 (1999), WO 00/23955). Purification of the assembledparticles displaying the fused antigen or antigenic determinant can beperformed in a number of ways, such as for example gel filtration orsucrose gradient ultracentrifugation (Chackerian, B. et al., Proc. Natl.Acad. Sci. USA 96:2373-2378 (1999), WO 00/23955).

In a further embodiment of the invention, the antigen or antigenicdeterminant is fused to a Ty protein capable of being incorporated intoa Ty VLP. In a more specific embodiment, the antigen or antigenicdeterminant is fused to the p1 or capsid protein encoded by the TYA gene(Roth, J. F., Yeast 16:785-795 (2000)). The yeast retrotransposons Ty1,2, 3 and 4 have been isolated from Saccharomyces Serevisiae, while theretrotransposon Tf1 has been isolated from Schizosaccharomyces Pombae(Boeke, J. D. and Sandmeyer, S. B., “Yeast Transposable elements,” inThe molecular and Cellular Biology of the Yeast Saccharomyces: Genomedynamics, Protein Synthesis, and Energetics, p. 193, Cold Spring HarborLaboratory Press (1991)). The retrotransposons Ty1 and 2 are related tothe copia class of plant and animal elements, while Ty3 belongs to thegypsy family of retrotransposons, which is related to plants and animalretroviruses. In the Ty1 retrotransposon, the p1 protein, also referredto as Gag or capsid protein, has a length of 440 amino acids. P1 iscleaved during maturation of the VLP at position 408, leading to the p2protein, the essential component of the VLP.

Fusion proteins to p1 and vectors for the expression of said fusionproteins in Yeast have been described (Adams, S. E., et al., Nature329:68-70 (1987)). So, for example, an antigen or antigenic determinantmay be fused to p1 by inserting a sequence coding for the antigen orantigenic determinant into the BamH1 site of the pMA5620 plasmid (Adams,S. E., et al., Nature 329:68-70 (1987)). The cloning of sequences codingfor foreign epitopes into the pMA5620 vector leads to expression offusion proteins comprising amino acids 1-381 of p1 of Ty1-15, fusedC-terminally to the N-terminus of the foreign epitope. Likewise,N-terminal fusion of an antigen or antigenic determinant, or internalinsertion into the p1 sequence, or substitution of part of the p1sequence are also meant to fall within the scope of the invention. Inparticular, insertion of an antigen or antigenic determinant into the Tysequence between amino acids 30-31, 67-68, 113-114 and 132-133 of the Typrotein p1 (EP0677111) leads to preferred embodiments of the invention.

Further VLPs suitable for fusion of antigens or antigenic determinantsare, for example, Retrovirus-like-particles (WO9630523), HIV2 Gag (Kang,Y. C., et al, Biol. Chem. 380:353-364 (1999)), Cowpea Mosaic Virus(Taylor, K. M. et al., Biol. Chem. 380:387-392 (1999)), parvovirus VP2VLP (Rueda, P. et al., Virology 263:89-99 (1999)), HBsAg (U.S. Pat. No.4,722,840, EP0020416B1).

Examples of chimeric VLPs suitable for the practice of the invention arealso those described in Intervirology 39:1 (1996). Further examples ofVLPs contemplated for use in the invention are: HPV-1, HPV-6, HPV-11,HPV-16, HPV-18, HPV-33, HPV-45, CRPV, COPV, HIV GAG, Tobacco MosaicVirus. Virus-like particles of SV-40, Polyomavirus, Adenovirus, HerpesSimplex Virus, Rotavirus and Norwalk virus have also been made, andchimeric VLPs of those VLPs comprising an antigen or antigenicdeterminant are also within the scope of the present invention.

As indicated, embodiments comprising antigens fused to the virus-likeparticle by insertion within the sequence of the virus-like particlebuilding monomer are also within the scope of the present invention. Insome cases, antigens can be inserted in a form of the virus-likeparticle building monomer containing deletions. In these cases, thevirus-like particle building monomer may not be able to form virus-likestructures in the absence of the inserted antigen.

In some instances, recombinant DNA technology can be utilized to fuse aheterologous protein to a VLP protein (Kratz, P. A., et al., Proc. Natl.Acad. Sci. USA 96:1915 (1999)). For example, the present inventionencompasses VLPs recombinantly fused or chemically conjugated (includingboth covalently and non-covalently conjugations) to an antigen (orportion thereof, preferably at least 10, 20 or 50 amino acids) of thepresent invention to generate fusion proteins or conjugates. The fusiondoes not necessarily need to be direct, but can occur through linkersequences. More generally, in the case that epitopes, either fused,conjugated or otherwise attached to the virus-like particle, are used asantigens in accordance with the invention, spacer or linker sequencesare typically added at one or both ends of the epitopes. Such linkersequences preferably comprise sequences recognized by the proteasome,proteases of the endosomes or other vesicular compartment of the cell.

One way of coupling is by a peptide bond, in which the conjugate can bea contiguous polypeptide, i.e. a fusion protein. In a fusion proteinaccording to the present invention, different peptides or polypeptidesare linked in frame to each other to form a contiguous polypeptide. Thusa first portion of the fusion protein comprises an antigen or immunogenand a second portion of the fusion protein, either N-terminal orC-terminal to the first portion, comprises a VLP. Alternatively,internal insertion into the VLP, with optional linking sequences on bothends of the antigen, can also be used in accordance with the presentinvention.

When HBcAg is used as the VLP, it is preferred that the antigen islinked to the C-terminal end of the HBcAg particle. The hepatitis B coreantigen (HBcAg) exhibiting a C-terminal fusion of the MHC class Irestricted peptide p33 derived from lymphocytic choriomeningitis virus(LCMV) glycoprotein was used as a model antigen (HBcAg-p33). The 185amino acids long wild type HBc protein assembles into highly structuredparticles composed of 180 subunits assuming icosahedral geometry. Theflexibility of the HBcAg and other VLPs in accepting relatively largeinsertions of foreign sequences at different positions while retainingthe capacity to form structured capsids is well documented in theliterature. This makes the HBc VLPs attractive candidates for the designof non-replicating vaccines.

A flexible linker sequence (e.g. a polyglycine/polyserine-containingsequence such as [Gly₄ Ser]₂ (Huston et al., Meth. Enzymol 203:46-88(1991) (SEQ ID NO:129)) can be inserted into the fusion protein betweenthe antigen and ligand. Also, the fusion protein can be constructed tocontain an “epitope tag”, which allows the fusion protein to bind anantibody (e.g. monoclonal antibody) for example for labeling orpurification purposes. An example of an epitope tag is a Glu-Glu-Phetripeptide which is recognized by the monoclonal antibody YL1/2.

The invention also relates to the chimeric DNA which contains a sequencecoding for the VLP and a sequence coding for the antigen/immunogen. TheDNA can be expressed, for example, in insect cells transformed withBaculoviruses, in yeast or in bacteria. There are no restrictionsregarding the expression system, of which a large selection is availablefor routine use. Preferably, a system is used which allows expression ofthe proteins in large amounts. In general, bacterial expression systemsare preferred on account of their efficiency. One example of a bacterialexpression system suitable for use within the scope of the presentinvention is the one described by Clarke et al., J. Gen. Virol. 71:1109-1117 (1990); Borisova et al., J. Virol. 67: 3696-3701 (1993); andStudier et al., Methods Enzymol. 185:60-89 (1990). An example of asuitable yeast expression system is the one described by Emr, MethodsEnzymol. 185:231-3 (1990); Baculovirus systems, which have previouslybeen used for preparing capsid proteins, are also suitable. Constitutiveor inducible expression systems can be used. By the choice and possiblemodification of available expression systems it is possible to controlthe form in which the proteins are obtained.

In a specific embodiment of the invention, the antigen to which anenhanced immune response is desired is coupled, fused or otherwiseattached in frame to the Hepatitis B virus capsid (core) protein(HBcAg). However, it will be clear to all individuals in the art thatother virus-like particles can be utilized in the fusion proteinconstruct of the invention.

In a further preferred embodiment of the present invention, the at leastone antigen or antigenic determinant is bound to the virus-like particleby at least one covalent bond. Preferably, the least one antigen orantigenic determinant is bound to the virus-like particle by at leastone covalent bond, said covalent bond being a non-peptide bond leadingto an antigen or antigenic determinant array and antigen or antigenicdeterminant—VLP conjugate, respectively. This antigen or antigenicdeterminant array and conjugate, respectively, has typically andpreferably a repetitive and ordered structure since the at least oneantigen or antigenic determinant is bound to the VLP in an orientedmanner. The formation of a repetitive and ordered antigen or antigenicdeterminant—VLP array and conjugate, respectively, is ensured by anoriented and directed as well as defined binding and attachment,respectively, of the at least one antigen or antigenic determinant tothe VLP as will become apparent in the following. Furthermore, thetypical inherent highly repetitive and organized structure of the VLPsadvantageously contributes to the display of the antigen or antigenicdeterminant in a highly ordered and repetitive fashion leading to ahighly organized and repetitive antigen or antigenic determinant—VLParray and conjugate, respectively.

Therefore, the preferred inventive conjugates and arrays, respectively,differ from prior art conjugates in their highly organized structure,dimensions, and in the repetitiveness of the antigen on the surface ofthe array. The preferred embodiment of this invention, furthermore,allows expression of the particle in an expression host guaranteeingproper folding and assembly of the VLP, to which the antigen is thenfurther coupled

The present invention discloses methods of binding of antigen orantigenic determinant to VLPs. As indicated, in one aspect of theinvention, the at least one antigen or antigenic determinant is bound tothe VLP by way of chemical cross-linking, typically and preferably byusing a heterobifunctional cross-linker. Several hetero-bifunctionalcross-linkers are known to the art. In preferred embodiments, thehetero-bifunctional cross-linker contains a functional group which canreact with preferred first attachment sites, i.e. with the side-chainamino group of lysine residues of the VLP or at least one VLP subunit,and a further functional group which can react with a preferred secondattachment site, i.e. a cysteine residue fused to the antigen orantigenic determinant and optionally also made available for reaction byreduction. The first step of the procedure, typically called thederivatization, is the reaction of the VLP with the cross-linker. Theproduct of this reaction is an activated VLP, also called activatedcarrier. In the second step, unreacted cross-linker is removed usingusual methods such as gel filtration or dialysis. In the third step, theantigen or antigenic determinant is reacted with the activated VLP, andthis step is typically called the coupling step. Unreacted antigen orantigenic determinant may be optionally removed in a fourth step, forexample by dialysis. Several hetero-bifunctional cross-linkers are knownto the art. These include the preferred cross-linkers SMPH (Pierce),Sulfo-MBS, Sulfo-EMCS, Sulfo-GMBS, Sulfo-SIAB, Sulfo-SMPB, Sulfo-SMCC,SVSB, SIA and other cross-linkers available for example from the PierceChemical Company (Rockford, Ill., USA), and having one functional groupreactive towards amino groups and one functional group reactive towardscysteine residues. The above mentioned cross-linkers all lead toformation of a thioether linkage. Another class of cross-linkerssuitable in the practice of the invention is characterized by theintroduction of a disulfide linkage between the antigen or antigenicdeterminant and the VLP upon coupling. Preferred cross-linkers belongingto this class include for example SPDP and Sulfo-LC-SPDP (Pierce). Theextent of derivatization of the VLP with cross-linker can be influencedby varying experimental conditions such as the concentration of each ofthe reaction partners, the excess of one reagent over the other, the pH,the temperature and the ionic strength. The degree of coupling, i.e. theamount of antigens or antigenic determinants per subunits of the VLP canbe adjusted by varying the experimental conditions described above tomatch the requirements of the vaccine.

A particularly favored method of binding of antigens or antigenicdeterminants to the VLP, is the linking of a lysine residue on thesurface of the VLP with a cysteine residue on the antigen or antigenicdeterminant. In some embodiments, fusion of an amino acid linkercontaining a cysteine residue, as a second attachment site or as a partthereof, to the antigen or antigenic determinant for coupling to the VLPmay be required.

In general, flexible amino acid linkers are favored. Examples of theamino acid linker are selected from the group consisting of: (a) CGG(SEQ ID NO:130); (b) N-terminal gamma 1-linker; (c) N-terminal gamma3-linker; (d) Ig hinge regions; (e) N-terminal glycine linkers; (f)(G)_(k)C(G)_(n) with n=0-12 and k=0-5 (SEQ ID NO:131); (g) N-terminalglycine-serine linkers; (h) (G)_(k)C(G)_(m)(S)_(l)(GGGGS). (SEQ IDNO:127) with n=0-3, k=0-5, m=0-10, 1=0-2; (i) GGC (SEQ ID NO:135); (k)GGC-NH2 (SEQ ID NO:136); (l) C-terminal gamma 1-linker; (m) C-terminalgamma 3-linker; (n) C-terminal glycine linkers; (o) (G)_(n)C(G)_(k) withn=0-12 and k=0-5 (SEQ ID NO:132); (p) C-terminal glycine-serine linkers;(q) (G)_(m)(S)_(l)(GGGGS)_(n)(G)_(o)C(G)_(k) with n=0-3, k=0-5, m=0-10,1=0-2, and o=0-8 (SEQ ID NO:128).

Further examples of amino acid linkers are the hinge region ofImmunoglobulins, glycine serine linkers (GGGGS)_(n) (SEQ ID NO:133), andglycine linkers (G)_(n) all further containing a cysteine residue assecond attachment site and optionally further glycine residues.Typically preferred examples of said amino acid linkers are N-terminalgamma1: CGDKTHTSPP (SEQ ID NO:7); C-terminal gamma 1: DKTHTSPPCG (SEQ IDNO:8); N-terminal gamma 3: CGGPKPSTPPGSSGGAP (SEQ ID NO:9); C-terminalgamma 3: PKPSTPPGSSGGAPGGCG (SEQ ID NO:83); N-terminal glycine linker:GCGGGG (SEQ ID NO:84) and C-terminal glycine linker: GGGGCG (SEQ IDNO:85).

Other amino acid linkers particularly suitable in the practice of theinvention, when a hydrophobic antigen or antigenic determinant is boundto a VLP, are CGKKGG (SEQ ID NO:86), or CGDEGG (SEQ ID NO:87) forN-terminal linkers, or GGKKGC (SEQ ID NO:88) and GGEDGC (SEQ ID NO:89),for the C-terminal linkers. For the C-terminal linkers, the terminalcysteine is optionally C-terminally amidated.

In preferred embodiments of the present invention, GGCG (SEQ ID NO:134),GGC (SEQ ID NO:135) or GGC-NH2 (SEQ ID NO: 136, “NH2” stands foramidation) linkers at the C-terminus of the peptide or CGG at itsN-terminus are preferred as amino acid linkers. In general, glycineresidues will be inserted between bulky amino acids and the cysteine tobe used as second attachment site, to avoid potential steric hindranceof the bulkier amino acid in the coupling reaction. In the mostpreferred embodiment of the invention, the amino acid linker GGC-NH2(SEQ ID NO:136) is fused to the C-terminus of the antigen or antigenicdeterminant.

The cysteine residue present on the antigen or antigenic determinant hasto be in its reduced state to react with the hetero-bifunctionalcross-linker on the activated VLP, that is a free cysteine or a cysteineresidue with a free sulfhydryl group has to be available. In theinstance where the cysteine residue to function as binding site is in anoxidized form, for example if it is forming a disulfide bridge,reduction of this disulfide bridge with e.g. DTT, TCEP orβ-mercaptoethanol is required. Low concentrations of reducing agent arecompatible with coupling as described in WO 02/05690, higherconcentrations inhibit the coupling reaction, as a skilled artisan wouldknow, in which case the reductand has to be removed or its concentrationdecreased prior to coupling, e.g. by dialysis, gel filtration or reversephase HPLC.

Binding of the antigen or antigenic determinant to the VLP by using ahetero-bifunctional cross-linker according to the preferred methodsdescribed above, allows coupling of the antigen or antigenic determinantto the VLP in an oriented fashion. Other methods of binding the antigenor antigenic determinant to the VLP include methods wherein the antigenor antigenic determinant is cross-linked to the VLP using thecarbodiimide EDC, and NHS. In further methods, the antigen or antigenicdeterminant is attached to the VLP using a homo-bifunctionalcross-linker such as glutaraldehyde, DSG, BM[PEO]₄, BS³, (PierceChemical Company, Rockford, Ill., USA) or other known homo-bifunctionalcross-linkers with functional groups reactive towards amine groups orcarboxyl groups of the VLP.

Other methods of binding the VLP to an antigen or antigenic determinantinclude methods where the VLP is biotinylated, and the antigen orantigenic determinant expressed as a streptavidin-fusion protein, ormethods wherein both the antigen or antigenic determinant and the VLPare biotinylated, for example as described in WO 00/23955. In this case,the antigen or antigenic determinant may be first bound to streptavidinor avidin by adjusting the ratio of antigen or antigenic determinant tostreptavidin such that free binding sites are still available forbinding of the VLP, which is added in the next step. Alternatively, allcomponents may be mixed in a “one pot” reaction. Other ligand-receptorpairs, where a soluble form of the receptor and of the ligand isavailable, and are capable of being cross-linked to the VLP or theantigen or antigenic determinant, may be used as binding agents forbinding antigen or antigenic determinant to the VLP. Alternatively,either the ligand or the receptor may be fused to the antigen orantigenic determinant, and so mediate binding to the VLP chemicallybound or fused either to the receptor, or the ligand respectively.Fusion may also be effected by insertion or substitution.

As already indicated, in a favored embodiment of the present invention,the VLP is the VLP of a RNA phage, and in a more preferred embodiment,the VLP is the VLP of RNA phage Qβ coat protein.

One or several antigen molecules, i.e. one or several antigens orantigenic determinants, can be attached to one subunit of the capsid orVLP of RNA phages coat proteins, preferably through the exposed lysineresidues of the VLP of RNA phages, if sterically allowable. A specificfeature of the VLP of the coat protein of RNA phages and in particularof the Qβ coat protein VLP is thus the possibility to couple severalantigens per subunit. This allows for the generation of a dense antigenarray.

In a preferred embodiment of the invention, the binding and attachment,respectively, of the at least one antigen or antigenic determinant tothe virus-like particle is by way of interaction and association,respectively, between at least one first attachment site of thevirus-like particle and at least one second attachment of the antigen orantigenic determinant.

VLPs or capsids of Qβ coat protein display a defined number of lysineresidues on their surface, with a defined topology with three lysineresidues pointing towards the interior of the capsid and interactingwith the RNA, and four other lysine residues exposed to the exterior ofthe capsid. These defined properties favor the attachment of antigens tothe exterior of the particle, rather than to the interior of theparticle where the lysine residues interact with RNA. VLPs of other RNAphage coat proteins also have a defined number of lysine residues ontheir surface and a defined topology of these lysine residues.

In further preferred embodiments of the present invention, the firstattachment site is a lysine residue and/or the second attachmentcomprises sulfhydryl group or a cysteine residue. In a very preferredembodiment of the present invention, the first attachment site is alysine residue and the second attachment is a cysteine residue.

In very preferred embodiments of the invention, the antigen or antigenicdeterminant is bound via a cysteine residue, to lysine residues of theVLP of RNA phage coat protein, and in particular to the VLP of Qβ coatprotein.

Another advantage of the VLPs derived from RNA phages is their highexpression yield in bacteria that allows production of large quantitiesof material at affordable cost.

As indicated, the inventive conjugates and arrays, respectively, differfrom prior art conjugates in their highly organized structure,dimensions, and in the repetitiveness of the antigen on the surface ofthe array. Moreover, the use of the VLPs as carriers allow the formationof robust antigen arrays and conjugates, respectively, with variableantigen density. In particular, the use of VLPs of RNA phages, andhereby in particular the use of the VLP of RNA phage Qβ coat proteinallows to achieve very high epitope density. In particular, a density ofmore than 1.5 epitopes per subunit could be reached by coupling thehuman Aβ1-6 peptide to the VLP of Qβ coat protein. The preparation ofcompositions of VLPs of RNA phage coat proteins with a high epitopedensity can be effected using the teaching of this application. Inpreferred embodiment of the invention, when an antigen or antigenicdeterminant is coupled to the VLP of Qβ coat protein, an average numberof antigen or antigenic determinant per subunit of 0.5, 0.6, 0.7, 0.8,0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2,2.3, 2.4 2.5, 2.6, 2.7, 2.8, 2.9, or higher is preferred.

The second attachment site, as defined herein, may be either naturallyor non-naturally present with the antigen or the antigenic determinant.In the case of the absence of a suitable natural occurring secondattachment site on the antigen or antigenic determinant, such a, thennon-natural second attachment has to be engineered to the antigen.

As described above, four lysine residues are exposed on the surface ofthe VLP of Qβ coat protein. Typically these residues are derivatizedupon reaction with a cross-linker molecule. In the instance where notall of the exposed lysine residues can be coupled to an antigen, thelysine residues which have reacted with the cross-linker are left with across-linker molecule attached to the ε-amino group after thederivatization step. This leads to disappearance of one or severalpositive charges, which may be detrimental to the solubility andstability of the VLP. By replacing some of the lysine residues witharginines, as in the disclosed Qβ coat protein mutants described below,we prevent the excessive disappearance of positive charges since thearginine residues do not react with the cross-linker. Moreover,replacement of lysine residues by arginines may lead to more definedantigen arrays, as fewer sites are available for reaction to theantigen.

Accordingly, exposed lysine residues were replaced by arginines in thefollowing Qβ coat protein mutants and mutant Qβ VLPs disclosed in thisapplication: Qβ-240 (Lys13-Arg; SEQ ID NO:23), Qβ-250 (Lys 2-Arg,Lys13-Arg; SEQ ID NO: 25) and Qβ-259 (Lys 2-Arg, Lys16-Arg; SEQ IDNO:27). The constructs were cloned, the proteins expressed, the VLPspurified and used for coupling to peptide and protein antigens. Qβ-251;(SEQ ID NO: 26) was also constructed, and guidance on how to express,purify and couple the VLP of Qβ-251 coat protein can be found throughoutthe application.

In a further embodiment, we disclose a Qβ mutant coat protein with oneadditional lysine residue, suitable for obtaining even higher densityarrays of antigens. This mutant Qβ coat protein, Qβ-243 (Asn 10-Lys; SEQID NO: 24), was cloned, the protein expressed, and the capsid or VLPisolated and purified, showing that introduction of the additionallysine residue is compatible with self-assembly of the subunits to acapsid or VLP. Thus, antigen or antigenic determinant arrays andconjugates, respectively, may be prepared using VLP of Qβ coat proteinmutants. A particularly favored method of attachment of antigens toVLPs, and in particular to VLPs of RNA phage coat proteins is thelinking of a lysine residue present on the surface of the VLP of RNAphage coat proteins with a cysteine residue added to the antigen. Inorder for a cysteine residue to be effective as second attachment site,a sulfhydryl group must be available for coupling. Thus, a cysteineresidue has to be in its reduced state, that is, a free cysteine or acysteine residue with a free sulfhydryl group has to be available. Inthe instant where the cysteine residue to function as second attachmentsite is in an oxidized form, for example if it is forming a disulfidebridge, reduction of this disulfide bridge with e.g. DTT, TCEP orβ-mercaptoethanol is required. The concentration of reductand, and themolar excess of reductand over antigen has to be adjusted for eachantigen. A titration range, starting from concentrations as low as 10 μMor lower, up to 10 to 20 mM or higher reductand if required is tested,and coupling of the antigen to the carrier assessed. Although lowconcentrations of reductand are compatible with the coupling reaction asdescribed in WO 02/056905, higher concentrations inhibit the couplingreaction, as a skilled artisan would know, in which case the reductandhas to be removed or its concentration decreased, e.g. by dialysis, gelfiltration or reverse phase HPLC. Advantageously, the pH of the dialysisor equilibration buffer is lower than 7, preferably 6. The compatibilityof the low pH buffer with antigen activity or stability has to betested.

Epitope density on the VLP of RNA phage coat proteins can be modulatedby the choice of cross-linker and other reaction conditions. Forexample, the cross-linkers Sulfo-GMBS and SMPH typically allow reachinghigh epitope density. Derivatization is positively influenced by highconcentration of reactands, and manipulation of the reaction conditionscan be used to control the number of antigens coupled to VLPs of RNAphage coat proteins, and in particular to VLPs of Qβ coat protein.

Prior to the design of a non-natural second attachment site the positionat which it should be fused, inserted or generally engineered has to bechosen. The selection of the position of the second attachment site may,by way of example, be based on a crystal structure of the antigen. Sucha crystal structure of the antigen may provide information on theavailability of the C- or N-termini of the molecule (determined forexample from their accessibility to solvent), or on the exposure tosolvent of residues suitable for use as second attachment sites, such ascysteine residues. Exposed disulfide bridges, as is the case for Fabfragments, may also be a source of a second attachment site, since theycan be generally converted to single cysteine residues through mildreduction, with e.g. 2-mercaptoethylamine, TCEP, β-mercaptoethanol orDTT. Mild reduction conditions not affecting the immunogenicity of theantigen will be chosen. In general, in the case where immunization witha self-antigen is aiming at inhibiting the interaction of thisself-antigen with its natural ligands, the second attachment site willbe added such that it allows generation of antibodies against the siteof interaction with the natural ligands. Thus, the location of thesecond attachment site will be selected such that steric hindrance fromthe second attachment site or any amino acid linker containing the sameis avoided. In further embodiments, an antibody response directed at asite distinct from the interaction site of the self-antigen with itsnatural ligand is desired. In such embodiments, the second attachmentsite may be selected such that it prevents generation of antibodiesagainst the interaction site of the self-antigen with its naturalligands.

Other criteria in selecting the position of the second attachment siteinclude the oligomerization state of the antigen, the site ofoligomerization, the presence of a cofactor, and the availability ofexperimental evidence disclosing sites in the antigen structure andsequence where modification of the antigen is compatible with thefunction of the self-antigen, or with the generation of antibodiesrecognizing the self-antigen.

In very preferred embodiments, the antigen or antigenic determinantcomprises a single second attachment site or a single reactiveattachment site capable of association with the first attachment siteson the core particle and the VLPs or VLP subunits, respectively. Thisfurther ensures a defined and uniform binding and association,respectively, of the at least one, but typically more than one,preferably more than 10, 20, 40, 80, 120 antigens to the core particleand VLP, respectively. The provision of a single second attachment siteor a single reactive attachment site on the antigen, thus, ensures asingle and uniform type of binding and association, respectively leadingto a very highly ordered and repetitive array. For example, if thebinding and association, respectively, is effected by way of alysine—(as the first attachment site) and cysteine—(as a secondattachment site) interaction, it is ensured, in accordance with thispreferred embodiment of the invention, that only one cysteine residueper antigen, independent whether this cysteine residue is naturally ornon-naturally present on the antigen, is capable of binding andassociating, respectively, with the VLP and the first attachment site ofthe core particle, respectively.

In some embodiments, engineering of a second attachment site onto theantigen require the fusion of an amino acid linker containing an aminoacid suitable as second attachment site according to the disclosures ofthis invention. Therefore, in a preferred embodiment of the presentinvention, an amino acid linker is bound to the antigen or the antigenicdeterminant by way of at least one covalent bond. Preferably, the aminoacid linker comprises, or alternatively consists of, the secondattachment site. In a further preferred embodiment, the amino acidlinker comprises a sulfhydryl group or a cysteine residue. In anotherpreferred embodiment, the amino acid linker is cysteine. Some criteriaof selection of the amino acid linker as well as further preferredembodiments of the amino acid linker according to the invention havealready been mentioned above.

In another specific embodiment of the invention, the attachment site isselected to be a lysine or cysteine residue that is fused in frame tothe HBcAg. In a preferred embodiment, the antigen is fused to theC-terminus of HBcAg via a three leucine linker.

When an antigen or antigenic determinant is linked to the VLP through alysine residue, it may be advantageous to either substitute or deleteone or more of the naturally resident lysine residues, as well as otherlysine residues present in HBcAg variants.

In many instances, when the naturally resident lysine residues areeliminated, another lysine will be introduced into the HBcAg as anattachment site for an antigen or antigenic determinant. Methods forinserting such a lysine residue are known in the art. Lysine residuesmay also be added without removing existing lysine residues.

The C-terminus of the HBcAg has been shown to direct nuclearlocalization of this protein. (Eckhardt et al., J. Virol. 65:575-582(1991)). Further, this region of the protein is also believed to conferupon the HBcAg the ability to bind nucleic acids.

As indicated, HBcAgs suitable for use in the practice of the presentinvention also include N-terminal truncation mutants. Suitabletruncation mutants include modified HBcAgs where 1, 2, 5, 7, 9, 10, 12,14, 15, or 17 amino acids have been removed from the N-terminus.However, variants of virus-like particles containing internal deletionswithin the sequence of the subunit composing the virus-like particle arealso suitable in accordance with the present invention, provided theircompatibility with the ordered or particulate structure of thevirus-like particle. For example, internal deletions within the sequenceof the HBcAg are suitable (Preikschat, P., et al., J. Gen. Virol.80:1777-1788 (1999)).

Further HBcAgs suitable for use in the practice of the present inventioninclude N- and C-terminal truncation mutants. Suitable truncationmutants include HBcAgs where 1, 2, 5, 7, 9, 10, 12, 14, 15, and 17 aminoacids have been removed from the N-terminus and 1, 5, 10, 15, 20, 25,30, 34, 35, 36, 37, 38, 39 40, 41, 42 or 48 amino acids have beenremoved from the C-terminus.

Vaccine compositions of the invention can comprise mixtures of differentHBcAgs. Thus, these vaccine compositions can be composed of HBcAgs whichdiffer in amino acid sequence. For example, vaccine compositions couldbe prepared comprising a “wild-type” HBcAg and a modified HBcAg in whichone or more amino acid residues have been altered (e.g., deleted,inserted or substituted). In most applications, however, only one typeof a HBcAg will be used.

The present invention is applicable to a wide variety of antigens. In apreferred embodiment, the antigen is a protein, polypeptide or peptide.In another embodiment the antigen is DNA. The antigen can also be alipid, a carbohydrate, or an organic molecule, in particular a smallorganic molecule such as nicotine.

Antigens of the invention can be selected from the group consisting ofthe following: (a) polypeptides suited to induce an immune responseagainst cancer cells; (b) polypeptides suited to induce an immuneresponse against infectious diseases; (c) polypeptides suited to inducean immune response against allergens; (d) polypeptides suited to inducean immune response in farm animals or pets; and (e) fragments (e.g., adomain) of any of the polypeptides set out in (a)-(d).

Preferred antigens include those from a pathogen (e.g. virus, bacterium,parasite, fungus) and tumors (especially tumor-associated antigens or“tumor markers”). Other preferred antigens are autoantigens.

In the specific embodiments described in the Examples, the antigen isthe peptide p33 derived from lymphocytic choriomeningitis virus (LCMV).The p33 peptide represents one of the best studied CTL epitopes (Pircheret al., “Tolerance induction in double specific T-cell receptortransgenic mice varies with antigen,” Nature 342:559 (1989); Tissot etal., “Characterizing the functionality of recombinant T-cell receptorsin vitro: a pMHC tetramer based approach,” J Immunol Methods 236:147(2000); Bachmann et al., “Four types of Ca2+-signals after stimulationof naive T cells with T cell agonists, partial agonists andantagonists,” Eur. J. Immunol. 27:3414 (1997); Bachmann et al.,“Functional maturation of an anti-viral cytotoxic T cell response,” J.Virol. 71:5764 (1997); Bachmann et al., “Peptide induced TCR-downregulation on naive T cell predicts agonist/partial agonist propertiesand strictly correlates with T cell activation,” Eur. J. Immunol.27:2195 (1997); Bachmann et al., “Distinct roles for LFA-1 and CD28during activation of naive T cells: adhesion versus costimulation,”Immunity 7:549 (1997)). p33-specific T cells have been shown to inducelethal diabetic disease in transgenic mice (Ohashi et al., “Ablation of‘tolerance’ and induction of diabetes by virus infection in viralantigen transgenic mice,” Cell 65:305 (1991)) as well as to be able toprevent growth of tumor cells expressing p33 (Kundig et al.,“Fibroblasts act as efficient antigen-presenting cells in lymphoidorgans,” Science 268:1343 (1995); Speiser et al., “CTL tumor therapyspecific for an endogenous antigen does not cause autoimmune disease,”J. Exp. Med. 186:645 (1997)). This specific epitope, therefore, isparticularly well suited to study autoimmunity, tumor immunology as wellas viral diseases.

In one specific embodiment of the invention, the antigen or antigenicdeterminant is one that is useful for the prevention of infectiousdisease. Such treatment will be useful to treat a wide variety ofinfectious diseases affecting a wide range of hosts, e.g., human, cow,sheep, pig, dog, cat, other mammalian species and non-mammalian speciesas well. Treatable infectious diseases are well known to those skilledin the art, and examples include infections of viral etiology such asHIV, influenza, Herpes, viral hepatitis, Epstein Bar, polio, viralencephalitis, measles, chicken pox, Papilloma virus etc.; or infectionsof bacterial etiology such as pneumonia, tuberculosis, syphilis, etc.;or infections of parasitic etiology such as malaria, trypanosomiasis,leishmaniasis, trichomoniasis, amoebiasis, etc. Thus, antigens orantigenic determinants selected for the compositions of the inventionwill be well known to those in the medical art; examples of antigens orantigenic determinants include the following: the HIV antigens gp140 andgp160; the influenza antigens hemagglutinin, M2 protein andneuraminidase, Hepatitis B surface antigen or core and circumsporozoiteprotein of malaria or fragments thereof.

As discussed above, antigens include infectious microbes such asviruses, bacteria and fungi and fragments thereof, derived from naturalsources or synthetically. Infectious viruses of both human and non-humanvertebrates include retroviruses, RNA viruses and DNA viruses. The groupof retroviruses includes both simple retroviruses and complexretroviruses. The simple retroviruses include the subgroups of B-typeretroviruses, C-type retroviruses and D-type retroviruses. An example ofa B-type retrovirus is mouse mammary tumor virus (MMTV). The C-typeretroviruses include subgroups C-type group A (including Rous sarcomavirus (RSV), avian leukemia virus (ALV), and avian myeloblastosis virus(AMV)) and C-type group B (including murine leukemia virus (MLV), felineleukemia virus (FeLV), murine sarcoma virus (MSV), gibbon ape leukemiavirus (GALV), spleen necrosis virus (SNV), reticuloendotheliosis virus(RV) and simian sarcoma virus (SSV)). The D-type retroviruses includeMason-Pfizer monkey virus (MPMV) and simian retrovirus type 1 (SRV-1).The complex retroviruses include the subgroups of lentiviruses, T-cellleukemia viruses and the foamy viruses. Lentiviruses include HIV-1, butalso include HIV-2, SIV, Visna virus, feline immunodeficiency virus(FIV), and equine infectious anemia virus (EIAV). The T-cell leukemiaviruses include HTLV-1, HTLV-II, simian T-cell leukemia virus (STLV),and bovine leukemia virus (BLV). The foamy viruses include human foamyvirus (HFV), simian foamy virus (SFV) and bovine foamy virus (BFV).

Examples of RNA viruses that are antigens in vertebrate animals include,but are not limited to, the following: members of the family Reoviridae,including the genus Orthoreovirus (multiple serotypes of both mammalianand avian retroviruses), the genus Orbivirus (Bluetongue virus,Eugenangee virus, Kemerovo virus, African horse sickness virus, andColorado Tick Fever virus), the genus Rotavirus (human rotavirus,Nebraska calf diarrhea virus, murine rotavirus, simian rotavirus, bovineor ovine rotavirus, avian rotavirus); the family Picomaviridae,including the genus Enterovirus (poliovirus, Coxsackie virus A and B,enteric cytopathic human orphan (ECHO) viruses, hepatitis A, C, D, E andG viruses, Simian enteroviruses, Murine encephalomyelitis (ME) viruses,Poliovirus muris, Bovine enteroviruses, Porcine enteroviruses, the genusCardiovirus (Encephalomyocarditis virus (EMC), Mengovirus), the genusRhinovirus (Human rhinoviruses including at least 113 subtypes; otherrhinoviruses), the genus Apthovirus (Foot and Mouth disease (FMDV); thefamily Calciviridae, including Vesicular exanthema of swine virus, SanMiguel sea lion virus, Feline picornavirus and Norwalk virus; the familyTogaviridae, including the genus Alphavirus (Eastern equine encephalitisvirus, Semliki forest virus, Sindbis virus, Chikungunya virus,O'Nyong-Nyong virus, Ross river virus, Venezuelan equine encephalitisvirus, Western equine encephalitis virus), the genus Flavirius (Mosquitoborne yellow fever virus, Dengue virus, Japanese encephalitis virus, St.Louis encephalitis virus, Murray Valley encephalitis virus, West Nilevirus, Kunjin virus, Central European tick borne virus, Far Eastern tickborne virus, Kyasanur forest virus, Louping III virus, Powassan virus,Omsk hemorrhagic fever virus), the genus Rubivirus (Rubella virus), thegenus Pestivirus (Mucosal disease virus, Hog cholera virus, Borderdisease virus); the family Bunyaviridae, including the genus Bunyvirus(Bunyamwera and related viruses, California encephalitis group viruses),the genus Phlebovirus (Sandfly fever Sicilian virus, Rift Valley fevervirus), the genus Nairovirus (Crimean-Congo hemorrhagic fever virus,Nairobi sheep disease virus), and the genus Uukuvirus (Uukuniemi andrelated viruses); the family Orthomyxoviridae, including the genusInfluenza virus (Influenza virus type A, many human subtypes); Swineinfluenza virus, and Avian and Equine Influenza viruses; influenza typeB (many human subtypes), and influenza type C (possible separate genus);the family paramyxoviridae, including the genus Paramyxovirus(Parainfluenza virus type 1, Sendai virus, Hemadsorption virus,Parainfluenza viruses types 2 to 5, Newcastle Disease Virus, Mumpsvirus), the genus Morbillivirus (Measles virus, subacute sclerosingpanencephalitis virus, distemper virus, Rinderpest virus), the genusPneumovirus (respiratory syncytial virus (RSV), Bovine respiratorysyncytial virus and Pneumonia virus of mice); forest virus, Sindbisvirus, Chikungunya virus, O'Nyong-Nyong virus, Ross river virus,Venezuelan equine encephalitis virus, Western equine encephalitisvirus), the genus Flavirius (Mosquito borne yellow fever virus, Denguevirus, Japanese encephalitis virus, St. Louis encephalitis virus, MurrayValley encephalitis virus, West Nile virus, Kunjin virus, CentralEuropean tick borne virus, Far Eastern tick borne virus, Kyasanur forestvirus, Louping III virus, Powassan virus, Omsk hemorrhagic fever virus),the genus Rubivirus (Rubella virus), the genus Pestivirus (Mucosaldisease virus, Hog cholera virus, Border disease virus); the familyBunyaviridae, including the genus Bunyvirus (Bunyamwera and relatedviruses, California encephalitis group viruses), the genus Phlebovirus(Sandfly fever Sicilian virus, Rift Valley fever virus), the genusNairovirus (Crimean-Congo hemorrhagic fever virus, Nairobi sheep diseasevirus), and the genus Uukuvirus (Uukuniemi and related viruses); thefamily Orthomyxoviridae, including the genus Influenza virus (Influenzavirus type A, many human subtypes); Swine influenza virus, and Avian andEquine Influenza viruses; influenza type B (many human subtypes), andinfluenza type C (possible separate genus); the family paramyxoviridae,including the genus Paramyxovirus (Parainfluenza virus type 1, Sendaivirus, Hemadsorption virus, Parainfluenza viruses types 2 to 5,Newcastle Disease Virus, Mumps virus), the genus Morbillivirus (Measlesvirus, subacute sclerosing panencephalitis virus, distemper virus,Rinderpest virus), the genus Pneumovirus (respiratory syncytial virus(RSV), Bovine respiratory syncytial virus and Pneumonia virus of mice);the family Rhabdoviridae, including the genus Vesiculovirus (VSV),Chandipura virus, Flanders-Hart Park virus), the genus Lyssavirus(Rabies virus), fish Rhabdoviruses and filoviruses (Marburg virus andEbola virus); the family Arenaviridae, including Lymphocyticchoriomeningitis virus (LCM), Tacaribe virus complex, and Lassa virus;the family Coronoaviridae, including Infectious Bronchitis Virus (IBV),Mouse Hepatitis virus, Human enteric corona virus, and Feline infectiousperitonitis (Feline coronavirus).

Illustrative DNA viruses that are antigens in vertebrate animalsinclude, but are not limited to: the family Poxviridae, including thegenus Orthopoxvirus (Variola major, Variola minor, Monkey pox Vaccinia,Cowpox, Buffalopox, Rabbitpox, Ectromelia), the genus Leporipoxvirus(Myxoma, Fibroma), the genus Avipoxvirus (Fowlpox, other avianpoxvirus), the genus Capripoxvirus (sheeppox, goatpox), the genusSuipoxvirus (Swinepox), the genus Parapoxvirus (contagious postulardermatitis virus, pseudocowpox, bovine papular stomatitis virus); thefamily Iridoviridae (African swine fever virus, Frog viruses 2 and 3,Lymphocystis virus of fish); the family Herpesviridae, including thealpha-Herpesviruses (Herpes Simplex Types 1 and 2, Varicella-Zoster,Equine abortion virus, Equine herpes virus 2 and 3, pseudorabies virus,infectious bovine keratoconjunctivitis virus, infectious bovinerhinotracheitis virus, feline rhinotracheitis virus, infectiouslaryngotracheitis virus) the Beta-herpesviruses (Human cytomegalovirusand cytomegaloviruses of swine, monkeys and rodents); thegamma-herpesviruses (Epstein-Barr virus (EBV), Marek's disease virus,Herpes saimiri, Herpesvirus ateles, Herpesvirus sylvilagus, guinea pigherpes virus, Lucke tumor virus); the family Adenoviridae, including thegenus Mastadenovirus (Human subgroups A, B, C, D and E and ungrouped;simian adenoviruses (at least 23 serotypes), infectious caninehepatitis, and adenoviruses of cattle, pigs, sheep, frogs and many otherspecies, the genus Aviadenovirus (Avian adenoviruses); andnon-cultivatable adenoviruses; the family Papoviridae, including thegenus Papillomavirus (Human papilloma viruses, bovine papilloma viruses,Shope rabbit papilloma virus, and various pathogenic papilloma virusesof other species), the genus Polyomavirus (polyomavirus, Simianvacuolating agent (SV-40), Rabbit vacuolating agent (RKV), K virus, BKvirus, JC virus, and other primate polyoma viruses such as Lymphotrophicpapilloma virus); the family Parvoviridae including the genusAdeno-associated viruses, the genus Parvovirus (Feline panleukopeniavirus, bovine parvovirus, canine parvovirus, Aleutian mink diseasevirus, etc.). Finally, DNA viruses may include viruses which do not fitinto the above families such as Kuru and Creutzfeldt-Jacob diseaseviruses and chronic infectious neuropathic agents (CHINA virus).

Each of the foregoing lists is illustrative, and is not intended to belimiting.

In a specific embodiment of the invention, the antigen comprises one ormore cytotoxic T cell epitopes, Th cell epitopes, or a combination ofthe two epitopes.

In addition to enhancing an antigen specific immune response in humans,the methods of the preferred embodiments are particularly well suitedfor treatment of other mammals or other animals, e.g., birds such ashens, chickens, turkeys, ducks, geese, quail and pheasant. Birds areprime targets for many types of infections.

An example of a common infection in chickens is chicken infectiousanemia virus (CIAV). CIAV was first isolated in Japan in 1979 during aninvestigation of a Marek's disease vaccination break (Yuasa et al.,Avian Dis. 23:366-385 (1979)). Since that time, CIAV has been detectedin commercial poultry in all major poultry producing countries (vanBulow et al., pp. 690-699 in “Diseases of Poultry”, 9th edition, IowaState University Press 1991).

Vaccination of birds, like other vertebrate animals can be performed atany age. Normally, vaccinations are performed at up to 12 weeks of agefor a live microorganism and between 14-18 weeks for an inactivatedmicroorganism or other type of vaccine. For in ovo vaccination,vaccination can be performed in the last quarter of embryo development.The vaccine can be administered subcutaneously, by spray, orally,intraocularly, intratracheally, nasally, in ovo or by other methodsdescribed herein.

Cattle and livestock are also susceptible to infection. Disease whichaffect these animals can produce severe economic losses, especiallyamongst cattle. The methods of the invention can be used to protectagainst infection in livestock, such as cows, horses, pigs, sheep andgoats.

Cows can be infected by bovine viruses. Bovine viral diarrhea virus(BVDV) is a small enveloped positive-stranded RNA virus and isclassified, along with hog cholera virus (HOCV) and sheep border diseasevirus (BDV), in the pestivirus genus. Although Pestiviruses werepreviously classified in the Togaviridae family, some studies havesuggested their reclassification within the Flaviviridae family alongwith the flavivirus and hepatitis C virus (HCV) groups.

Equine herpesviruses (EHV) comprise a group of antigenically distinctbiological agents which cause a variety of infections in horses rangingfrom subclinical to fatal disease. These include Equine herpesvirus-1(EHV-1), a ubiquitous pathogen in horses. EHV-1 is associated withepidemics of abortion, respiratory tract disease, and central nervoussystem disorders. Other EHV's include EHV-2, or equine cytomegalovirus,EHV-3, equine coital exanthema virus, and EHV-4, previously classifiedas EHV-1 subtype 2.

Sheep and goats can be infected by a variety of dangerous microorganismsincluding visna-maedi.

Primates such as monkeys, apes and macaques can be infected by simianimmunodeficiency virus. Inactivated cell-virus and cell-free wholesimian immunodeficiency vaccines have been reported to afford protectionin macaques (Stott et al., Lancet 36:1538-1541 (1990); Desrosiers etal., PNAS USA 86:6353-6357 (1989); Murphey-Corb et al., Science246:1293-1297 (1989); and Carlson et al., AIDS Res. Human Retroviruses6:1239-1246 (1990)). A recombinant HIV gp120 vaccine has been reportedto afford protection in chimpanzees (Berman et al., Nature 345:622-625(1990)).

Cats, both domestic and wild, are susceptible to infection with avariety of microorganisms. For instance, feline infectious peritonitisis a disease which occurs in both domestic and wild cats, such as lions,leopards, cheetahs, and jaguars. When it is desirable to preventinfection with this and other types of pathogenic organisms in cats, themethods of the invention can be used to vaccinate cats to prevent themagainst infection.

Domestic cats may become infected with several retroviruses, includingbut not limited to feline leukemia virus (FeLV), feline sarcoma virus(FeSV), endogenous type C oncomavirus (RD-114), and felinesyncytia-forming virus (FeSFV). The discovery of feline T-lymphotropiclentivirus (also referred to as feline immunodeficiency) was firstreported in Pedersen et al., Science 235:790-793 (1987). Felineinfectious peritonitis (FIP) is a sporadic disease occurringunpredictably in domestic and wild Felidae. While FIP is primarily adisease of domestic cats, it has been diagnosed in lions, mountainlions, leopards, cheetahs, and the jaguar. Smaller wild cats that havebeen afflicted with FIP include the lynx and caracal, sand cat andpallas cat.

Viral and bacterial diseases in fin-fish, shellfish or other aquaticlife forms pose a serious problem for the aquaculture industry. Owing tothe high density of animals in the hatchery tanks or enclosed marinefarming areas, infectious diseases may eradicate a large proportion ofthe stock in, for example, a fin-fish, shellfish, or other aquatic lifeforms facility. Prevention of disease is a more desired remedy to thesethreats to fish than intervention once the disease is in progress.Vaccination of fish is the only preventative method which may offerlong-term protection through immunity. Nucleic acid based vaccinationsof fish are described, for example, in U.S. Pat. No. 5,780,448.

The fish immune system has many features similar to the mammalian immunesystem, such as the presence of B cells, T cells, lymphokines,complement, and immunoglobulins. Fish have lymphocyte subclasses withroles that appear similar in many respects to those of the B and T cellsof mammals. Vaccines can be administered orally or by immersion orinjection.

Aquaculture species include but are not limited to fin-fish, shellfish,and other aquatic animals. Fin-fish include all vertebrate fish, whichmay be bony or cartilaginous fish, such as, for example, salmonids,carp, catfish, yellowtail, seabream and seabass. Salmonids are a familyof fin-fish which include trout (including rainbow trout), salmon andArctic char. Examples of shellfish include, but are not limited to,clams, lobster, shrimp, crab and oysters. Other cultured aquatic animalsinclude, but are not limited to, eels, squid and octopi.

Polypeptides of viral aquaculture pathogens include but are not limitedto glycoprotein or nucleoprotein of viral hemorrhagic septicemia virus(VHSV); G or N proteins of infectious hematopoietic necrosis virus(IHNV); VP1, VP2, VP3 or N structural proteins of infectious pancreaticnecrosis virus (IPNV); G protein of spring viremia of carp (SVC); and amembrane-associated protein, tegumin or capsid protein or glycoproteinof channel catfish virus (CCV).

Polypeptides of bacterial pathogens include but are not limited to aniron-regulated outer membrane protein, (IROMP), an outer membraneprotein (OMP), and an A-protein of Aeromonis salmonicida which causesfurunculosis, p57 protein of Renibacterium salmoninarum which causesbacterial kidney disease (BKD), major surface associated antigen (msa),a surface expressed cytotoxin (mpr), a surface expressed hemolysin(ish), and a flagellar antigen of Yersiniosis; an extracellular protein(ECP), an iron-regulated outer membrane protein (IROMP), and astructural protein of Pasteurellosis; an OMP and a flagellar protein ofVibrosis anguillarum and V. ordalii; a flagellar protein, an OMPprotein, aroA, and purA of Edwardsiellosis ictaluri and E. tarda; andsurface antigen of Ichthyophthirius; and a structural and regulatoryprotein of Cytophaga columnari; and a structural and regulatory proteinof Rickettsia.

Polypeptides of a parasitic pathogen include but are not limited to thesurface antigens of Ichthyophthirius.

In another aspect of the invention, there is provided vaccinecompositions suitable for use in methods for preventing and/orattenuating diseases or conditions which are caused or exacerbated by“self” gene products (e.g., tumor necrosis factors). Thus, vaccinecompositions of the invention include compositions which lead to theproduction of antibodies that prevent and/or attenuate diseases orconditions caused or exacerbated by “self” gene products. Examples ofsuch diseases or conditions include graft versus host disease,IgE-mediated allergic reactions, anaphylaxis, adult respiratory distresssyndrome, Crohn's disease, allergic asthma, acute lymphoblastic leukemia(ALL), non-Hodgkin's lymphoma (NHL), Graves' disease, systemic lupuserythematosus (SLE), inflammatory autoimmune diseases, myastheniagravis, immunoproliferative disease lymphadenopathy (IPL),angioimmunoproliferative lymphadenopathy (AIL), immunoblastivelymphadenopathy (IBL), rheumatoid arthritis, diabetes, prion diseases,multiple sclerosis, Alzheimer disease and osteoporosis.

In related specific embodiments, compositions of the invention are animmunotherapeutic that can be used for the treatment and/or preventionof allergies, cancer or drug addiction.

The selection of antigens or antigenic determinants for the preparationof compositions and for use in methods of treatment for allergies wouldbe known to those skilled in the medical arts treating such disorders.Representative examples of such antigens or antigenic determinantsinclude the following: bee venom phospholipase A₂, Bet v I (birch pollenallergen), 5 Dol m V (white-faced hornet venom allergen), and Der p I(House dust mite allergen), as well as fragments of each which can beused to elicit immunological responses.

The selection of antigens or antigenic determinants for compositions andmethods of treatment for cancer would be known to those skilled in themedical arts treating such disorders (see Renkvist et al., Cancer.Immunol. Immunother. 50:3-15 (2001) which is incorporated by reference),and such antigens or antigenic determinants are included within thescope of the present invention. Representative examples of such types ofantigens or antigenic determinants include the following: Her2 (breastcancer); GD2 (neuroblastoma); EGF-R (malignant glioblastoma); CEA(medullary thyroid cancer); CD52 (leukemia); human melanoma proteingp100; human melanoma protein gp100 epitopes such as amino acids 154-162(sequence: KTWGQYWQV, SEQ ID NO:90), 209-217 (ITDQVPFSV, SEQ ID NO:91),280-288 (YLEPGPVTA, SEQ ID NO:92), 457-466 (LLDGTATLRL, SEQ ID NO:93)and 476-485 (VLYRYGSFSV, SEQ ID NO:94); human melanoma proteinmelan-A/MART-1; human melanoma protein melan-A/MART-1 epitopes such asamino acids 27-35 (AAGIGILTV, SEQ ID NO:95) and 32-40 (ILTVILGVL, SEQ IDNO:96); tyrosinase and tyrosinase related proteins (e.g., TRP-1 andTRP-2); tyrosinase epitopes such as amino acids 1-9 (MLLAVLYCL, SEQ IDNO:97) and 369-377 (YMDGTMSQV, SEQ ID NO:98); NA17-A nt protein; NA17-Ant protein epitopes such as amino acids 38-64 (VLPDVFIRC, SEQ ID NO:99);MAGE-3 protein; MAGE-3 protein epitopes such as amino acids 271-279(FLWGPRALV, SEQ ID NO:100); other human tumors antigens, e.g. CEAepitopes such as amino acids 571-579 (YLSGANLNL, SEQ ID NO:101); p53protein; p53 protein epitopes such as amino acids 65-73 (RMPEAAPPV),149-157 (STPPPGTRV, SEQ ID NO:102) and 264-272 (LLGRNSFEV, SEQ IDNO:103); Her2/neu epitopes such as amino acids 369-377 (KIFGSLAFL, SEQID NO:104) and 654-662 (IISAVVGIL, SEQ ID NO:105); NY-ESO-1 peptides157-165 and 157-167, 159-167; HPV16 E7 protein; HPV16 E7 proteinepitopes such as amino acids 86-93 (TLGIVCPI, SEQ ID NO:106); as well asfragments of each which can be used to elicit immunological responses.

The selection of antigens or antigenic determinants for compositions andmethods of treatment for drug addiction, in particular recreational drugaddiction, would be known to those skilled in the medical arts treatingsuch disorders. Representative examples of such antigens or antigenicdeterminants include, for example, opioids and morphine derivatives suchas codeine, fentanyl, heroin, morphium and opium; stimulants such asamphetamine, cocaine, MDMA (methylenedioxymethamphetamine),methamphetamine, methylphenidate and nicotine; hallucinogens such asLSD, mescaline and psilocybin; as well as cannabinoids such as hashishand marijuana.

The selection of antigens or antigenic determinants for compositions andmethods of treatment for other diseases or conditions associated withself antigens would be also known to those skilled in the medical artstreating such disorders. Representative examples of such antigens orantigenic determinants are, for example, lymphotoxins (e.g. Lymphotoxinα (LT α), Lymphotoxin β (LT β)), and lymphotoxin receptors, Receptoractivator of nuclear factor kappaB ligand (RANKL), vascular endothelialgrowth factor (VEGF) and vascular endothelial growth factor receptor(VEGF-R), Interleukin 17 and amyloid beta peptide (Aβ₁₋₄₂), TNFα, MIF,MCP-1, SDF-1, Rank-L, M-CSF, Angiotensin II, Endoglin, Eotaxin, Grehlin,BLC, CCL21, IL-13, IL-17, IL-5, IL-8, IL-15, Bradykinin, Resistin, LHRH,GHRH, GIH, CRH, TRH and Gastrin, as well as fragments of each which canbe used to elicit immunological responses.

In a particular embodiment of the invention, the antigen or antigenicdeterminant is selected from the group consisting of: (a) a recombinantpolypeptide of HIV; (b) a recombinant polypeptide of Influenza virus(e.g., an Influenza virus M2 polypeptide or a fragment thereof); (c) arecombinant polypeptide of Hepatitis C virus; (d) a recombinantpolypeptide of Hepatitis B virus (e) a recombinant polypeptide ofToxoplasma; (f) a recombinant polypeptide of Plasmodium falciparum; (g)a recombinant polypeptide of Plasmodium vivax; (h) a recombinantpolypeptide of Plasmodium ovale; (i) a recombinant polypeptide ofPlasmodium malariae; (j) a recombinant polypeptide of breast cancercells; (k) a recombinant polypeptide of kidney cancer cells; (l) arecombinant polypeptide of prostate cancer cells; (m) a recombinantpolypeptide of skin cancer cells; (n) a recombinant polypeptide of braincancer cells; (o) a recombinant polypeptide of leukemia cells; (p) arecombinant profiling; (q) a recombinant polypeptide of bee stingallergy; (r) a recombinant polypeptide of nut allergy; (s) a recombinantpolypeptide of pollen; (t) a recombinant polypeptide of house-dust; (u)a recombinant polypeptide of cat or cat hair allergy; (v) a recombinantprotein of food allergies; (w) a recombinant protein of asthma; (x) arecombinant protein of Chlamydia; and (y) a fragment of any of theproteins set out in (a)-(x).

In another embodiment of the present invention, the antigen, beingcoupled, fused or otherwise attached to the virus-like particle, is a Tcell epitope, either a cytotoxic or a Th cell epitope. In a furtherpreferred embodiment, the antigen is a combination of at least two,preferably different, epitopes, wherein the at least two epitopes arelinked directly or by way of a linking sequence. These epitopes arepreferably selected from the group consisting of cytotoxic and Th cellepitopes.

It should also be understood that a mosaic virus-like particle, e.g. avirus-like particle composed of subunits attached to different antigensand epitopes, respectively, is within the scope of the presentinvention. Such a composition of the present invention can be, forexample, obtained by transforming E. coli with two compatible plasmidsencoding the subunits composing the virus-like particle fused todifferent antigens and epitopes, respectively. In this instance, themosaic virus-like particle is assembled either directly in the cell orafter cell lysis. Moreover, such an inventive composition can also beobtained by attaching a mixture of different antigens and epitopes,respectively, to the isolated virus-like particle.

The antigen of the present invention, and in particular the indicatedepitope or epitopes, can be synthesized or recombinantly expressed andcoupled to the virus-like particle, or fused to the virus-like particleusing recombinant DNA techniques. Exemplary procedures describing theattachment of antigens to virus-like particles are disclosed in WO00/32227, in WO 01/85208 and in WO 02/056905, the disclosures of whichare herewith incorporated by reference in its entirety

The invention also provides a method of producing a composition forenhancing an immune response in an animal comprising a VLP and animmunostimulatory substance, preferably an unmethylated CpG-containingoligonucleotide bound to the VLP which comprises incubating the VLP withthe immunostimulatory substance and oligonucleotide, respectively,adding RNase and purifying said composition. In an equally preferredembodiment, the method comprises incubating the VLP with RNase, addingthe immunostimulatory substance and oligonucleotide, respectively, andpurifying the composition. In one embodiment, the VLP is produced in abacterial expression system. In another embodiment, the RNase is RNaseA.

The invention further provides a method of producing a composition forenhancing an immune response in an animal comprising a VLP bound to animmunostimulatory substance, preferably to an unmethylatedCpG-containing oligonucleotide which comprises disassembling the VLP,adding the immunostimulatory substance and oligonucleotide,respectively, and reassembling the VLP. The method can further compriseremoving nucleic acids of the disassembled VLP and/or purifying thecomposition after reassembly.

The invention also provides vaccine compositions which can be used forpreventing and/or attenuating diseases or conditions. Vaccinecompositions of the invention comprise, or alternatively consist of, animmunologically effective amount of the inventive immune enhancingcomposition together with a pharmaceutically acceptable diluent, carrieror excipient. The vaccine can also optionally comprise an adjuvant.

The invention further provides vaccination methods for preventing and/orattenuating diseases or conditions in animals. In one embodiment, theinvention provides vaccines for the prevention of infectious diseases ina wide range of animal species, particularly mammalian species such ashuman, monkey, cow, dog, cat, horse, pig, etc. Vaccines can be designedto treat infections of viral etiology such as HIV, influenza, Herpes,viral hepatitis, Epstein Bar, polio, viral encephalitis, measles,chicken pox, etc.; or infections of bacterial etiology such aspneumonia, tuberculosis, syphilis, etc.; or infections of parasiticetiology such as malaria, trypanosomiasis, leishmaniasis,trichomoniasis, amoebiasis, etc.

In another embodiment, the invention provides vaccines for theprevention of cancer in a wide range of species, particularly mammalianspecies such as human, monkey, cow, dog, cat, horse, pig, etc. Vaccinescan be designed to treat all types of cancer including, but not limitedto, lymphomas, carcinomas, sarcomas and melanomas.

As would be understood by one of ordinary skill in the art, whencompositions of the invention are administered to an animal, they can bein a composition which contains salts, buffers, adjuvants or othersubstances which are desirable for improving the efficacy of thecomposition. Examples of materials suitable for use in preparingpharmaceutical compositions are provided in numerous sources includingREMINGTON'S PHARMACEUTICAL SCIENCES (Osol, A, ed., Mack Publishing Co.,(1990)).

Various adjuvants can be used to increase the immunological response,depending on the host species, and include but are not limited to,Freund's (complete and incomplete), mineral gels such as aluminumhydroxide, surface active substances such as lysolecithin, pluronicpolyols, polyanions, peptides, oil emulsions, keyhole limpethemocyanins, dinitrophenol, and potentially useful human adjuvants suchas BCG (bacille Calmette-Guerin) and Corynebacterium parvum. Suchadjuvants are also well known in the art. Further adjuvants that can beadministered with the compositions of the invention include, but are notlimited to, Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21,QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvanttechnology. The adjuvants can also comprise a mixture of thesesubstances.

Compositions of the invention are said to be “pharmacologicallyacceptable” if their administration can be tolerated by a recipientindividual. Further, the compositions of the invention will beadministered in a “therapeutically effective amount” (i.e., an amountthat produces a desired physiological effect).

The compositions of the present invention can be administered by variousmethods known in the art. The particular mode selected will depend ofcourse, upon the particular composition selected, the severity of thecondition being treated and the dosage required for therapeuticefficacy. The methods of the invention, generally speaking, can bepracticed using any mode of administration that is medically acceptable,meaning any mode that produces effective levels of the active compoundswithout causing clinically unacceptable adverse effects. Such modes ofadministration include oral, rectal, parenteral, intracistemal,intravaginal, intraperitoneal, topical (as by powders, ointments, dropsor transdermal patch), bucal, or as an oral or nasal spray. The term“parenteral” as used herein refers to modes of administration whichinclude intravenous, intramuscular, intraperitoneal, intrasternal,subcutaneous and intraarticular injection and infusion. The compositionof the invention can also be injected directly in a lymph node.

Components of compositions for administration include sterile aqueous(e.g., physiological saline) or non-aqueous solutions and suspensions.Examples of non-aqueous solvents are propylene glycol, polyethyleneglycol, vegetable oils such as olive oil, and injectable organic esterssuch as ethyl oleate. Carriers or occlusive dressings can be used toincrease skin permeability and enhance antigen absorption.

Combinations can be administered either concomitantly, e.g., as anadmixture, separately but simultaneously or concurrently; orsequentially. This includes presentations in which the combined agentsare administered together as a therapeutic mixture, and also proceduresin which the combined agents are administered separately butsimultaneously, e.g., as through separate intravenous lines into thesame individual. Administration “in combination” further includes theseparate administration of one of the compounds or agents given first,followed by the second.

Dosage levels depend on the mode of administration, the nature of thesubject, and the quality of the carrier/adjuvant formulation. Typicalamounts are in the range of about 0.1 μg to about 20 mg per subject.Preferred amounts are at least about 1 μg to about 100 μg per subject.Multiple administration to immunize the subject is preferred, andprotocols are those standard in the art adapted to the subject inquestion.

The compositions can conveniently be presented in unit dosage form andcan be prepared by any of the methods well-known in the art of pharmacy.Methods include the step of bringing the compositions of the inventioninto association with a carrier which constitutes one or more accessoryingredients. In general, the compositions are prepared by uniformly andintimately bringing the compositions of the invention into associationwith a liquid carrier, a finely divided solid carrier, or both, andthen, if necessary, shaping the product.

Compositions suitable for oral administration can be presented asdiscrete units, such as capsules, tablets or lozenges, each containing apredetermined amount of the compositions of the invention. Othercompositions include suspensions in aqueous liquids or non-aqueousliquids such as a syrup, an elixir or an emulsion.

Other delivery systems can include time-release, delayed release orsustained release delivery systems. Such systems can avoid repeatedadministrations of the compositions of the invention described above,increasing convenience to the subject and the physician. Many types ofrelease delivery systems are available and known to those of ordinaryskill in the art.

Other embodiments of the invention include processes for the productionof the compositions of the invention and methods of medical treatmentfor cancer and allergies using said compositions.

Further aspects and embodiments of the present invention will becomeapparent in the following examples and the appended claims.

The following examples are illustrative only and are not intended tolimit the scope of the invention as defined by the appended claims. Itwill be apparent to those skilled in the art that various modificationsand variations can be made in the methods of the present inventionwithout departing from the spirit and scope of the invention. Thus, itis intended that the present invention cover the modifications andvariations of this invention provided they come within the scope of theappended claims and their equivalents.

All patents and publications referred to herein are expresslyincorporated by reference in their entirety.

Example 1 Generation of p33-HBcAg VLPs

The DNA sequence of HBcAg containing peptide p33 from LCMV is given inFIG. 1B. The p33-HBcAg VLPs (p33-VLPs) were generated as follows:Hepatitis B clone pEco63 containing the complete viral genome ofHepatitis B virus was purchased from ATCC. The gene encoding HBcAg wasintroduced into the EcoRI/HindIII restriction sites of expression vectorpkk223.3 (Pharmacia) under the control of a strong tac promoter. The p33peptide (KAVYNFATM, SEQ ID NO:107) derived from lymphocyticchoriomeningitis virus (LCMV) was fused to the C-terminus of HBcAg(1-185) via a three leucine-linker by standard PCR methods. A clone ofE. coli K802 selected for good expression was transfected with theplasmid, and cells were grown and resuspended in 5 ml lysis buffer (10mM Na₂HPO₄, 30 mM NaCl, 10 mM EDTA, 0.25% Tween-20, pH 7.0). 200 μl oflysozyme solution (20 mg/ml) was added. After sonication, 4 μl Benzonaseand 10 mM MgCl₂ was added and the suspension was incubation for 30minutes at RT, centrifuged for 15 minutes at 15,000 rpm at 4° C. and thesupernatant was retained.

Next, 20% (w/v) (0.2 g/ml lysate) ammonium sulfate was added to thesupernatant. After incubation for 30 minutes on ice and centrifugationfor 15 minutes at 20,000 rpm at 4° C. the supernatant was discarded andthe pellet resuspended in 2-3 ml PBS. 20 ml of the PBS-solution wasloaded onto a Sephacryl S-400 gel filtration column (Amersham PharmaciaBiotechnology AG), fractions were loaded onto a SDS-Page gel andfractions with purified p33-VLP capsids were pooled. Pooled fractionswere loaded onto a Hydroxyappatite column. Flow through (which containspurified p33-VLP capsids) was collected (FIG. 2B). Electron microscopywas performed according to standard protocols. A representative exampleis shown in FIG. 2A.

Example 2 CpG-Containing Oligonucleotides can be Packaged into HBcAgVLPs

Recombinant p33-VLPs were run on a native agarose (1%) gelelectrophoresis and stained with ethidium bromide or Coomassie blue forthe detection of RNA/DNA or protein (FIG. 3). Bacterial produced VLPscontain high levels of single stranded RNA, which is presumably bindingto the arginine repeats appearing near the C-terminus of the HBcAgprotein and being geographically located inside the VLPs as shown byX-ray crystallography. The contaminating RNA can be easily digested andso eliminated by incubating the VLPs with RNase A. The highly activeRNase A enzyme has a molecular weight of about 14 kDa and is presumablysmall enough to enter the VLPs to eliminate the undesired ribonucleicacids.

The recombinant p33-VLPs were supplemented with CpG-oligonucleotides(FIG. 1A) before digestion with RNase A. As shown in FIG. 4 the presenceof CpG-oligonucleotides preserved the capsid structure as shown bysimilar migration compared to untreated p33-VLPs. TheCpG-oligonucleotide-containing VLPs were purified from unboundoligonucleotides via dialysis (4500-fold dilution in PBS for 24 hoursusing a 300 kDa MWCO dialysis membrane) (FIG. 5).

Example 3 CpG-Oligonucleotides can be Packaged into VLPs by Removal ofthe RNA with RNAse and Subsequent Packaging of Oligonucleotides intoVLPs

The p33-VLPs (containing bacterial single-stranded RNA) were firstincubated with RNase A to remove the RNA and in a second step theimmunostimulating CpG-oligonucleotides (with normal phosphodiester bondsbut also with phosphorothioate modification of the phosphate backbone)was supplemented to the samples (FIG. 6). This experiment clearly showsthat the CpG-oligonucleotides are not absolutely required simultaneouslyduring the RNA degradation reaction but can be added at a later time.

Example 4 VLPs Containing CpG-Oligonucleotides (with PhosphorothioateModification of the Phosphate Backbone or Normal Phosphodiester Bonds)Induce Enhanced Anti-Viral Protection

Mice were subcutaneously primed with 100 μg CpG-oligonucleotidecontaining p33-VLPs. Before immunization, p33-VLP preparations wereextensively purified from unbound CpG-oligonucleotides via dialysis (seeExample 2 and FIG. 5). As controls mice were subcutaneously primed with100 μg p33-VLP alone, mixed with 20 nmol CpG-oligonucleotide, with 20nmol CpG-oligonucleotide alone or left untreated. Twenty-one days later,mice were challenged with LCMV (200 pfu, intravenously) and viral titerswere assessed in the spleens 5 days later as described in Bachmann, M.F., “Evaluation of lymphocytic choriomeningitis virus-specific cytotoxicT cell responses,” in Immunology Methods Manual, Lefkowitz, I., ed.,Academic Press Ltd., New York, N.Y. (1997) p. 1921. The results areshown in FIGS. 7, 8 and 9.

Example 5 Generation of BKV Polyoma Capsids

BK virus (BKV) is a non-enveloped double stranded DNA virus belonging tothe polyoma virus subfamily of the papovaviridae. VP1 is the majorcapsid protein. VP1 has 362 amino acids (FIG. 10, SEQ ID NO:3) and is 42kDa in size. When produced in E. coli, insect cells or yeast VP1spontaneously forms capsid structures (Salunke D. M., et al., Cell46(6):895-904 (1986); Sasnauskas, K., et al., Biol. Chem. 380(3):381-6(1999); Sasnauskas, K., et al., 3^(rd) International Workshop“Virus-like particles as vaccines” Berlin, Sep. 26-29 (2001); Touze, A.,et al., J Gen Virol. 82(Pt 12):3005-9 (2001). The capsid is organized in72 VP1 pentamers forming an icosahedral structure. The capsids have adiameter of approximately 45 nm.

Example 6 Fluorescein Labeled CpG-Containing Oligonucleotides can bePackaged into BKV VLPs

VLPs produced in yeast contain small amounts of RNA which can be easilydigested and so eliminated by incubating the VLPs with RNase A. Thehighly active RNase A enzyme has a molecular weight of about 14 kDa andis small enough to enter the VLPs to eliminate the undesired ribonucleicacids. Recombinantly produced BKV VLPs were concentrated to 1 mg/ml inPBS buffer pH7.2 and incubated in the absence or presence of RNase A(200 μg/ml, Roche Diagnostics Ltd, Switzerland) for 3 h at 37° C. AfterRNase A digestion BKV VLPs were supplemented with 75 nmol/ml fluoresceinlabeled phosphorothioate CpG-FAM oligonucleotide and incubated for 3 hat 37° C. Subsequently BKV VLPs were subjected to DNaseI digestion for 3h at 37° C. (40 u/ml AMPD1, Sigma, Division of Fluka AG, Switzerland) orloaded without DNaseI digestion. The samples were complemented with6-fold concentrated DNA-loading buffer (10 mM Tris pH7.5, 10% v/vglycerol, 0.4% orange G) and run for 1 h at 65 volts in a 0.8% nativetris-acetate pH 7.5 agarose gel.

FIG. 12 shows BKV VLPs in a native 0.8% agarose gel electrophoresisafter control incubation or after digestion with RNase A and subsequentincubation with fluorescent CpG-FAM oligonucleotides (oligonucleotidefrom FIG. 1A with a 5′-fluorescein-label) upon staining with ethidiumbromide or without ethidium bromide staining. In the presence ofethidium bromide nucleic acids are detected, while in its absence UVexcitation leads to fluorescence of the fluorescein-label in theCpG-FAM.

The RNase A digestion leads to a change in migration of the VLP, visibleon Coomassie stained agarose gel, presumably due to the lack of negativecharges from the RNA (FIGS. 13 and 14). Addition of CpG-oligonucleotiderestores the migration of BKV VLPs and results in a fluorescent bandwith the same migration as the RNA band present in untreated VLPs. Thisclearly shows that CpG-FAM oligonucleotides have been packaged intoVLPs.

Example 7 Large Double Stranded Oligonucleotides can be Packaged intoBKV VLPs

To introduce double stranded (ds) nucleotide sequences, the RNase Atreated recombinant BKV VLPs (Example 6) were supplemented with 50μg/m(ds) DNA fragments (246 bp in length, FIG. 11, SEQ ID NO:4) andincubated for 3 h at 37° C. The samples were complemented with 6-foldconcentrated DNA-loading buffer (10 mM Tris pH8.0, 10% v/v glycerol,0.4% orange G) and run for 1 h at 65 volts in a 0.8% native tris-acetatepH8.0 agarose gel.

FIG. 13 shows BKV VLPs (15 μg) in a native 0.8% agarose gelelectrophoresis after control incubation or after digestion with RNase Aand subsequent incubation with (ds) DNA upon staining with ethidiumbromide or Coomassie Blue in order to assess the presence of RNA/DNA orprotein. Packaged DNA molecules are visible in the presence of ethidiumbromide as a band with the same migration as the VLP band visualizedwith Coomassie Blue.

Addition of (ds) DNA restores the migration of BKV VLPs and results in aDNA band with the same migration as the Coomassie Blue stained VLPs.This clearly shows that (ds) DNA has been packaged into BKV VLPs.

Example 8 CpG-Containing Oligonucleotides can be Packaged into BKV VLPs

To introduce immunostimulatory CpG-oligonucleotides, the RNase A treatedrecombinant BKV VLPs (Example 6) were supplemented with 150 nmol/mlCpG-oligonucleotides with phosphodiester backbone or withphosphorothioate backbone and incubated for 3 h at 37° C. VLPpreparations for mouse immunization were extensively dialysed(10,000-fold diluted) for 24 h against PBS pH7.2 with a 300 kDa MWCOdialysis membrane (Spectrum Medical industries Inc., Houston, USA) toeliminate RNase A and the excess of CpG-oligonucleotides. The sampleswere complemented with 6-fold concentrated DNA-loading buffer (10 mMTris pH7.5, 10% v/v glycerol, 0.4% orange G) and run for 1 h at 65 voltsin a 0.8% native tris-acetate pH7.5 agarose gel.

FIG. 14 shows BKV VLPs (15 μg) in a native 0.8% agarose gelelectrophoresis after control incubation or after digestion with RNase Aand subsequent incubation with CpG-oligonucleotides (withphosphodiester- or with phosphorothioate backbone) upon staining withethidium bromide (A) or Coomassie Blue (B) in order to assess thepresence of RNA/DNA or protein and the reduction of unboundCpG-oligonucleotides after dialysis. Unbound CpG-oligonucleotides arevisible as a low molecular weight ethidium bromide stained band.

Addition of CpG-oligonucleotides restores the migration of BKV VLPs andresults in a DNA band with the same migration as the Coomassie Bluestained VLPs. This clearly shows that CpG-oligonucleotides are packagedinto BKV VLPs.

Example 9 VLPs Containing CpG-Oligonucleotides (with PhosphorothioateModification of the Phosphate Backbone) Induce Enhanced Th1 DirectedImmune Response

Female BALB/c mice (three mice per group) were subcutaneously injectedwith 10 μg BKV VLPs containing phosphorothioate CpG-oligonucleotide(FIG. 1A, SEQ ID NO:109). As controls mice were subcutaneously injectedwith either 10 μg of RNase treated BKV VLPs alone or BKV VLPs mixed with0.3 nmol or 20 nmol phosphorothioate CpG-oligonucleotides in 200 μl PBSpH7.2 or were left untreated. BKV VLPs were prepared as described inExample 8 and before immunization extensively purified from unboundCpG-oligonucleotide by dialysis. On day 14 after immunization blood wastaken and IgG1 and IgG2a antibody response to BKV VLPs was determined.

FIG. 15 shows IgG1 and IgG2a antibody response to BKV VLPs on day 14after immunization. Immunization with RNase A treated BKV VLPscontaining phosphorothioate CpG-oligonucleotides results in a decreasedIgG1 and an increased anti-BKV VLP IgG2a titer as compared toimmunization with the same amount (0.3 nmol) of CpG-oligonucleotidesmixed with BKV VLPs or BKV VLPs alone. Mice immunized with BKV VLPsmixed with 20 nmol phosphorothioate CpG-oligonucleotides show very lowIgG1 and high IgG2a titers. The decrease in IgG1 titer and the increasein IgG2a titer as compared to controls demonstrates a Th1 cell directedimmune response induced by phosphorothioate CpG-oligonucleotidespackaged in BKV VLPs. FIG. 15 clearly demonstrates the higher potency ofBKV VLPs containing CpG-oligonucleotides packaged within the particlesas compared to BKV VLPs simply mixed with CpG-oligonucleotides.

Example 10 Linear Double-Stranded DNA (dsDNA) can be Packaged into VLPsby First RNAse Digestion and Subsequently Addition of dsDNA

The p33-VLPs preparations (containing bacterial RNA) (EXAMPLE 1) werefirst incubated with RNaseA to remove the RNA and in a second step thelinear dsDNA (350 bp long) was supplemented to the samples (FIG. 16).The migration of the p33-VLPs packaged with the dsDNA was similar to theone of p33-VLP containing RNA. This experiment shows that linear dsDNAof at least 350 base pairs in length can be packaged into the virus-likeparticles.

Example 11 Immunostimulatory Nucleic Acids can be Packaged into HBcAgVLPs Comprising Fusion Proteins with Antigens

HBcAg VLPs, when produced in E. coli by expressing the Hepatitis B coreantigen fusion protein HBc33 (Example 1) or the fusion protein to thepeptide P1A (HBcP1A), contain RNA which can be digested and soeliminated by incubating the VLPs with RNase A.

The gene PIA codes for a protein that is expressed by the mastocytomatumor cell line P815. The dominant CTL epitope, termed P1A peptide,binds to MHC class I (Ld) and the complex is recognized by specific CTLclones (Brändle et al., 1998, Eur. J. Immunol. 28: 4010-4019). Fusion ofpeptide P1A-1 (LPYLGWLVF, SEQ ID NO:108) to the C-terminus of HBcAg (aa185, see Example 1) was performed by PCR using appropriate primers usingstandard molecular biology techniques. A three leucine linker was clonedbetween the HBcAg and the peptide sequence. Expression was performed asdescribed in Example 1. The fusion protein of HBcAg with NA, termedHBcP1A, formed capsids when expressed in E. coli which could be purifiedsimilar to the procedure described in Example 1.

Enzymatic RNA Hydrolysis: Recombinantly produced HBcAg-p33 (HBc33) andHBcAg-P1A (HBcP1A) VLPs at a concentration of 1.0 mg/ml in 1×PBS buffer(KCl 0.2 g/L, KH2PO4 0.2 g/L, NaCl 8 g/L, Na2HPO4 1.15 g/L) pH 7.4, wereincubated in the presence of 300 μg/ml RNase A (Qiagen AG, Switzerland)for 3 h at 37° C. in a thermomixer at 650 rpm.

Packaging of Immunostimulatory Nucleic Acids: After RNA digestion withRNAse A HBcAg-p33 VLPs were supplemented with 130 nmol/mlCpG-oligonucleotides B-CpG (SEQ ID NO:112), NKCpG (SEQ ID NO:114),G10-PO (SEQ ID NO:116) (Table I). Similarly, the 150mer single-strandedCy150-1 (SEQ ID NO:123) and 253mer double stranded dsCyCpG-253 (SEQ IDNO:124), both containing multiple copies of CpG motifs, were added at130 nmol/ml or 1.2 nmol/ml, respectively, and incubated in a thermomixerfor 3 h at 37° C. Double stranded CyCpG-253 DNA was produced by cloninga double stranded multimer of CyCpG into the EcoRV site of pBluescriptKS-. The resulting plasmid, produced in E. coli XL1-blue and isolatedusing the Qiagen Endofree plasmid Giga Kit, was digested withrestriction endonucleases XhoI and XbaI and resulting restrictionproducts were separated by agarose electrophoresis. The 253 bp insertwas isolated by electro-elution and ethanol precipitation. Sequence wasverified by sequencing of both strands.

TABLE 1 Sequences of immunostimulatory nucleic acids used inthe Examples. Small letters indicate deoxynucleotidesconnected via phosphorothioate bonds while larger lettersindicate deoxynucleotides connected via phosphodiester bonds CyCpGpttccatgacgttcctgaataat (SEQ ID NO: 109) CyCpGTCCATGACGTTCCTGAATAAT (SEQ ID NO: 110) B-CpGpttccatgacgttcctgacgtt (SEQ ID NO: 111) B-CpGTCCATGACGTTCCTGACGTT (SEQ ID NO: 112) NKCpGptggGGTCAACGTTGAggggg (SEQ ID NO: 113) NKCpGGGGGTCAACGTTGAGGGGG (SEQ ID NO: 114) CyCpG-rev-ptAttattcaggaacgtcatgga (SEQ ID NO: 115) g10gacga-PO(G10-PO)GGGGGGGGGGGACGATCGTCGGGGGGGGGG (SEQ ID NO: 116) g10gacga-PS(G10-PS)gggggggggggacgatcgtcgggggggggg (SEQ ID NO: 117) (CpG)20OpACGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG

CGCGAAATGCATGTCAAAGACAGCAT (SEQ ID NO: 118) Cy(CpG)20TCCATGACGTTCCTGAATAATCGCGCGCGCGCGC

GCGCGCGCGCGCGCGCGCGCGCGCG (SEQ ID NO: 119) Cy(CpG)20-OpATCCATGACGTTCCTGAATAATCGCGCGCGCGCGC

GCGCGCGCGCGCGCGCGCGCGCGCGAAATGCATG

AAAGACAGCAT (SEQ ID NO: 120) CyOpA TCCATGACGTTCCTGAATAATAAATGCATGTCAA

ACAGCAT (SEQ ID NO: 121) CyCyCy TCCATGACGTTCCTGAATAATTCCATGACGTTCC

AATAATTCCATGACGTTCCTGAATAAT (SEQ ID NO: 122) Cy150-1TCCATGACGTTCCTGAATAATTCCATGACGTTCC

AATAATTCCATGACGTTCCTGAATAATTGGATGA

TTGGTGAATAATTCCATGACGTTCCTGAATAATT

ATGACGTTCCTGAATAATTCCATGACGTTCCTGA

AATTCC (SEQ ID NO: 123) dsCyCpG-253 CTAGAACTAGTGGATCCCCCGGGCTGCAGGAATT

(complementary strand n

ATTCATGACTTCCTGAATAATTCCATGACGTTGG

shown) AATAATTCCATGACGTTCCTGAATAATTCCATGA

TTCCTGAATAATTCCATGACGTTCCTGAATAATT

ATGACGTTCCTGAATAATTCCATGACGTTCCTGA

AATTCCATGACGTTCCTGAATAATTCCATGACGT

CTGAAAATTCCAATCAAGCTTATCGATACCGTCG

C (SEQ ID NO: 124)

indicates data missing or illegible when filed

DNAse I Treatment: Packaged HBcAg-p33 VLPs were subsequently subjectedto DNaseI digestion (5 U/ml) for 3 h at 37° C. (DNaseI, RNase free FlukaAG, Switzerland) and were extensively dialysed (2× against 200-foldvolume) for 24 h against PBS pH 7.4 with a 300 kDa MWCO dialysismembrane (Spectrum Medical industries Inc., Houston, USA) to eliminateRNAse A and the excess of CpG-oligonucleotides.

Benzonase Treatment: Since some single stranded oligodeoxynucleotideswere partially resistant to DNaseI treatment, Benzonase treatment wasused to eliminate free oligonucleotides from the preparation. 100-120U/ml Benzonase (Merck KGaA, Darmstadt, Germany) and 5 mM MgCl₂ wereadded and incubated for 3 h at 37° C. before dialysis.

Dialysis: VLP preparations packaged with immunostimulatroy nucleic acidsused in mouse immunization experiments were extensively dialysed (2×against 200 fold volume) for 24 h against PBS pH 7.4 with a 300 kDa MWCOdialysis membrane (Spectrum Medical Industries, Houston, US) toeliminate added enzymes and free nucleic acids.

Analytics of Packaging: Release of Packaged Immunostimulatory NucleicAcids: To 50 μl capsid solution 1 μl of proteinase K (600 U/ml, Roche,Mannheim, Germany), 3 μl 10% SDS-solution and 6 μl 10 fold proteinasebuffer (0.5 M NaCl, 50 mM EDTA, 0.1 M Tris pH 7.4) were added andsubsequently incubated overnight at 37° C. VLPs are completed hydrolysedunder these conditions. Proteinase K was inactivated by heating for 20min at 65° C. 1 μl RNAse A (Qiagen, 100 μg/ml, diluted 250 fold) wasadded to 25 μl of capsid. 2-30 μg of capsid were mixed with 1 volume of2× loading buffer (1×TBE, 42% w/v urea, 12% w/v Ficoll, 0.01%Bromphenolblue), heated for 3 min at 95° C. and loaded on a 10% (foroligonucleotides of about 20 nt length) or 15% (for > than 40 mernucleic acids) TBE/urea polyacrylamid gel (Invitrogen). Alternativelysamples were loaded on a 1% agarose gel with 6× loading dye (10 mM TrispH 7.5, 50 mM EDTA, 10% v/v glycerol, 0.4% orange G). TBE/urea gels werestained with CYBRGold and agarose gels with stained with ethidiumbromide.

FIGS. 17, 18 and 19 show the packaging of B-CpG (SEQ ID NO:112), NKCpG(SEQ ID NO:114) and G10-PO (SEQ ID NO:116) oligonucleotides into HBc33.RNA content in the VLPs was strongly reduced after RNaseA treatment(FIG. 17A, 18A, 19A) while most of the capsid migrated as a slowmigrating smear presumably due to the removal of the negatively chargedRNA (FIG. 17B, 18B, 19B). After incubation with an excess ofoligonucleotid the capsids contained a higher amount of nucleic acidthan the RNAseA treated capsids and therefore migrated at similarvelocity as the untreated capsids. Additional treatment with DNAse I orBenzonase degraded the free oligonucleotides while oligonucleotidespackaged in the capsids did not degrade, clearly showing packaging ofoligonucleotides. In some cases packaging of oligonucleotides wasconfirmed by proteinase K digestion (as described in Examples 15 and 16)after DNAseI/Benzonase treatment and dialysis. The finding thatoligonucleotides released from the capsid with the procedure describedabove were of the same size than the oligonucleotide used for packagingclearly demonstrated packaging of oligonucleotides (FIG. 17C, 18C).

FIG. 20 shows packaging of a large single-stranded oligonucleotideCy150-1 (SEQ ID NO:123) into HBc33. Cy150-1 contains 7.5 repeats ofCyCpG and was synthesized according standard oligonucleotide synthesismethods (IBA, Göttingen, Germany). RNA content in the capsid wasstrongly reduced after RNaseA treatment while most of the capsidmigrated as a slow migrating smear (FIG. 20A, B). Capsid were dilutedwith 4 volumes of water and concentrated to 1 mg/ml. After incubationwith an excess of Cy150-1 the capsid contained a bigger amount ofnucleic acid and thus migrated at similar velocity as the untreatedcapsids. Additional treatment with DNAseI degraded the free, notpackaged oligonucleotides while oligonucleotides in capsids were notdegraded (FIG. 20A). Release of the DNAseI-resistant nucleic acid fromthe packaged VLPs by heating for 3 min at 95° C. in TBE/urea loadingbuffer revealed the presence of the 150 mer (FIG. 20 C).

FIG. 21 shows packaging of oligonucleotide NKCpGpt (SEQ ID NO:113) inHBcP1A. Treatment with RNAse reduced nucleic acid content and slowedmigration of the capsids. Addition of NKCpGpt restored nucleic acidcontent in capsids and fast migration.

FIG. 17 depicts the analysis of B-CpG (SEQ ID NO:112) packaging intoHBc33 VLPs on a 1% agarose gel stained with ethidium bromide (A) andCoomassie Blue (B). Loaded on the gel are 50 μg of the followingsamples: 1. HBc33 VLP untreated; 2. HBc33 VLP treated with RNase A; 3.HBc33 VLP treated with RNase A and packaged with B-CpG; 4. HBc33 VLPtreated with RNase A, packaged with B-CpG and treated with DNaseI; 5.HBc33 VLP treated with RNase A, packaged with B-CpG, treated with DNaseIand dialysed; 6. 1 kb MBI Fermentas DNA ladder. (C) depicts the analysisof the amount of packaged oligo extracted from the VLP on a 1.5% agarosegel stained with ethidium bromide: Loaded on gel are the followingsamples: 1. 0.5 nmol B-CpG control; 2. 0.5 nmol B-CpG control; 3. B-CpGoligo content HBc33 after phenol/chloroform extraction; 4. B-CpG oligocontent HBc33 after phenol/chloroform extraction and RNase A treatment;5. B-CpG oligo content HBc33 after phenol/chloroform extraction andDNaseI treatment; 6. empty; 7. MBI Fermentas 100 bp DNA ladder

FIG. 18 depicts the analysis of NKCpG (SEQ ID NO:114) packaging intoHBc33 VLPs on a 1% agarose gel stained with ethidium bromide (A) andCoomassie Blue (B). Loaded on the gel are 15 μg of the followingsamples: 1. HBc33 VLP untreated; 2. HBc33 VLP treated with RNase A; 3.HBc33 VLP treated with RNase A and packaged with NKCpG; 4. HBc33 VLPtreated with RNase A, packaged with NKCpG, treated with DNaseI anddialysed; 5. 1 kb MBI Fermentas DNA ladder. (C) depicts the analysis ofthe amount of packaged oligo extracted from the VLP on a 15% TBE/ureagel stained with CYBR Gold. Loaded on gel are the following samples: 1.NKCpG oligo content HBc33 after proteinase K digestion and RNase Atreatment; 2. 20 pmol NKCpG control; 3. 10 pmol NKCpG control; 4. 40pmol NKCpG control

FIG. 19 depicts the analysis of g10gacga-PO (SEQ ID NO:116) packaginginto HBc33 VLPs on a 1% agarose gel stained with ethidium bromide (A)and Coomassie Blue (B). Loaded on the gel are 15 μg of the followingsamples: 1. 1 kb MBI Fermentas DNA ladder; 2. HBc33 VLP untreated; 3.HBc33 VLP treated with RNase A; 4. HBc33 VLP treated with RNase A andpackaged with g10gacga-PO; 5. HBc33 VLP treated with RNase A, packagedwith g10gacga-PO, treated with Benzonase and dialysed.

FIG. 20 depicts the analysis of CyCpG-150 (SEQ ID NO:123) packaging intoHBc33 VLPs on a 1% agarose gel stained with ethidium bromide (A) andCoomassie Blue (B). Loaded on the gel are 15 μg of the followingsamples: 1. 1 kb MBI Fermentas DNA ladder; 2. HBc33 VLP untreated; 3.HBc33 VLP treated with RNase A; 4. HBc33 VLP treated with RNase A andpackaged with CyCpG-150; 5. HBc33 VLP treated with RNase A, packagedwith CyCpG-150, treated with DNaseI and dialysed; 6. HBc33 VLP treatedwith RNase A, packaged with CyCpG-150, treated with DNaseI and dialysed.(C) depicts the analysis of the amount of packaged oligo extracted fromthe VLP on a 10% TBE/urea gel stained with CYBR Gold. Loaded on gel arethe following samples: 1. 20 pmol CyCpG-150 control; 2. 10 pmolCyCpG-150 control; 3. 4 pmol CyCpG-150 control; 4. CyCpG-150 oligocontent of 4 μg HBc33 after 3 min at 95° C. with 1 volume TBE/ureasample buffer.

FIG. 21 depicts the analysis of NKCpGpt (SEQ ID NO:113) packaging intoHBcP1A VLPs on a 1% agarose gel stained with ethidium bromide (A) andCoomassie Blue (B). Loaded on the gel are 15 μg of the followingsamples: 1. 1 kb MBI Fermentas DNA ladder; 2. HBcP1A VLP untreated; 3.HBcP1A VLP treated with RNase A; 4. HBcP1A VLP treated with RNase A andpackaged with NKCpGpt.

Example 12 Immunostimulatory Nucleic Acids can be Packaged in HBcAg-WtCoupled with Antigens

Recombinantly produced HBcAg-wt VLPs were packaged after coupling withpeptide p33 (CGG-KAVYNFATM, (SEQ ID NO:125), derived from lymphocyticchoriomeningitis virus (LCMV). For coupling HBcAg-wt VLPs (2 mg/ml) werederivatized with 25× molar excess of SMPH(Succinimidyl-6-[(B-maleimido-propionamido)hexanoate], Pierce) for 1 hat 25° C. in a thermomixer. The derivatized VLPs were dialyzed to Mesbuffer (2-(N-morpholino) ethanesulphonic acid) pH 7.4 for 2×2 h usingMWCO 10.000 kD dialysis membranes at 4° C. VLPs (50 μM) weresubsequently coupled to the N-terminal cysteine of the p33 peptide (250μM) during a 2 h incubation in a thermomixer at 25° C. Samples weredialyzed (MWCO 300.000) extensively to 1×PBS pH 7.4 to eliminateundesired free peptide.

FIG. 22 shows SDS-PAGE analysis of HBcAg wt VLPs derivatization withSMPH and coupling to p33 peptide. Samples were analysed by 16% SDS PAGEand stained with Coomassie Blue. HBcAg-wt was visible as a 21 kD proteinband. Due to the low molecular weight of SMPH is the derivatised productonly slightly larger and can not be distinguished by SDS-PAGE. Peptidealone was visible as a 3 kD band and coupled product, termed HBx33,showed a strong secondary band at approximately 24 kD accounting formore than 50% of total HBcAg-wt.

Enzymatic RNA Hydrolysis: HBx33 VLPs (0.5-1.0 mg/ml, 1×PBS buffer pH7.4)in the presence of RNase A (300 μg/ml, Qiagen AG, Switzerland) werediluted with 4 volumes H₂O to decrease salt concentration to a final0.2×PBS concentration and incubated for 3 h at 37° C. in a thermomixerat 650 rpm.

Packaging of Immunostimulatory Nucleic Acids: After RNase A digestionHBx33 VLPs were concentrated using Millipore Microcon or Centriplusconcentrators, then supplemented with 130 nmol/ml CpG-oligonucleotideB-CpGpt (SEQ ID NO:111) and incubated in a thermomixer for 3 h at 37° C.in 0.2×PBS pH 7.4. Subsequently, reaction mixtures were subjected toDNaseI digestion (5 U/ml) for 3 h at 37° C. (DNaseI, RNase free FlukaAG, Switzerland). VLP preparations for mouse immunization wereextensively dialysed (2× against 200-fold volume) for 24 h against PBSpH 7.4 with a 300 kDa MWCO dialysis membrane (Spectrum Medicalindustries Inc., Houston, USA) to eliminate RNase A and the excess ofCpG-oligonucleotides. FIG. 23 shows that RNAse treatment reduced thenucleic acid content of the capsids and slowed their migration. Additionof B-CpGpt restored nucleic acid content and fast migration of capsids.DNAse I only digested the free oligonucleotides while the packagedoligonucleotides remained in the VLP also after dialysis (FIG. 23).

FIG. 22 depicts the SDS-PAGE analysis of the p33 coupling to HBc VLPsafter Coomassie Blue staining. Loaded on the gel are the followingsamples: 1.NEB Prestained Protein Marker, Broad Range (#7708S), 10 μl;2. CGG-p33 peptide (SEQ ID NO:125); 3. HBc VLP derivatized with SMPH,before dialysis; 4. HBc VLP derivatized with SMPH, after dialysis; 5.HBc VLP coupled with CGG-p33, supernatant; 6. HBc VLP coupled withCGG-p33, pellet.

FIG. 23 depicts the analysis of B-CpGpt (SEQ ID NO:111) packaging intoHBx33 VLPs on a 1% agarose gel stained with ethidium bromide (A) andCoomassie Blue (B). Loaded on the gel are 50 μg of the followingsamples: 1. HBx33 VLP untreated; 2. HBx33 VLP treated with RNase A; 3.HBx33 VLP treated with RNase A and packaged with B-CpGpt; 4. HBx33 VLPtreated with RNase A, packaged with B-CpGpt and treated with DNaseI; 5.HBx33 VLP treated with RNase A, packaged with B-CpGpt, treated withDNaseI and dialysed; 6. 1 kb MBI Fermentas DNA ladder.

Example 13 Immunostimulatory Nucleic Acids can be Packaged into Qβ VLPsCoupled with Antigens Coupling of p33 Peptides to Qβ VLPs:

Recombinantly produced Qβ VLPs were used after coupling to p33 peptidescontaining an N-terminal CGG or and C-terminal GGC extension(CGG-KAVYNFATM(SEQ ID NO: 125) and KAVYNFATM-GGC (SEQ ID NO:126)).Recombinantly produced Qβ VLPs were derivatized with a 10 molar excessof SMPH (Pierce) for 0.5 h at 25° C., followed by dialysis against 20 mMHEPES, 150 mM NaCl, pH 7.2 at 4° C. to remove unreacted SMPH. Peptideswere added in a 5 fold molar excess and allowed to react for 2 h in athermomixer at 25° C. in the presence of 30% acetonitrile. FIG. 24 showsthe SDS-PAGE analysis demonstrating multiple coupling bands consistingof one, two or three peptides coupled to the Qβ monomer (Arrows, FIG. 24A, B).

Qβ VLPs, when produced in E. coli by expressing the bacteriophage Qβcapsid protein, contain RNA which can be digested and so eliminated byincubating the VLPs with RNase A.

Low Ionic Strength and Low Qβ Concentration Allow RNA Hydrolysis of QβVLPs by RNAse A:

Qβ VLPs at a concentration of 1.0 mg/ml in 20 mM Hepes/150 mM NaClbuffer (HBS) pH 7.4 were either digested directly by addition of RNase A(300 μg/ml, Qiagen AG, Switzerland) or were diluted with 4 volumes H₂Oto a final 0.2×HBS concentration and then incubated with RNase A (60μg/ml, Qiagen AG, Switzerland). Incubation was allowed for 3 h at 37° C.in a thermomixer at 650 rpm. FIG. 25 demonstrates that in 1×HBS only avery weak reduction of RNA content was observed, while in 0.2×HBS mostof the RNA were hydrolysed. In agreement, capsid migration was unchangedafter addition of RNAse A in 1×HBS, while migration was slower afteraddition of RNAse in 0.2×HBS (FIG. 25 B, D).

Low Ionic Strength Increases Nucleic Acid Packaging in Qβ VLPs:

After RNase A digestion in 0.2×HBS the Qβ VLPs were concentrated to 1mg/ml using Millipore Microcon or Centriplus concentrators and aliquotswere dialysed against 1×HBS or 0.2×HBS. Qβ VLPs were supplemented with130 nmol/ml CpG-oligonucleotide B-CpG (SEQ ID NO:112) and incubated in athermomixer for 3 h at 37° C. Subsequently Qβ VLPs were subjected toBenzonase digestion (100 U/ml) for 3 h at 37° C. Samples were analysedon 1% agarose gels after staining with ethidium bromide or CoomassieBlue. FIG. 26 shows that in 1×HBS only a very low amount ofoligonucleotides could be packaged, while in 0.2×HBS a strong ethidiumbromide stained band was detectable, which colocalized with theCoomassie blue stain of the capsids.

Different Immunostimulatory Nucleic Acids can be Packaged in Qβ VLPs:

After RNase A digestion in 0.2×HBS the Qβ VLPs were concentrated to 1mg/ml using Millipore Microcon or Centriplus concentrators andsupplemented with 130 nmol/ml CpG-oligonucleotides B-CpGpt (SEQ IDNO:111), g10gacga and the 253 mer dsCyCpG-253 (SEQ ID NO: 124) (Table I)and incubated in a thermomixer for 3 h at 37° C. Subsequently Qβ VLPswere subjected to DNAse I digestion (5 U/ml) or Benzonase digestion (100U/ml) for 3 h at 37° C. Samples were analysed on 1% agarose gels afterstaining with ethidium bromide or Coomassie Blue. FIG. 27 shows that thedifferent nucleic acids B-CpGpt, g10gacga and the 253mer dsDNA could bepackaged into Qbx33. Packaged nucleic acids were resistant to DNAse Idigestion and remained packaged during dialysis (FIG. 27). Packaging ofB-CpGpt was confirmed by release of the nucleic acid by proteinase Kdigestion followed by agarose electrophoresis and ethidium bromidestaining (FIG. 27C).

FIG. 24 depicts the SDS-PAGE analysis of the p33 coupling to Qβ VLPsafter Coomassie Blue staining. Loaded are the following samples: (A) 1.NEB Prestained Protein Marker, Broad Range (#7708S), 10 μl; 2. Qβ VLP,14 μg; 3. Qβ VLP derivatized with SMPH, after dialysis; 4. Qβ VLPcoupled with CGG-p33, supernatant. (B) 1. NEB Prestained Protein Marker,Broad Range (#7708S), 10 μl; 2. Qβ VLP, 10 μg; 3. Qβ VLP coupled withGGC-p33, supernatant.

FIG. 25 depicts the analysis of RNA hydrolysis from Qβ VLPs by RNase Aunder low and high ionic strength on a 1% agarose gel stained withethidium bromide (A, C) and Coomassie Blue (B, D). Loaded on the gel arethe following samples: (A, B) 1. MBI Fermentas 1 kb DNA ladder; 2. QβVLP untreated; 3. Qβ VLP treated with RNase A inlx HBS buffer pH7.2. (C,D) 1. MBI Fermentas 1 kb DNA ladder; 2. Qβ VLP untreated; 3. Qβ VLPtreated with RNase A in 0.2×HBS buffer pH7.2.

FIG. 26 depicts the analysis of B-CpG (SEQ ID NO:112) packaging into QβVLPs under low and high ionic strength on a 1% agarose gel stained withethidium bromide (A) and Coomassie Blue (B). Loaded on the gel are thefollowing samples: 1. Qβ VLP untreated; 2. Qβ VLP treated with RNase A;3. Qβ VLP treated with RNase A and packaged with B-CpG in 0.2×HBS bufferpH7.2 and treated with Benzonase; 4. HBx33 VLP treated with RNase A,packaged with B-CpG in 1×HBS buffer pH7.2 and treated with Benzonase.

FIG. 27 depicts the analysis of B-CpGpt (SEQ ID NO:113) packaging intoQbx33 VLPs on a 1% agarose gel stained with ethidium bromide (A) andCoomassie Blue (B). Loaded on the gel are 50 μg of the followingsamples: 1. Qbx33 VLP untreated; 2. Qbx33 VLP treated with RNase A; 3.Qbx33 VLP treated with RNase A and packaged with B-CpGpt; 4. Qbx33 VLPtreated with RNase A, packaged with B-CpGpt, treated with DNaseI anddialysed; 5. 1 kb MBI Fermentas DNA ladder. (C) depicts the analysis ofthe amount of packaged oligo extracted from the VLP on a 15% TBE/ureastained with CYBR Gold. Loaded on gel are the following samples: 1.B-CpGpt oligo content of 2 μg Qbx33 VLP after proteinase K digestion andRNase A treatment; 2. 20 pmol B-CpGpt control; 3. 10 pmol B-CpGptcontrol; 4. 5 pmol B-CpGpt control.

FIGS. 27 D and E depict the analysis of g10gacga-PO (SEQ ID NO:116)packaging into Qbx33 VLPs on a 1% agarose gel stained with ethidiumbromide (D) and Coomassie Blue (E). Loaded on the gel are 15 μg of thefollowing samples: 1. MBI Fermentas 1 kb DNA ladder; 2. Qbx33 VLPuntreated; 3. Qbx33 VLP treated with RNase A; 4. Qbx33 VLP treated withRNase A and packaged with g10gacga-PO; 5. Qbx33 VLP treated with RNaseA, packaged with g10gacga-PO, treated with Benzonase and dialysed.

FIGS. 27 E and F depict the analysis of dsCyCpG-253 (SEQ ID NO:124)packaging into Qbx33 VLPs on a 1% agarose gel stained with ethidiumbromide (E) and Coomassie Blue (F). Loaded on the gel are 15 μg of thefollowing samples: 1. MBI Fermentas 1 kb DNA ladder; 2. Qbx33 VLPuntreated; 3. Qbx33 VLP treated with RNase A; 4. Qbx33 VLP treated withRNase A, packaged with dsCyCpG-253 and treated with DNaseI; 5. Qbx33 VLPtreated with RNase A, packaged with dsCyCpG-253, treated with DNaseI anddialysed.

Example 14 Qβ Disassembly Reassembly and Packaging of ImmunostimulatoryNucleic Acids Disassembly and Reassembly of Qβ VLP

Disassembly: 70 mg of pure lyophilized Qβ VLP gave a protein content ofabout 35 mg, according to spectrophotometric determination using theaverage result obtained with the following three formulae: 1.(183*OD^(230 nm)−75.8*OD^(260 nm))*volume (ml)−2.((OD^(235 nm)−OD^(280 nm))/2.51)×volume−3.((OD^(228.5 nm)−OD^(234.5 nm))*0.37)×volume. The pure lyophilized Qβ VLPwas solubilized in 7 ml of 6 M GuHC1 and incubated overnight at 4° C.The solution was clarified for 15 minutes, at 6000 rpm (Eppendorf 5810R, in fixed angle rotor F34-6-38, used in all the following steps). Anegligible sediment was discarded, and the supernatant was dialysed 5×against 200-300 ml NET buffer (20 mM Tris-HCl, pH 7.8 with 5 mM EDTA and150 mM NaCl) over 3 days. Alternatively, the supernatant was dialyzed ina continuous mode against 1.5 l NET buffer over 3-4 days. The resultingsuspension was centrifuged at 12000 rpm for 20 minutes. The pellet wasresolubilized in 2-3 ml 8 M urea, while the supernatant was precipitatedwith solid ammonium sulphate at 60% saturation. A saturated ammoniumsulphate solution was added to the pellet previously resolubilized inurea to 60% saturation, and the solution was left to precipitate 4 daysat 4° C., with subsequent centrifugation at 12000 rpm for 20 minutes.This pellet, and the pellet of the initial supernatant wereresolubilized and joined in a total volume of 3 ml of 7 M urea, 10 mMDTT. This material was loaded on a Sephadex G75 column, eluted at 2 ml/hwith 7 M urea, 10 mM DTT. Two peaks were isolated. A high molecularweight peak preceded a peak of lower apparent molecular weight.Calibration of the column with chymotrypsin in the same elution bufferrevealed that the apparent molecular weight of the second peak isconsistent with Qβ coat protein being in a dimeric form. Fractionscontaining this dimer material were pooled and precipitated withammonium sulphate (2 days, at 4° C.). The pellet was washed with a fewdroplets of water, centrifuged again, and solubilized in 2 ml of 7 Murea, 10 mM DTT. This material was then purified on a short (1.5×27 cm)Sepharose 4B column. One peak eluted from the column and the fractionswere pooled, leading to a protein preparation with a volume of 10 ml,and a ratio of absorbance at 280 nm vs. 260 nm of 0.68/0.5, yieldingabout 450 nmol of Qβ coat protein (giving a maximum of 2.5 nmol VLPafter reassembly, considering that there are 180 subunits in the VLP)and a protein concentration of 630 μg/ml (calculated using thespectrophotometric methods described above).

Reassembly: β-mercaptoethanol was added to the 10 ml dimer fraction to afinal concentration of 10%, and 300 μl of a solution of (CpG)₂₀OpAoligodeoxynucleotide (SEQ ID NO:118), containing 12.3 nmol ofoligonucleotide, were added. The reassembly mixture was first dialyzedagainst 30 ml NET buffer containing 10% beta-mercaptoethanol for 2 hoursat 4° C., and then dialyzed in a continuous mode, with a flow of NETbuffer of 8 ml/h over 4 days at 4° C. The reassembly mixture was thendesalted against water by dialysis, with 6 buffer exchanges (4×100 ml,2×1 liter).

The ratio of absorbance at 280 nm vs. 260 nm was of 0.167/0.24. Theprotein was dried by lyophilization. The dried protein was resolubilizedin water and purified by ultracentrifugation on a sucrose gradient in aBeckman L 8-80 centrifuge, with the SW 50.1 rotor at 22 000 rpm, for 17h at +4° C. The sucrose gradient purification was performed as follows.5 layers of 1 ml of the following sucrose concentrations (w/v) weredispensed into a centrifuge tube: 50%, 43%, 36%, 29% and 22%. The soformed succession of layers was left standing overnight at 4° C. 0.5 mlof the protein sample was layered on the gradient, and centrifuged for17 h as indicated above. The gradient was eluted from the bottom of thecentrifuge tube, and the 5 ml of the gradient were divided in 16fractions of approximately 300 μl. The fractions in the gradient wereanalyzed by SDS-PAGE (FIG. 28) and Ouchterlony assay. Fractions 6-9contained Qβ coat protein and gave the precipitation band typical of QβVLP in an Ouchterlony assay. Fractions 11-15, with a lower apparentdensity and containing Qβ protein gave no capsid band in the Ouchterlonyassay. The reassembled Qβ had the same apparent density as wt Qβ withinexperimental error. The fractions 6-9 of the sucrose gradient werepooled, dialyzed against water and lyophilized. This material was thenresolubilized for electron microscopy (EM) analysis (FIG. 29) andOuchterlony assay (FIGS. 30A and B). The EM procedure was as follows: Asuspension of the proteins was absorbed on carbon-formvar coated gridsand stained with 2% phosphotungstic acid (pH 6,8). The grids wereexamined with a JEM 100C (JEOL, Japan) electron microscope at anaccelerating voltage of 80 kV. Photographic records (negatives) wereperformed on Kodak electron image film and electron micrographs wereobtained by printing of negatives on Kodak Polymax paper. Both methodsindicate that the reassembled VLPs have the same macromolecularproperties as intact Qβ VLP. In addition, the pattern of disulfide bondsdisplayed by the purified reassembled Qβ VLP is indistinguishable fromthe disulfide bond pattern displayed by the untreated Qβ VLP, with thetypical pattern of pentamers and hexamers (FIG. 31 A).

Analysis of Nucleic Acid Content: Reassembled Qβ VLP was digested withpancreatic DNAse I as follows. To 200 μl of a 0.5 mg/ml solution of QβVLP reassembled with (CpG)₂₀OpA oligodeoxynucleotide were added 20 μl ofa 1 U/μl DNAse I (Fluka) solution, and 22 μl of DNAse I buffer (20 mMMgCl₂, 200 mM Tris, pH 8.3). The reaction mixture was incubated for 2 h30 min. at 37° C. The nucleic acid content of the sample wassubsequently isolated by phenol/chloroform extraction, and loaded on a2% agarose gel stained with ethidium bromide (FIG. 31B). A band of thesize of the packaged oligodeoxynucleotide was detected on the gel. Aband migrating at a higher apparent molecular weight was also visible.We cannot exclude the presence of multimers of the (CpG)₂₀OpAoligodeoxynucleotide which would lead to a band at this height. The gelthus shows that DNAse I protected oligodeoxynucleotides of the rightsize were present in the reassembled Qβ VLP, since theoligodeoxynuleotides could subsequently be digested by DNAse I, but notby RNAse A. Oligodeoxynucleotides could thus be successfully packaged inQβ VLP after initial disassembly of the VLP, purification of thedisassembled coat protein from nucleic acids and subsequent reassemblyof the VLP in the presence of oligodeoxynucleotide.

FIG. 28 shows the SDS-PAGE analysis of the fractions from the sucrosegradient centrifugation. Loaded on the gels were the following samples.Lane 1-10: fractions 6-15 of the sucrose gradient ultracentrifugation.

FIG. 29 shows the EM pictures of (A) intact Qβ VLP and (B) Qβ VLP afterdisassembly and reassembly in the presence of oligonucleotide(CpG)₂₀OpA, and subsequent purification by sucrose gradientultracentrifugation. A dense overlay of capsids is observed, and thosecapsids display the same structural features and properties as theintact Qβ VLPs.

FIG. 30 shows the Ouchterlony analysis (immunodiffusion) of thereconstructed Qβ VLP. In FIG. 30 A, Qβ VLP reassembled witholigonucleotide (CpG)20 OpA was loaded next to intact Qβ VLP. The twocharacteristic precipitation bands are indicated by black arrows. Thetwo precipitation bands are concurrent, indicating that the reassembledQβ VLP diffuse as the intact Qβ VLP. In FIG. 30 B, sample 1 is Qβ VLPreassembled in the presence of ribosomal RNA, while sample 2 is intactQβ VLP and sample 3 is Qβ VLP reassembled with oligonucleotide(CpG)20OpA. The precipitation bands are indicated by white arrows.

FIG. 31 A shows the analysis of the untreated and reassembled Qβ VLP bynon-reducing SDS-PAGE. The pentamers and hexamers of Qβ VLP areindicated by arrows.

FIG. 31 B shows the agarose gel electrophoresis analysis of thenucleotide content extracted after DNAse I digestion of Qβ VLPreassembled with oligonucleotide (CpG)20 OpA. The nucleic acid contentwas either untreated (lane 1), or subsequently digested with DNAse I(lane2) or RNAse A (lane 3); 33 μg of reassembled Qβ VLP were loaded oneach lane. 300 ng of a 50 bp oligonucleotide were loaded on lane 4,while 10 μl of the GeneRuler 100 bp DNA ladder+marker (MBI Fermentas)was loaded on lane 5.

Example 15 Qβ Disassembly Reassembly with Different ImmunostimulatoryNucleic Acids

Disassembly and Reassembly of Qβ VLP with Oligodeoxynucleotides ofVarious Sequences

The disassembly of Qβ VLP was performed essentially as described inExample 1, but for the use of 8 M urea instead of 7 M urea to resuspendthe ammonium sulphate pellets.

The reassembly of Qβ VLP with the oligos CyOpA (SEQ ID NO:121), CyCyCy(SEQ ID NO:122), (CpG)20-OpA (SEQ ID NO:118) and CyCpG (SEQ ID NO:110)was performed essentially as described in Example 1, but for thefollowing variations. A dialysis step against 10% β-mercaptoethanol inNET buffer (20 mM Tris-HCl, pH 7.8 with 5 mM EDTA and 150 mM NaCl) for 1hour at 4° C. was added to the procedure before addition of theoligodeoxynucleotide solution to the dimer solution in the dialysis bag.The oligodeoxynucleotides were then added to the dimer solutions,resulting approx. in a ten-fold molar excess of oligonucleotide tocapsid (180 subunits) as described previously. The reassembly mixturewas first dialyzed against 30 ml NET buffer containing 10%β-mercaptoethanol for 1 hours at 4° C., and then dialyzed in acontinuous mode, with a flow of NET buffer of 8 ml/h over 4 days at 4°C. A sample of the reassembly reaction of Qβ VLP witholigodeoxynucleotide CyOpA was taken for EM analysis (FIG. 32) at theend of the reassembly reaction. The EM procedure using phosphotungsticacid and described above was used. The reassembly mixtures were thendesalted against water by dialysis and dried.

The dried protein was resolubilized in water and purified byultracentrifugation on a sucrose gradient. The purified reassembled QβVLPs were also analyzed by EM (FIG. 33 A-D). The electron micrographsindicate that the reassembled VLPs have the same macromolecularproperties as intact Qβ VLP. Purification notably enriches thepreparations for reassembled particles. Thus, Qβ VLP was successfullyreassembled with oligodeoxynucleotides of various lengths and sequences.

Coupling of the p33 Peptide to Reassembled Qβ VLP: Qβ VLP reassembledwith the oligodeoxynucleotide CyOpA was reacted at a concentration of1.5 mg/ml, with the cross-linker SMPH diluted from a stock solution inDMSO at a final concentration of cross-linker of 536 μM for 35 minutesat 26° C. in 20 mM Hepes pH 7.4. The derivatized Qβ VLP was dialyzed 2×2hours against a thousand volumes of 20 mM Hepes, 150 mM NaCl, pH 7.4.The dialysed derivatized Qβ VLP at a concentration of 1.4 mg/ml wassubsequently reacted with the p33GGC peptide (sequence: KAVYNFATMGGC,SEQ ID NO:126) at a final concentration of peptide of 250 μM for 2 hoursat 15° C. in 20 mM Hepes, 150 mM NaCl, pH 7.4. The gel of FIG. 34indicates successful coupling of the p33 peptide to Qβ VLP. Couplingbands corresponding to one, respectively two peptides coupled persubunit are indicated by an arrow in the Figure.

Analysis of nucleic acid content: The nucleic acid content ofreassembled and coupled Qβ VLP was analysed by proteinase K digestion,phenol cloroform extraction and subsequent loading of the extractedoligonucleotide on a TBE/Urea PAGE gel. The analysis procedure was asfollows. 25 μl reassembled Qβ VLP (0.5-1 mg/ml) were supplemented with0.5 μl proteinase K, 1.5 μl 10% SDS and 3 μl 10× proteinase buffer (0.5M NaCl, 50 mM EDTA, 0.1 M Tris pH7.4). After incubation overnight at 37°C., proteinase K was inactivated by heating 20 min at 65° C. and thenucleic acid content was extracted from the samples by 1× phenol and 1×chloroform extraction. Subsequently the samples were incubated 2 h at37° C. with 1 μl RNAseA (Qiagen, 100 μg/ml, diluted 250×). Theequivalent of 2 μg starting protein was heated 3 min at 95° C. with 1volume of 2× loading buffer (1 ml 10×TBE, 4.2 g Urea, 1.2 g Ficoll, 1 ml0.1% Bromophenolblue, H₂O up to 10 ml) and loaded on a 15% TBE/Ureapolyacrylamide gel (Invitrogen). The gel was run for 1.5 h at 180 V, andfixed in 10% acetic acid/20% ethanol and stained with CYBR Gold(Molecular Probes, Eugene, Oreg., USA). For quantification, 10 and 20pmol of the oligonucleotide used for the reassembly were applied on thegel as a reference. Resistance of the nucleic acid content to RNAse andits size proved that the packaged nucleic acid was the oligonucleotideused for reassembly. Quantification of the packaged oligodeoxynucleotidewas performed by comparison of the band intensity of the extractedoligonucleotide with the band intensity of a reference amount of thesame oligonucleotide loaded on the same gel. A figure of 1.75 nmolCyOpA/100 μg Qβ VLP was obtained, giving a ratio of 44 oligonucleotidesper VLP on average.

FIG. 32 depicts the electron micrographs of the reassembly reaction ofQβ VLP with the oligonucleotide CyOpA (SEQ ID NO:121) beforepurification. The magnification was 200 000 fold.

FIG. 33 A-D show the electron micrographs of the purified reassemblyreactions of Qβ VLP with the oligodeoxynucleotides Cy(CpG)20 (SEQ IDNO:119) (A), CyCyCy (SEQ ID NO:122) (B), CyCpG (SEQ ID NO:110) (C) andCyOpA (SEQ ID NO:121) (D). The magnification was 200 000 fold.

FIG. 34 depicts the SDS-PAGE analysis of the coupling of Qβ VLPreassembled with the oligodeoxynucleotide CyOpA (SEQ ID NO:121) to thep33GGC peptide. Loaded on the gel were the following samples: 1.Prestained Protein Marker, Broad Range (#7708S) 10 μl; 2. Qβ VLPreassembled with CyOpA [1.5 mg/ml] 10 μl; 3. Qβ VLP reassembled withCyOpA [1.5 mg/ml] and derivatized with SMPH 10 μl; 4. Qβ VLP reassembledwith CyOpA [1.5 mg/ml], derivatized with SMPH and coupled withp33-peptide 10 μl; 5. Qβ VLP reassembled with CyOpA [1.5 mg/ml],derivatized with SMPH and coupled with p33-peptide, ⅕^(th) vol of thepellet.

FIG. 35 depicts the analysis of the extracted packagedoligodeoxynucleotides by Urea Polyacrylamide gel electrophoresis,stained with CYBR Gold. The following samples were loaded on the gel: 1.Qβ VLP reassembled with oligonucleotide CyOpA (SEQ ID NO:121) andcoupled to p33 GGC peptide, 2 μg protein loaded on the gel. 2. Qβ VLPreassembled with oligonucleotide CyOpA and coupled to p33GGC peptide,frozen and thawed before loading on the gel, 2 μg protein. 3. Qβ VLPreassembled with oligonucleotide Cy(CpG)₂₀ and coupled to p33GGCpeptide, frozen and thawed before loading on the gel; 2 μg protein. 4.CyOpA oligonucleotide, 20 pmol. 5. CyOpA oligonucleotide, 10 pmol.

Example 16 Qβ Disassembly Reassembly and Packaging Disassembly andReassembly of Qβ VLP

Disassembly: 10 mg Qβ VLP (as determined by Bradford analysis) in 20 mMHEPES, pH 7.4, 150 mM NaCl was precipitated with solid ammonium sulfateat a final saturation of 60%. Precipitation was performed over night at4° C. and precipitated VLPs were sedimented by centrifugation for 60minutes at 4° C. (SS-34 rotor). Pellets were resuspended in 1 ml of 6 MGuanidine hydrochloride (GuHCl) containing 100 mM DTT (finalconcentration) and incubated for 8 h at 4° C.

Purification of Qβ Coat Protein by Size Exclusion Chromatography: Thesolution was clarified for 10 minutes at 14000 rpm (Eppendorf 5417 R, infixed angle rotor F45-30-11, used in all the following steps) anddialysed against a buffer containing 7 M urea, 100 mM TrisHCl, pH 8.0,10 mM DTT (2000 ml) over night. Dialysis buffer was exchanged once anddialysis continued for another 2 h. The resulting suspension wascentrifuged at 14 000 rpm for 10 minutes at 4° C. A negligible sedimentwas discarded, and the supernatant was kept as “load fraction”containing dissasembled coat protein and RNA. Protein concentration wasdetermined by Bradford analysis and 5 mg total protein was applied ontoa HiLoad™ Superdex™ 75 prep grade column (26/60, Amersham Biosciences)equilibrated with 7 M urea, 100 mM TrisHCl and 10 mM DTT. Size exclusionchromatography was performed with the equilibration buffer (7 M urea,100 mM TrisHCl pH 8.0, 10 mM DTT) at 12° C. with a flow-rate of 0.5ml/min. During the elution absorbance at 254 nm and 280 nm wasmonitored. Two peaks were isolated. A high molecular weight peakpreceded a peak of lower apparent molecular weight. Peaks were collectedin fractions of 1.5 ml and aliquots were analysed by SDS-PAGE followedby Coomassie staining as well as SYBR® Gold staining (FIG. 36 A-H).

Purification of Qβ coat protein by ion exchange chromatography:Alternatively, the clearified supernatant was dialysed against a buffercontaining 7 M urea, 20 mM MES, 10 mM DTT, pH 6.0 (2000 ml) over night.Dialysis buffer was exchanged once and dialysis continued for another 2h. The resulting suspension was centrifuged at 14 000 rpm for 10 minutesat 4° C. A negligible sediment was discarded, and the supernatant waskept as “load fraction” containing disassembled coat protein and RNA.Protein concentration was determined by Bradford analysis and 10 mgtotal protein was diluted to a final volume of 10 ml with buffer A (seebelow) and applied with a flowrate of 1 ml/min to a 1 ml HiTrap™ SP HPcolumn (Amersham Biosciences, Cat. No. 17-1151-01) equilibrated withbuffer A: 7 M urea, 20 mM MES, 10 mM DTT, pH 6.0. The flowthrough whichcontained the RNA was collected as one fraction. After the column wasextensively washed with buffer A (30 CV) the bound Qβ coat protein waseluted in a linear gradient from 0%-100% buffer B (gradient length was 5CV; buffer A: see above, buffer B: 7 M urea, 20 mM MES, 10 mM DTT, 2 MNaCl, pH 6.0). During the loading, wash and elution the absorbance at254 nm and 280 nm was monitored. Peak fractions of 1 ml were collectedand analysed by SDS-PAGE followed by Coomassie staining as well as SYBR®Gold staining. Fractions containing the Q13 coat protein but not the RNAwere identified and the pH was adjusted by addition of 100 μl 1 MTrisHCl, pH 8.0.

Samples containing the Q13 coat protein but no RNA were pooled anddialysed against 0.87 M urea, 100 mM TrisHCl, 10 mM DTT (2000 ml) overnight and buffer was exchanged once and dialysis continued for another 2h. The resulting suspension was centrifuged at 14 000 rpm for 10 minutesat 4° C. A negligible sediment was discarded, and the supernatant waskept as “disassembled coat protein”. Protein concentration wasdetermined by Bradford analysis.

Reassembly: Purified Qβ coat protein with a concentration of 0.5 mg/mlwas used for the reassembly of VLPs in the presence of anoligodeoxynucleotide. For the reassembly reaction theoligodeoxynucleotide was used in a tenfold excess over the calculatedtheoretical amount of Qβ-VLP capsids (monomer concentration divided by180). After the Qβ coat protein was mixed with the oligodeoxynucleotideto be packaged during the reassembly reaction, this solution (volume upto 5 ml) was first dialysed for 2 h against 500 ml NET buffer containing10% β-mercaptoethanol at 4° C., then dialyzed in a continuous mode, witha flow of NET buffer of 8 ml/h over 72 h at 4° C., and finally foranother 72 h with the same continuos mode with a buffer composed of 20mM TrisHCl pH 8.0, 150 mM NaCl. The resulting suspension was centrifugedat 14 000 rpm for 10 minutes at 4° C. A negligible sediment wasdiscarded, and the supernatant contained the reassembled and packagedVLPs. Protein concentration was determined by Bradford analysis and ifneeded reassembled and packaged VLPs were concentrated with centrifugalfilter devices (Millipore, UFV4BCC25, 5K NMWL) to a finalproteinconcentration of 3 mg/ml.

Purification of reassembled and packaged VLPs: Up to 10 mg total proteinwas loaded onto a Sepharose™ CL-4B column (16/70, Amersham Biosciences)equilibrated with 20 mM HEPES pH 7.4, 150 mM NaCl. Size exclusionchromatography was performed with the equilibration buffer (20 mM HEPESpH 7.4, 150 mM NaCl) at room temperature with a flow-rate of 0.4 ml/min.During the elution absorbance at 254 nm and 280 nm was monitored. Twopeaks were isolated. A high molecular weight peak preceded a peak oflower apparent molecular weight. Fractions of 0.5 ml were collected andanalysed by SDS-PAGE followed by Coomassie blue staining (FIG. 37).Calibration of the column with intact and highly purified Qβ capsidsfrom E. coli revealed that the apparent molecular weight of the majorfirst peak was consistent with Qβ capsids.

Analysis of Qβ VLPs which had been reassembled in the presence ofoligodeoxynucleotides:

-   A) Overall structure of the capsids: Qβ VLPs that were reassembled    either in the presence of one of the following oligodeoxynucleotides    (CyOpA (SEQ ID NO:121), Cy(CpG)20OpA (SEQ ID NO:120), Cy(CpG)20 (SEQ    ID NO:119), CyCyCy (SEQ ID NO:122), (CpG)20pA) (SEQ ID NO:118), or    in the presence of tRNA from E. coli (Roche Molecular Biochemicals,    Cat. No. 109541) were analyzed by electron microscopy (negative    staining with uranylacetate pH 4.5) and compared to intact Qβ VLPs    purified from E. coli. As a negative control served a reassembly    reaction where nucleic acid was omitted. Reassembled capsids display    the same structural features and properties as the intact Qβ VLPs    (FIG. 38).-   B) Hydrodynamic size of reassembled capsids: Qβ capsids which had    been reassembled in the presence of oligodeoxynucleotides were    analyzed by dynamic light scattering (DLS) and compared to intact Qβ    VLPs which had been purified from E. coli. Reassembled capsids    showed the same hydrodynamic size (which depends both on mass and    conformation) as the intact Qβ VLPs.-   C) Disulfide-bond formation in reassembled capsids: Reassembled Qβ    VLPs were analyzed by native polyacrylamid gelelectrophoresis and    compared to intact Qβ VLPs which had been purified from E. coli.    Reassembled capsids displayed the same disulfide-bond pattern as the    intact Qβ VLPs (FIG. 39).-   D) Analysis of nucleic acid content of the Qβ VLPs which had been    reassembled in the presence of oligodeoxynucleotides by agarose    gelelectrophoresis: 5 μg reassembled Qβ VLPs were incubated in total    reaction volume of 25 μl either with 0.35 units RNase A (Qiagen,    Cat. No. 19101), 15 units DNAse I (Fluka, Cat. No. 31136), or    without any further addition of enzymes for 3 h at 37° C. Intact Qβ    VLPs which had been purified from E. coli served as control and were    incubated under the same conditions as described for the capsids    which had been reassembled in the presence of oligodeoxynucleotides.    The reactions were then loaded on a 0.8% agarose gel that was first    stained with ethidumbromide (FIG. 40A) and subsequently with    Coomassie blue (FIG. 40B). The ethidium bromide stain shows, that    none of the added enzymes could digest the nucleic acid content in    the reassembled Qβ capsids showing that the nucleic acid content    (i.e. the oligodeoxynucleotides) is protected. This result indicates    that the added oligodeoxynucleotides were packaged into the newly    formed capsids during the reassembly reaction. In contrast, the    nucleic acid content in the intact Qβ VLPs which had been purified    from E. coli was degraded upon addition of RNase A, indicating that    the nucleic acid content in this VLPs consists of RNA. In addition,    both the ethidium bromide stain and the Coomasie blue stain of the    agarose gel shows that the nucleic acid containing Qβ VLPs    (reassembled and purified from E. coli, respectively) are migrating    at about the same size, which indicates that the reassembly reaction    led to Qβ VLPs of comparable size to intact Qβ VLPs which had been    purified from E. coli.

The gel thus shows that DNAse I protected oligodeoxynucleotides werepresent in the reassembled Qβ VLP. Furthermore, after the packagedoligodeoxynuleotides had been extracted by phenol/chloroform they weredigestable by DNAse I, but not by RNAse A. Oligodeoxynucleotides couldthus be successfully packaged into Qβ VLPs after initial disassembly ofthe VLP, purification of the disassembled coat protein from nucleicacids and subsequent reassembly of the VLPs in the presence ofoligodeoxynucleotides.

-   E) Analysis of nucleic acid content of the Qβ VLPs which had been    reassembled in the presence of oligodeoxynucleotides by denaturing    polyacrylamide TBE-Urea gelelectrophoresis: 40 μg reassembled Qβ    VLPs (0.8 mg/ml) were incubated in a total reaction volume of 60 μl    with 0.5 mg/ml proteinase K (PCR-grade, Roche Molecular    Biochemicals, Cat. No. 1964364) and a reaction buffer according to    the manufacturers instructions for 3 h at 37° C. Intact Qβ VLPs    which had been purified from E. coli served as control and were    incubated with proteinase K under the same conditions as described    for the capsids which had been reassembled in the presence of    oligodeoxynucleotides. The reactions were then mixed with a TBE-Urea    sample buffer and loaded on a 15% polyacrylamide TBE-Urea gel    (Novex®, Invitrogen Cat. No. EC6885). As a qualitative as well as    quantitative standard, 1 pmol, 5 pmol and 10 pmol of the    oligodeoxynucleotide which was used for the reassembling reaction,    were loaded onto the same gel. This gel was fixed with 10% acetic    acid, 20% methanol, equilibrated to neutral pH and stained with    SYBR®-Gold (Molecular Probes Cat. No. S-11494). The SYBR®-Gold stain    showed (FIG. 41), that the reassembled Qβ capsids contained nucleic    acid comigrating with the oligodeoxynucleotides which were used in    the reassembly reaction. Note that intact Qβ VLPs (which had been    purified from E. coli) did not contain a nucleic acid of similar    size. Taken together, analysis of the nucleic acid content of the Qβ    VLPs which had been reassembled in the presence of    oligodeoxynucleotides showed that oligodeoxynucleotides were    protected from DNase I digestion, meaning that they were packaged)    and that the added oligodeoxynucleotides could be reisolated by    proper means (e.g. proteinase K digestion of the Qβ VLP).

FIGS. 37 A-D shows the purification of disassembled Qβ coat protein bysize exclusion chromatography. 5 μl of the indicated fractions (#) weremixed with sample buffer and loaded onto 16% Tris-Glycine gels (Novex®by Invitrogen, Cat. No. EC64952). After the run was completed the gelswere stained first with Coomassie blue (A) and after documentation thesame gels were stained with SYBR®-Gold (B). Note that the first highmolecular weight peak (fractions #15-#20) contained no protein butnucleic acids. On the other hand, the second peak of lower apparentmolecular weight contained disassembled coat protein which was therebyseparated from the nucleic acids.

FIG. 38 shows the purification of reassembled Qβ VLPs by size exclusionchromatography.

10 μl of the indicated fractions (#) were mixed with sample buffer andloaded onto a 16% Tris-Glycine gel (Novex® by Invitrogen, Cat. No.EC64952). After the run was completed the gel was stained with Coomassieblue. Due to the reducing conditions, disulfide bonds were reduced andthe proteinaceous monomer of the reassembled VLPs is visible as 14 kDacoat protein.

FIGS. 36 A-H shows electron micrographs of Qβ VLPs that were reassembledin the presence of different oligodeoxynucleotides. The VLPs had beenreassembled in the presence of the indicated oligodeoxynucleotides or inthe presence of tRNA but had not been purified to a homogenoussuspension by size exclusion chromatography. As positive control servedpreparation of “intact” Qβ VLPs which had been purified from E. coli.Importantly, by adding any of the indicated nucleic acids during thereassembly reaction, VLPs of the correct size and conformation could beformed, when compared to the “positive” control. This implicates thatthe reassembly process in general is independent of the nucleotidesequence and the length of the used oligodeoxynucleotides. Note thatadding of nucleic acids during the reassembly reaction is required forthe formation of Qβ VLPs, since no particles had been formed if nucleicacids were omitted from the reassembly reaction.

FIG. 39 shows the analysis of the disulfide-bond pattern in reassembledand purified Qβ capsids. 5 μg of the indicated capsids were mixed withsample buffer that either contained a reducing agent or not and loadedonto a 16% Tris-Glycine gel. After the run was completed the gel wasstained with Coomassie blue. When compared to “intact” capsids purifiedfrom E. coli, the reassembled Qβ VLPs displayed the same disulfide bondpattern.

FIG. 40 shows the analysis of nucleic acid content of the reassembled QβVLPs by nuclease treatment and agarose gelelectrophoresis: 5 μg ofreassembled and purified Qβ VLPs and 5 μg of Qβ VLPs which had beenpurified from E. coli, respectively, were treated as indicated. Afterthis treatment, samples were mixed with loading dye and loaded onto a0.8% agarose gel. After the run the gel was stained first with ethidumbromide (A) and after documentation the same gel was stained withCoomassie blue (B). Note that the nucleic acid content of thereassembled and purified Qβ VLPs were resistant towards RNase Adigestion while the nucleic acid content of Qβ VLPs purified from E.coli was digested upon incubation with RNase A. This indicates that thenucleic acid content of the reassembled Qβ capsids consists out ofdeoxynucleotides which of course are protected from RNase A digestion.Hence, oligodeoxynucleotides were packaged into Qβ VLPs during thereassembly reaction.

FIG. 41 shows the analysis of nucleic acid content of the reassembled QβVLPs by proteinase K treatment and polyacrylamide TBE/Ureagelelectrophoresis: The equivalent of 1 ug Qβ VLPs which had beendigested by proteinase K-treatment was mixed with a TBE-Urea samplebuffer and loaded on a 15% polyacrylamide TBE-Urea gel (Novex®,Invitrogen Cat. No. EC6885). As qualitative as well as quantitativestandard, 1 pmol, 5 pmol and 10 pmol of the oligodeoxynucleotide whichwas used for the reassembly reaction, was loaded onto the same gel.After the run was completed, the gel was fixed, equilibrated to neutralpH and stained with SYBR®-Gold (Molecular Probes Cat. No. S-11494). Notethat intact Qβ VLPs (which had been purified from E. coli) did notcontain nucleic acids of similar size than those which had beenextracted from reassembled Qβ capsids. In addition, nucleic acidsisolated from reassembled VLPs were comigrating with theoligodeoxynucleotides which had been used in the reassembly reaction.This results confirmed that the used oligodeoxynucleotides were packagedinto reassembled Qβ capsids.

Example 17 AP205 Disassembly-Purification-Reassembly and Packaging ofImmunostimulatory Nucleic Acids

A. Disassembly and Reassembly of AP205 VLP from Material Able toReassemble without Addition of Oligonucleotide

Disassembly: 40 mg of lyophilized purified AP205 VLP were resolubilizedin 4 ml 6 M GuHC1, and incubated overnight at 4° C. The disassemblymixture was centrifuged at 8000 rpm (Eppendorf 5810 R, in fixed anglerotor F34-6-38, used in all the following steps). The pellet wasresolubilized in 7 M urea, while the supernatant was dialyzed 3 daysagainst NET buffer (20 mM Tris-HCl, pH 7.8 with 5 mM EDTA and 150 mMNaCl) with 3 changes of buffer. Alternatively, dialysis was conducted incontinuous mode over 4 days. The dialyzed solution was centrifuged at8000 rpm for 20 minutes, and the pellet was resolubilized in 7 M urea,while the supernatant was pelletted with ammonium sulphate (60%saturation), and resolubilized in a 7 M urea buffer containing 10 mMDTT. The previous pellets all resolubilized in 7 M urea were joined, andprecipitated with ammonium sulphate (60% saturation), and resolubilizedin a 7 M urea buffer containing 10 mM DTT. The materials resolubilizedin the 7 M urea buffer containing 10 mM DTT were joined and loaded on aSephadex G75 column equilibrated and eluted with the 7 M urea buffercontaining 10 mM DTT at 2 ml/h. One peak eluted from the column.Fractions of 3 ml were collected. The peak fractions containing AP205coat protein were pooled and precipitated with ammonium sulphate (60%saturation). The pellet was isolated by centrifugation at 8000 rpm, for20 minutes. It was resolubilized in 7 M urea, 10 mM DTT, and loaded on ashort Sepharose 4B column (1.5×27 cm Sepharose 4B, 2 ml/h, 7 M urea, 10mM DTT as elution buffer). Mainly one peak, with a small shoulder elutedfrom the column. The fractions containing the AP205 coat protein wereidentified by SDS-PAGE, and pooled, excluding the shoulder. This yieldeda sample of 10.3 ml. The protein concentration was estimatedspectrophotometrically by measuring an aliquot of protein diluted25-fold for the measurement, using the following formula:(1.55×OD280-0.76×OD260)×volume. The average concentration was of 1nmol/ml of VLP (2.6 mg/ml). The ratio of absorbance at 280 nm vs. 260 nmwas of 0.12/0.105.

Reassembly: 1.1 ml beta-mercaptoethanol was added to the sample, and thefollowing reassembly reactions were set up:

-   -   1. 1 ml of AP205 coat protein, no nucleic acids    -   2. 1 ml of AP205 coat protein, rRNA (approx. 200 OD260 units, 10        nmol)    -   3. 9 ml of AP205 coat protein, CyCpG (SEQ ID NO:110) (370 ul of        225 pmol/μl solution, i.e. 83 nmol).

These mixtures were dialyzed 1 hour against 30 ml of NET buffercontaining 10% beta-mercaptoethanol. The mixture containing no nucleicacids was dialyzed separately. The dialysis was then pursued in acontinuous mode, and 1 l of NET buffer was exchanged over 3 days. Thereaction mixtures were subsequently extensively dialyzed against water(5 changes of buffer), and lyophilized. They were resolubilized inwater, and analyzed by EM. All mixtures contained capsids, showing thatAP205 VLP reassembly is independent of the presence of detectablenucleic acids, as measured by agarose gel electrophoresis using ethidiumbromide staining. The EM analysis of AP205 reassembled with CyCpG isshown on FIG. 42B. The EM procedure was as follows: A suspension of theproteins was absorbed on carbon-formvar coated grids and stained with 2%phosphotungstic acid (pH 6,8). The grids were examined with a JEM 100C(JEOL, Japan) electron microscope at an accelerating voltage of 80 kV.Photographic records (negatives) were performed on Kodak electron imagefilm and electron micrographs were obtained by printing of negatives onKodak Polymax paper. The VLP reassembled in the presence of the CyCpGwas purified over a Sepharose 4B column (1×50 cm), eluted with NETbuffer (1 ml/h). The fractions were analyzed by Ouchterlony assay, andthe fractions containing VLP were pooled. This resulted in a sample of 8ml, which was desalted against water by dialysis, and dried. The yieldof capsid was of 10 mg. Analysis of resolubilized material in a 0.6%agarose gel stained with ethidium-bromide showed that the capsids wereempty of nucleic acids. Samples of the reassembly reaction containingCyCpG taken after the reassembly step and before extensive dialysis wereanalysed on a 0.6% agarose gel and are shown in FIGS. 43A and B. A bandmigrating at the same height than intact AP205 VLP and staining both forethidium-bromide and Coomassie blue staining could be obtained, showingthat AP205 VLP containing oligodeoxynucleotide had been reassembled. Theextensive dialysis steps following the reassembly procedure are likelyto have led to diffusion of the oligodeoxynucleotide outside of theVLPs. Significantly, the AP205 VLPs could also be reassembled in theabsence of detectable oligodeoxynucleotide, as measured by agarose gelelectrophoresis using ethidium bromide staining. Oligodeoxynucleotidescould thus be successfully bound to AP205 VLP after initial disassemblyof the VLP, purification of the disassembled coat protein from nucleicacids and subsequent reassembly of the VLP in the presence ofoligodeoxynucleotide.

FIG. 42 shows electron micrographs of either intact recombinant AP205VLP used for the disassembly step (A), or AP205 VLP disassembled, andsubsequently reassembled in the presence of CyCpG (SEQ ID NO: 110) (B).

FIG. 43 shows the agarose gel-electrophoresis analysis of the AP205 VLPsample reassembled in the presence of CyCpG (SEQ ID NO:110), and takendirectly after the reassembly step before dialysis. The gel on FIG. 43Awas stained with ethidium-bromide. AP205 VLP reassembled with CyCpG wasloaded on lane1, while untreated pure AP205 VLP was loaded on lane 2.The arrow indicates the band of the reassembled AP205 VLP. The gel onFIG. 43 B was stained with Coomassie-brilliant blue. Untreated AP205 VLPwas loaded on lane 1, while AP205 VLP reassembled with CyCpG was loadedon lane 2.

B. Reassembly of AP205 VLP Using Disassembled Material which does notReassemble in the Absence of Added Oligonucleotide

Disassembly: 100 mg of purified and dried recombinant AP205 VLP (Cytospatent) were used for disassembly as described above. All steps wereperformed essentially as described under disassembly in part A, but forthe use of 8 M urea to solublize the pellets of the ammonium sulphateprecipitation steps and the omission of the gel filtration step using aCL-4B column prior to reassembly. The pooled fractions of the SephadexG-75 column contained 21 mg of protein as determined by spectroscopyusing the formula described in part A. The ratio of absorbance at 280 nmto the absorbance at 260 nm of the sample was of 0.16 to 0.125. Thesample was diluted 50 times for the measurement.

Reassembly: The protein preparation resulting from the Sephadex G-75 gelfiltration purification step was precipitated with ammonium sulphate at60% saturation, and the resulting pellet solubilized in 2 ml 7 M urea,10 mM DTT. The sample was diluted with 8 ml of 10% 2-mercaptoethanol inNET buffer, and dialyzed for 1 hour against 40 ml of 10%2-mercaptoethanol in NET buffer. Reassembly was initiated by adding 0.4ml of a CyCpG solution (109 nmol/ml) to the protein sample in thedialysis bag. Dialysis in continuos mode was set up, and NET buffer usedas eluting buffer. Dialysis was pursued for two days and a sample wastaken for EM analysis after completion of this dialysis step (FIG. 44B). The dialyzed reassembly solution was subsequently dialyzed against50% v/v Glycerol in NET buffer, to achieve concentration. One change ofbuffer was effected after one day of dialysis. The dialysis was pursuedover a total of three days.

The dialyzed and concentrated reassembly solution was purified by gelfiltration over a Sepharose 4-B column (1×60 cm) at a flow rate of 1ml/hour, in NET buffer. Fractions were tested in an Ouchterlony assay,and fractions containing capsids were dried, resuspended in water, andrechromatographed on the 4-B column equilibrated in 20 mM Hepes pH 7.6.Using each of the following three formula:

1·(183*OD^(230 nm)−75.8*OD^(260 nm))*volume(ml)−2·((OD^(235 nm)−OD^(280 nm)/2.51)×volume−3·((OD^(228.5 nm)−OD^(234.5 nm))*0.37)×volume

protein amounts of 6-26 mg of reassembled VLP were determined

The reassembled AP205 VLPs were analyzed by EM as described above,agarose gel electrophoresis and SDS-PAGE under non-reducing conditions.

The EM analysis of disassembled material shows that the treatment ofAP205 VLP with guanidinium-chloride essentially disrupts the capsidassembly of the VLP. Reassembly of this disassembled material with anoligonucleotide yielded capsids (FIG. 44B), which were purified andfurther enriched by gel filtration (FIG. 44 C). Two sizes of particleswere obtained; particles of about 25 nm diameter and smaller particlesare visible in the electron micrograph of FIG. 44C. No reassembly wasobtained in the absence of oligonucleotides. Loading of the reassembledparticles on agarose electrophoresis showed that the reassembledparticles contained nucleic acids. Extraction of the nucleic acidcontent by phenol extraction and subsequent loading on an agarose gelstained with ethidium bromide revealed that the particles contained theoligonucleotide used for reassembly (FIG. 45A). Identity of the packagedoligonucleotide was controlled by loading a sample of thisoligonucleotide side to side to the nucleic acid material extracted fromthe particles. The agarose gel where the reassembled AP205 VLP had beenloaded and previously stained with ethidium bromide was subsequentlystained with Coomassie blue, revealing comigration of theoligonucleotide content with the protein content of the particles (FIG.45B), showing that the oligonucleotide had been packaged in theparticles.

Loading of the reassembled AP205 VLP on an SDS-PAGE gel, run in theabsence of reducing agent (FIG. 46) demonstrated that the reassembledparticles have formed disulfide bridges, as is the case for theuntreated AP205 VLP. Moreover, the disulfide bridge pattern is identicalto the untreated particles.

Depicted on FIG. 44 A is an electron micrograph of the disassembledAP205 VLP protein, while FIG. 44 B shows the reassembled particlesbefore purification. FIG. 3 C shows an electron micrograph of thepurified reassembled AP205 VLPs. The magnification of FIG. 3A-C is 200000×.

FIGS. 45 A and B show the reassembled AP205 VLPs analyzed by agarose gelelectrophoresis. The samples loaded on the gel from both figures were,from left to right: untreated AP205 VLP, 3 samples with differing amountof AP205 VLP reassembled with CyCpG and purified, and untreated Qβ VLP.The gel on FIG. 45A was stained with ethidium bromide, while the samegel was stained with Coomassie blue in FIG. 45 B.

FIG. 46 depicts an SDS-PAGE analysis of reassembled AP205 VLP, loadedunder non-reducing conditions. 5 samples were loaded on the gel. Thesamples loaded on the gel are, from left to right: Protein Marker,untreated wt Qβ, reassembled wt Qβ, untreated AP205 VLP, reassembledAP205 VLP. The Molecular Weight of the AP205 VLP subunit is 14.0 kDa,while the molecular weight of the Qβ subunit is 14.3 kDa (both molecularweights calculated with the N-terminal methionine). The disulfide linkedmultimers are each indicated by an arrow on the figure.

C. Coupling of p33 Epitope (Sequence: H2N-KAVYNFATMGGC-COOH (SEQ IDNO:126), with Free N- and C-Termini) to AP205 VLPs Reassembled withCyCpG (SEQ ID NO: 110)

Reassembled AP205 VLP obtained as described in part B, and in 20 mMHepes, 150 mM NaCl, pH 7.4 was reacted at a concentration of 1.4 mg/mlwith a 5-fold excess of the crosslinker SMPH diluted from a 50 mM stockin DMSO for 30 minutes at 15° C. The obtained so-called derivatizedAP205 VLP was dialyzed 2×2 hours against at least a 1000-fold volume of20 mM Hepes, 150 mM NaCl, pH 7.4 buffer. The derivatized AP205 wasreacted at a concentration of 1 mg/ml with either a 2.5-fold, or with a5-fold excess of peptide, diluted from a 20 mM stock in DMSO, for 2hours at 15° C. The sample was subsequently flash frozen in liquidnitrogen for storage.

The result of the coupling reaction is shown in FIG. 6. A higher degreeof coupling could be achieved by using a 5-fold excess of peptide ratherthan with a 2.5 fold excess of peptide in the coupling reaction.

Depicted on FIG. 47 is the SDS-PAGE analysis of the coupling reaction.The following samples (from left to right) were loaded on the gel:protein marker; derivatized AP205 VLP (d); AP205 VLP coupled with a2.5-fold excess of peptide, supernatant (s); AP205 VLP coupled with a2.5-fold excess of peptide, pellet (p); AP205 VLP coupled with a 5-foldexcess of peptide, supernatant (s); AP205 VLP coupled with a 5-foldexcess of peptide, pellet (p).

Example 18 Free Immunostimulatory Nucleic Acids but notImmunostimulatory Nucleic Acids Packaged in VLPs Induce Splenomegaly

Mice were left untreated or immunized s.c. with 100 μg HBc33 alone, 20nmol CyCpGpt, 100 μg HBc33 mixed with 20 nmol CyCpGpt (SEQ ID NO:109),or 100 μg HBc33 packaged with CyCpGpt. Twelve days later, spleens wereisolated and spleen weights and splenic cellularity were assessed.CyCpGpt induced a massive increase in spleen weight and number of cellswhen given alone (FIG. 48 A, B). No such effect was seen with CyCpGptpackaged in HBc33 although this composition was able to induceprotection against viral challenge (see EXAMPLE 4).

Example 19 In-Vivo Virus Protection Assays Vaccinia Protection Assay

Groups of three female C57B1/6 mice were immunized s.c. with 100 μg VLPcoupled or fused to p33 alone, mixed with 20 nmol immunostimulatorynucleic acid or packaged with immunostimulatory nucleic acid. To assessantiviral immunity in peripheral tissues, mice were infected 7-9 dayslater, i.p., with 1.5×10⁶ pfu recombinant vaccinia virus expressing theLCMV-glycoprotein (inclusive of the p33 peptide). Five days later theovaries were collected and viral titers determined. Therefore, ovarieswere ground with a homogenizer in Minimum Essential Medium (Gibco)containing 5% fetal bovine serum and supplemented with glutamine,Earls's salts and antibiotics (penicillin/streptomycin/amphotericin).The suspension was titrated in tenfold dilution steps onto BSC40 cells.After overnight incubation at 37° C., the adherent cell layer wasstained with a solution consisting of 50% ethanol, 2% crystal violet and150 mM NaCl for visualization of viral plaques. Non-immunized naïve micewere used as control.

LCMV Protection Assay

Groups of three female C57B1/6 mice were immunized s.c. with 100 μg VLPcoupled or fused to p33 alone or mixed with adjuvant/20 nmol CpGoligonucleotide. To examine systemic antiviral immunity mice wereinfected i.p. 11-13 days later with 200 pfu LCMV-WE. Four days laterspleens were isolated and viral titers determined. The spleens wereground with a homogenizer in Minimum Essential Medium (Gibco) containing2% fetal bovine serum and supplemented with glutamine, earls's salts andantibiotics (penicillin/streptomycin/amphotericin). The suspension wastitrated in tenfold dilution steps onto MC57 cells. After incubation forone hour the cells were overlayed with DMEM containing 5% Fetal bovineserum, 1% methyl cellulose, and antibiotics(penicillin/streptomycin/amphotericin). Following incubation for 2 daysat 37° C. the cells were assessed for LCMV infection by theintracellular staining procedure (which stains the viral nucleoprotein):Cells were fixed with 4% Formaldehyde for 30 min followed by a 20 minlysing step with 1% Triton X-100. Incubation for 1 hour with 10% fetalbovine serum blocked unspecific binding. Cells were stained with a ratanti-LCMV-antibody (VL-4) for 1 hour. A peroxidase-conjugated goatanti-rat-IgG (Jackson ImmunoResearch Laboratories, Inc) was used assecondary antibody followed by a colour reaction with ODP substrateaccording to standard procedures.

Example 20 Different Immunostimulatory Nucleic Acids Packaged in VLPFused to Antigen Result in a Potent Antigen-Specific CTL Response andVirus Protection

The fusion protein of HBcAg with the peptide p33 (HBc33) was produced asdescribed in EXAMPLE 1 and packaged with different CpG nucleic acids asdescribed in EXAMPLE 11.

100 μg of vaccines were injected into mice and vaccina titers in theovaries after recombinant vaccinia challenge were detected as describedin EXAMPLE 19. Double stranded CyCpGpt (dsCyCpGpt) (SEQ ID NO:109) wasproduced by annealing 0.5 mM of DNA oligonucleotides CyCpGpt andCyCpG-rev-pt (Table I) in 15 mM Tris pH7.5 by a 10 min heating step at80° C. and subsequent cooling to RT. Oligonucleotide hybridization waschecked on a 20% TBE polyacrylamid gel (Novex).

HBc33 capsids containing CyCpG (SEQ ID NO:110), NKCpG (SEQ ID NO:114),B-CpG (SEQ ID NO:112) and g10gacga-PS (SEQ ID NO:117) did induce CTLresponses capable of completely inhibition viral infection (FIG. 49,FIG. 50). Protection was observed with nucleic acids containedphosphodiester or phosphothioate bonds (pt or PS). Even a doublestranded oligonucleotide dsCyCpGpt was inducing protection againstvaccinia challenge (FIG. 49).

Example 21 Immunostimulatory Nucleic Acids Packaged in HBcAg and Qβ VLPsResult in a Potent Antigen-Specific CTL Response and Virus Protection

The fusion protein of HBcAg with the peptide p33 (HBc33) was produced asdescribed in EXAMPLE 1 and packaged with oligonucleotide B-CpGpt (SEQ IDNO:112) as described in EXAMPLE 11. Peptide p33 was coupled to the RNAphage Qβ and oligonucleotide B-CpGpt were packaged as described inEXAMPLE 13. 100 μg, 30 μg, 10 μg or 3 μg of each vaccine was injectedinto mice and vaccina titers in the ovaries after recombinant vacciniachallenge were detected as described in EXAMPLE 19. 100 μg and 30 μgHBc33 and Qbx33 with packaged B-CpG did induce full protection againstviral challenge while at lower concentrations partial or no protectionwas observed (FIG. 51).

Example 22 Immunostimulatory Nucleic Acids Packaged in VLPs which areCoupled to Selfantigens can Overcome Tolerance to Self-Antigens

Transgenic mice expressing LCMV glycoprotein in pancreatic 13 isletcells (Ohasi et al., Cell 65, 305-317 (1991)) were immunized with 200pfu LCMV, 100 μg HBc33 mixed with 20 nmol CyCpGpt, 100 μg HBc33 packagedwith CyCpGpt or 100 μg p33 peptide mixed with 20 nmol CyCpGpt ascontrol. Blood glucose levels were measured every four days with theGlucotrend Plus Glucose test kit (Roche). Mice with blood glucose levelslarger 12 mM were considered diabetic Immunization with LCMV induceddiabetes in 4/4 animals at day 12. CyCpGpt mixed with HBc33 only causeddiabetes in 1/3 mice. Two of three mice immunized with HBc33 in whichCyCpGpt was packaged develop diabetes at day 12, the third mouse at day16. Immunization with peptide p33 mixed with CyCpGpt did not inducediabetes in three mice. This clearly shows that immunostimulatorynucleic acid packaged into VLP to which antigens are fused are much moreefficient in enhancing a strong CTL response than a mixture of nucleicacid and antigen. They even induced a stronger response than antigenfused to VLP and mixed with the immunostimulatory nucleic acid.

Example 23 Immunostimulatory Nucleic Acids Packaged in VLPs-Coupled toAntigens are Even More Efficient in Inducing Antigen-Specific CD8⁺ TCells than VLPs Mixed with Immunostimulatory Nucleic Acids

C57BL/6 mice were subcutaneously immunized with 100 μg HBc33 alone,mixed with CyCpGpt or, alternatively, packaged with CyCpGpt. Untreatedmice served as controls.

8 days after immunization blood lymphocytes were double-stained withPE-labeled p33-tetramers and FITC-coupled monoclonal anti-CD8 antibodiesfor p33-specific CD8+ T cell detection and percentage of p33-specificcells on the total CD8+ T cell population were determined by FACSanalysis.

TABLE II Induction of p33-specific CD8+ T cells after vaccination withp33-VLP mixed or packaged with CpGs. Numbers correspond to means offrequencies (in percent) and standard deviations. Frequencies of p33-specific CD8⁺ T Mice per Immunization cells group Untreated 0.2 2 HBc330.3 ± 0.1 4 HBc33 + CyCpGpt (SEQ ID 2.1 ± 0.9 5 NO: 109) (mixed)HBc33/CyCpGpt (SEQ ID 4.3 ± 1.1 5 NO: 109) (packaged)

HBc33 with packaged CyCpGpt induced a higher frequence of p33-specificCD8⁺ T cells than HBc33 mixed with CyCpGpt (SEQ ID NO: 109) (Table II).As the amount of packaged oligonucleotide is much lower (about 1/20) ofthe amount of oligonucleotide used in the mixed setting this clearlydemonstrates that VLPs with packaged immunostimulatory nucleic acids areeven more efficient in inducing high numbers of antigen-specific CD8⁺ Tcells.

Example 24 Immunostimulatory Nucleic Acids Packaged in VLPs are EvenMore Efficient in Inducing CTL Responses than VLPs Mixed withImmunostimulatory Nucleic Acids

Groups of C57BL/6 mice were subcutaneously primed with 100 μg p33-VLPgiven alone, mixed with 20 nmol CyCpGpt (SEQ ID NO:109), or,alternatively, packaged with CyCpGpt. For detection of primary ex vivocytotoxicity, effector cell suspensions were prepared from spleens ofvaccinated mice 9 days after priming EL-4 cells were pulsed with p33peptide (10⁻⁶ M, 2 h at 37° C. in 2% FCS MEM medium) and used in a 5 h⁵¹Cr release assay.

FIG. 52 shows the primary ex vivo cytotoxicity of groups of C57BL/6 micethat were subcutaneously primed with 100 μg p33-VLP given alone (A),mixed with 20 nmol CyCpGpt (SEQ ID NO:109) (B), or, alternatively,packaged with CyCpGpt (C). Nine days later spleen cells were tested fordirect ex vivo CTL activity in a 5-h ⁵¹Cr-release assay on p33-pulsed(filled symbols) or on unpulsed (open symbols) EL-4 target cells at theindicated effector to target cell ratios. Radioactivity in cell culturesupernatants was measured in a Cobra II Counter (Canberra Packard,Downers Growe, Ill.). Spontaneous release was always <10%. Two dilutionseries of effector cells per mouse were performed. In (A) two mice pergroup were used, whereas in (B) and (C) data from four mice per groupare shown.

FIG. 52 clearly demonstrates that 100 μg HBc33 alone did not induceprimary in vivo CTL response while the same amount HBc33 mixed with 20nmol CyCpGpt (SEQ ID NO:109) did induce a significant cytotoxicity.However, although the amount of packaged oligonucleotide was much lower(about 1/20) of the amount of oligonucleotide used in the mixed settingcytotoxicity was enhanced when 100 μg HBc33 with packaged CyCpGpt wereused for immunization (FIG. 52).

Example 25 Non-Enzymatic Hydrolysis of the RNA Content of VLPs andPackaging of Immunostimulatory Nucleic Acids ZnSO₄ Dependent Degradationof the Nucleic Acid Content of a VLP:

5 mg Qβ VLP (as determined by Bradford analysis) in 20 mM HEPES, pH 7.4,150 mM NaCl was dialysed either against 2000 ml of 50 mM TrisHCl pH 8.0,50 mM NaCl, 5% glycerol, 10 mM MgCl₂ or 2000 ml of 4 mM HEPES, pH 7.4,30 mM NaCl for 2 h at 4° C. in SnakeSkin™ pleated dialysis tubing(Pierce, Cat. No. 68035). Each of the dialysis buffers was exchangedonce and dialysis was allowed to continue for another 16 h at 4° C. Thedialysed solution was clarified for 10 minutes at 14 000 rpm (Eppendorf5417 R, in fixed angle rotor F45-30-11, used in all the following steps)and proteinconcentration was again determined by Bradford analysis. QβVLPs in 50 mM TrisHCl pH 8.0, 50 mM NaCl, 5% glycerol, 10 mM MgCl₂ werediluted with the corresponding buffer to a final protein concentrationof 1 mg/ml whereas Qβ VLPs in 4 mM HEPES pH 7.4, 30 mM NaCl were dilutedwith the corresponding buffer to a final protein concentration of 0.5mg/ml. This capsid-containing solutions were centrifuged again for 10minutes at 14 000 rpm at 4° C. The supernatants were than incubated withZnSO₄ which was added to a final concentration of 2.5 mM for 24 h at 60°C. in an Eppendorf Thermomixer comfort at 550 rpm. After 24 h thesolutions were clarified for 10 minutes at 14000 rpm and the sedimentwas discarded. The efficiency of the ZnSO₄-dependent degradation ofnucleic acids was confirmed by agarose gelelectrophoresis (FIG. 53). Thesupernatants were dialysed against 5000 ml of 4 mM HEPES pH 7.4, 30 mMNaCl for 2 h at 4° C. 5000 ml buffer was exchanged once and dialysiscontinued over night at 4° C. The dialysed solution was clarified for 10minutes at 14 000 rpm and 4° C., a negligible sediment was discarded andthe protein concentration of the supernatants were determined byBradford analysis.

Similar results were obtained with copperchloride/phenanthroline/hydrogen peroxide treatment of capsids. Thoseskilled in the art know alternative non-enzymatic procedures forhydrolysis or RNA.

Packaging of Oligodeoxynucleotides into ZnSO₄-Treated VLPs:

ZnSO₄-treated and dialysed Qβ capsids with a protein concentration (asdetermined by Bradford analysis) between 0.4 mg/ml and 0.9 mg/ml (whichcorresponds to a concentration of capsids of 159 nM and 357.5 nM,respectively) were used for the packaging of the oligodeoxynucleotides.The oligodeoxynucleotides were added at a 300-fold molar excess to theof Q3-VLP capsids and incubated for 3 h at 37° C. in an EppendorfThermomixer comfort at 550 rpm. After 3 h the reactions were centrifugedfor 10 minutes at 14 000 rpm and 4° C. The supernatants were dialysed inSpectra/Por®CE DispoDialyzer with a MWCO 300′000 (Spectrum, Cat. No. 135526) against 5000 ml of 20 mM HEPES pH 7.4, 150 mM NaCl for 8 h at 4° C.5000 ml buffer was exchanged once and dialysis continued over night at4° C. The protein concentration of the dialysed samples were determinedby Bradford analysis. Qβ capsids and their nucleic acid contents wereanalyzed as described in Examples 11 and 13.

FIG. 53 shows the analysis of ZnSO₄-treated Qβ VLPs by agarosegelelectrophoresis: Qβ VLPs which had been purified from E. coli anddialysed either against buffer 1 (50 mM TrisHCl pH 8.0, 50 mM NaCl, 5%glycerol, 10 mM MgCl₂) or buffer 2 (4 mM HEPES, pH 7.4, 30 mM NaCl) wereincubated either without or in the presence of 2.5 mM zinc sulfate(ZnSO₄) for 24 hrs at 60° C. After this treatment equal amounts of theindicated samples (5 μg protein) were mixed with loading dye and loadedonto a 0.8% agarose gel. After the run the gel was stained with ethidiumbromide. Note that treatment of VLPs with ZnSO₄ causes degradation ofthe nucleic acid content, while the mock-treated controls wereunaffected.

FIG. 54 shows the packaging of oligodeoxynucleotides into ZnSO₄-treatedVLPs and analysis of them by agarose gelelectrophoresis. Qβ VLPs whichhad been treated with 2.5 mM zinc sulfate (+ZnSO₄) were dialysed against4 mM HEPES, pH 7.4, 30 mM NaCl and incubated for 3 hrs at 37° C. with anexcess of oligodeoxynucleotides (due to the dialysis the concentrationof ZnSO₄ was decreased by an order of 10⁶, therefore its indicated onlyin parenthesis) After this incubation in presence ofoligodeoxynucleotides, equal amounts of the indicated samples (5 μgprotein) were mixed with loading dye and loaded onto a 0.8% agarose gel.After the run the gel was stained with ethidium bromide. Note thatadding of oligodeoxynucleotides to ZnSO₄-treated Qβ VLPs could restorethe electrophoretical behaviour of the so treated capsids when comparedto untreated Qβ capsids which had been purified from E. coli.

FIG. 55 shows the analysis of nucleic acid content of ZnSO₄— andoligodeoxynucleotide treated Qβ VLPs by Benzonase and proteinase Kdigestion and polyacrylamide TBE/Urea gelelectrophoresis:Oligodeoxynucleotides were packaged into ZnSO₄-treated Qβ VLPs asdescribed above. 25 μg of these VLPs were digested with 25 μl Benzonase(Merck, Cat. No. 1.01694.0001) according to the manufacturesinstructions. After heat-inactivation of the nuclease (30 minutes at 80°C.) the VLPs were treated with Proteinase K (final enzyme concentrationwas 0.5 mg/ml) according to the manufactures instructions. After 3 hrsthe equivalent of 2 ug Qβ VLPs which had been digested by Benzonase andproteinase K were mixed with TBE-Urea sample buffer and loaded on a 15%polyacrylamide TBE-Urea gel (Novex®, Invitrogen Cat. No. EC6885). Thecapsids loaded in lane 2 were treated with 2.5 mM ZnSO₄ in presence ofbuffer 1 (see above), while the capsids loaded in lane 3 were treatedwith 2.5 mM ZnSO₄ in presence of buffer 2 (see above). As qualitative aswell as quantitative standard, 1 pmol, 5 pmol and 10 pmol of theoligodeoxynucleotide which was used for the reassembly reaction, wasloaded onto the same gel (lanes 4-6). As control, Qβ capsids which hadbeen purified from E. coli were treated exactly the same and analyzed onthe same polyacrylamide TBE-Urea gel (lane 1). After the run wascompleted, the gel was fixed, equilibrated to neutral pH and stainedwith SYBR-Gold (Molecular Probes Cat. No. S-11494). Note that intact QβVLPs (which had been purified from E. coli) did not contain nucleicacids of similar size than those which had been extracted from ZnSO₄—and oligodeoxynucleotide treated Qβ capsids. In addition, nucleic acidsisolated from the latter VLPs were comigrating with theoligodeoxynucleotides which had been used in the reassembly reaction.This results confirmed that the used oligodeoxynucleotides were packagedinto ZnSO₄-treated Qβ capsids.

Example 26 VLPs Containing Immunostimulatory Nucleic Acids Induce T CellResponses that can be Boosted by Viral Vectors: LCMV

Mice were subcutaneously primed with 20 μg p33-VLPs containingimmunostimulatory nucleic acids. Before immunization, p33-VLPpreparations were extensively purified from unbound CpG-oligonucleotidesvia dialysis (see Example 2 and FIG. 5). 12 days later, blood was takenand frequencies of p33-specific T cells were determined by tetramerstaining. The mice were boosted with 200 pfu of live LCMV strain WE andfrequencies of specific T cells were determined 5 days later.Frequencies before boost were 3.5%+/−1.8% and after boost 15.5%+/−1.9%.

Example 27 VLPs Containing Immunostimulatory Nucleic Acids Induce T CellResponses that can be Boosted by Viral Vectors: Recombinant VacciniaVirus

Mice are subcutaneously primed with 20 μg p33-VLPs containingimmunostimulatory nucleic acids. Before immunization, p33-VLPpreparations are extensively purified from unbound CpG-oligonucleotidesvia dialysis (see Example 2 and FIG. 5). 12 days later, blood is takenand frequencies of p33-specific T cells are determined by tetramerstaining. The mice are boosted with 10⁶ pfu of recombinant vaccina virusexpressing LCMV-GP and frequencies of specific T cells are determined 5days later.

Example 28 VLPs Containing Immunostimulatory Nucleic Acids Induce T CellResponses that can be Boosted by Viral Vectors: Recombinant Canary PoxVirus

Mice are subcutaneously primed with 20 μg p33-VLPs containingimmunostimulatory nucleic acids. Before immunization, p33-VLPpreparations are extensively purified from unbound CpG-oligonucleotidesvia dialysis (see Example 2 and FIG. 5). 12 days later, blood is takenand frequencies of p33-specific T cells are determined by tetramerstaining. The mice are boosted with 10⁷ pfu of recombinant canary poxvirus expressing LCMV-GP and frequencies of specific T cells aredetermined 5 days later.

Example 29 VLPs Containing Immunostimulatory Nucleic Acids can Boost TCell Responses

Mice are infected intravenously with recombinant vacccina virusexpressing LCMV-GP. 20 days later, blood is taken and frequencies ofp33-specific T cells are determined by tetramer staining. The mice areboosted the same day with p33-VLP preparations containingimmunostimulatory nucleic acids (see Example 2 and FIG. 5) andfrequencies of specific T cells are determined 5 days later.

Example 30 Packaging of Immunostimulatory Ribonucleic Acids into VLPs

Immunostimulatory ribonucleic acids such as poly (I:C) (Sigma) orsynthetic double-stranded 30 mer of polyinosinic acid and polycytidylicacid either with phosphodiester or phosphorothiate backbone aredissolved in water. Alternatively, polydeoxyinosinic acid andpolydeoxyinosinic acid are used to prepare a double stranded poly(I:C)analogon. HBc33 VLPs and Qβ VLPs are treated with RNAse as described inExamples 11, 13 or 25 and nucleic acids are added at 1, 10 and 100nmol/ml in 0.2×HBS and incubated for 3 h at 37° C. in a thermomixer.Excess nucleic acids are removed by enzymatic hydrolysis or dialysis andanalysed as described in Example 11, 13 and 25.

Alternatively, immunostimulatory ribonucleic acids and their analogs arepackaged during reassembly of Qβ coat proteins as described in Examples14, 15, 16. Reassembly is performed by adding β-mercaptoethanol to the10 ml dimer fraction to a final concentration of 10%, and 300 μl of asolution of nucleic acid, resulting in a 1, 10 and 100 molar excess overcapsid concentration, are added. The reassembly mixtures are firstdialyzed against 30 ml NET buffer containing 10% beta-mercaptoethanolfor 2 hours at 4° C., and then dialyzed in a continuous mode, with aflow of NET buffer of 8 ml/h over 4 days at 4° C. The reassemblymixtures are then desalted against water by dialysis, with 6 bufferexchanges (4×100 ml, 2×1 liter). Reassembled Qβ VLPs are then isolatedby sucrose gradient centrifugation as described in Example 14 or by gelfiltration as described in Example 16.

1. A composition for enhancing an immune response in an animalcomprising: (a) a virus-like particle, wherein said virus-like particleis a virus-like particle of an RNA-phage; and (b) an immunostimulatorysubstance, wherein said immunostimulatory substance is an unmethylatedCpG-containing oligonucleotide; wherein said immunostimulatory substanceis packaged into said virus-like particle.
 2. The composition of claim 1further comprising at least one antigen, wherein said antigen is boundto said virus-like particle. 3-10. (canceled)
 11. The composition ofclaim 1, wherein said virus-like particle is a recombinant virus-likeparticle. 12-14. (canceled)
 15. The composition of claim 1, wherein saidvirus-like particle comprises recombinant proteins, or fragmentsthereof, of a RNA-phage, wherein said RNA-phage is selected from thegroup consisting of: (a) bacteriophage Qβ; (b) bacteriophage R17; (c)bacteriophage fr; (d) bacteriophage GA; (e) bacteriophage SP; (f)bacteriophage MS2; (g) bacteriophage M11; (h) bacteriophage MX1; (i)bacteriophage NL95; (k) bacteriophage f2; (l) bacteriophage PP7; and (m)bacteriophage AP205.
 16. (canceled)
 17. The composition of claim 1,wherein said virus-like particle comprises recombinant proteins, orfragments thereof, of RNA-phage Qβ.
 18. (canceled)
 19. The compositionof claim 1, wherein said unmethylated CpG-containing oligonucleotidecomprises the sequence: 5′ X₁X₂CGX₃X₄ 3′ wherein X₁, X₂, X₃, and X₄ areany nucleotide.
 20. The composition of claim 19, wherein at least one ofsaid nucleotide X₁, X₂, X₃, and X₄ has a phosphate backbonemodification. 21-36. (canceled)
 37. The composition of claim 1, whereinsaid unmethylated CpG-containing oligonucleotide comprises about 20 toabout 300 nucleotides. 38-48. (canceled)
 49. The composition of claim 2,wherein said at least one antigen is bound to said virus-like particleby at least one non-peptide covalent bond.
 50. The composition of claim2, wherein said at least one antigen is fused to said virus-likeparticle. 51-53. (canceled)
 54. The composition of claim 2, wherein saidantigen is an organic molecule.
 55. (canceled)
 56. (canceled)
 57. Thecomposition of claim 2, wherein said antigen is derived from the groupconsisting of: (a) viruses; (b) bacteria; (c) parasites; (d) prions; (e)tumors; (f) self-molecules; (g) non-peptidic hapten molecules (h)allergens; and (i) hormones.
 58. (canceled)
 59. The composition of claim57, wherein said antigen is a tumor antigen, and wherein said tumorantigen is selected from the group consisting of: (a) Her2; (b) GD2; (c)EGF-R; (d) CEA; (e) CD52; (f) CD21; (g) human melanoma protein gp100;(h) human melanoma protein melan-A/MART-1; (i) tyrosinase; (j) NA17-A ntprotein; (k) MAGE-3 protein; (l) p53 protein; (m) HPV 16 E7 protein; and(n) antigenic fragments of any of the tumor antigens from (a) to (m).60-71. (canceled)
 72. A method for enhancing an immune response in ananimal comprising introducing into said animal a composition comprising:(a) a virus-like particle, wherein said virus-like particle is avirus-like particle of an RNA-phage; and (b) an immunostimulatorysubstance, wherein said immunostimulatory substance is an unmethylatedCpG-containing oligonucleotide; wherein said immunostimulatory substanceis packaged into said virus-like particle.
 73. The method of claim 72,wherein said composition further comprises an antigen, wherein saidantigen is bound to said virus-like particle. 74-168. (canceled)
 169. Amethod of producing a composition for enhancing an immune response in ananimal comprising a virus-like particle and an immunostimulatorysubstance packaged into said virus-like particle which comprises: (a)disassembling said virus-like particle, wherein said virus-like particleis a virus-like particle of an RNA-phage; (b) adding saidimmunostimulatory substance, wherein said immunostimulatory substance isan unmethylated CpG-containing oligonucleotide; and (c) reassemblingsaid virus-like particle. 170-181. (canceled)
 182. A vaccine comprisingan immunologically effective amount of the composition of claim 1together with a pharmaceutically acceptable diluent, carrier orexcipient.
 183. (canceled)
 184. A method of immunizing or treating ananimal comprising administering to said animal an immunologicallyeffective amount of the vaccine of claim
 182. 185-186. (canceled)
 187. Avaccine comprising an immunologically effective amount of thecomposition of claim 2 together with a pharmaceutically acceptablediluent, carrier or excipient.
 188. (canceled)
 189. A method ofimmunizing or treating an animal comprising administering to said animalan immunologically effective amount of the vaccine of claim 187.190-207. (canceled)